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Rishi Raj Agrawal 
 
 Neurodegenerative diseases are highly multifaceted. Despite their heavy burden, treatment options 
are limited and our understanding of their molecular triggers even less so. In this thesis, I focus on the 
pathogenesis of Alzheimer’s Disease (AD) due to familial, sporadic and environmental causes. Previous 
research shows that early AD stages are characterized by upregulated functionality of mitochondria-
associated endoplasmic reticulum (ER) membranes. These “MAM” domains of the ER are dynamic 
contacts between the ER and mitochondria distinguished by a unique lipid composition equivalent to a lipid 
raft. These sites cluster a specific set of metabolic enzymes that regulate cellular lipid uptake, trafficking 
and turnover. We find that cleavage of the amyloid precursor protein at MAM domains is intimately involved 
in MAM regulation through localization of its C-terminal fragment of 99 a.a., C99, to MAM regions. C99 
upregulates MAM functionality by promoting cholesterol uptake and trafficking to the ER for esterification, 
observable in both familial and sporadic AD samples. Here, we recapitulated these phenotypes in a mouse 
model of an environmental AD trigger: traumatic brain injury (TBI). Through biochemical, transcriptional and 
lipidomic analyses, we observed MAM functionality to be upregulated following a single brain injury. This 
was determined by assessment of phospholipid synthesis and cholesterol esterification. This correlated 
with increased deposition of C99 in MAM domains as well as cell type-specific lipidomic alterations. 
Specifically, cholesterol esterification was predominant in microglia, triglyceride elevations were 
predominant in microglia and astrocytes, and polyunsaturated phospholipid elevations were predominant 
in neurons. We hypothesize that, in the acute phase, MAM upregulation serves to promote lipid synthesis 
for tissue repair. However, if these phenotypes are sustained (such as after multiple injuries), cognitive 
functions dependent on neuronal functionality could become compromised. Altogether, we propose that the 
induction of AD pathogenesis following brain injury may arise from chronic upregulation of MAM activities. 
This work advances our understanding of neurodegenerative disease etiology.  
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Chapter 1: Introduction    
 
Alzheimer Disease (AD) 
Chronic diseases cost the United States $1.1 trillion in 2016, or 6% of the country’s gross domestic 
product. Alzheimer disease (AD) comprised 17% of these expenditures, making AD the third most costly 
chronic disease in the U.S. (after cardiovascular disease and diabetes; Milken Institute). Of all dementias, 
AD accounts for 70% of cases and had a prevalence of 5.8 million in 2019 (Alzheimer's Association). In 
spite of over a century of research into AD pathogenesis, we have yet to find a cure for this disorder of 
progressive cognitive dysfunction. The first AD case was reported by Alois Alzheimer in 1906 upon the 
death of a female patient with progressive memory loss and delusions. Silver staining of brain tissue 
revealed the presence of neuritic plaques and neurofibrillary tangles, which are still considered pathological 
hallmarks of the disease [1]. A large portion of the AD field considers these plaques, composed of 
extracellular aggregates of the amyloid-β (Aβ) peptide, and tangles, composed of intracellular aggregates 
of the tau protein, to be primary drivers of AD pathology. In this section, I will explain the etiology of these 
hallmarks in detail, shed light on alternative hypotheses that have been proposed, and end with a unifying 
hypothesis that takes the perspective of multi-organelle dysfunction and relates to multiple molecular 
features of the disease. My goal is to illustrate the complexity of AD as a possible explanation for our 
continued failure to cure this disease, causing its rising prevalence in society.  
1.  
Clinical presentation and treatments 
 Presentation: AD can be stratified into subtypes based on age of onset. Early-onset, familial AD 
(FAD) patients begin to show symptoms in their 50s [2] while sporadic AD (SAD) symptoms usually begin 
after 65 [3]. The most common symptom is episodic memory impairment, with patients usually coming to 
the clinic due to an inability to recall recent events. Executive functions (ability to control behavior) can also 
be affected, often validated through testimony from a family member. Eventually, patients can exhibit social 
disengagement, irritability and wandering behavior, and may also lose the ability to carry out basic motor 
functions, sleep properly and multi-task. Increasing daily dependency on others for daily living is also 




or as long as 20 years. Even though AD affects multiple neurological functions, most cases converge on a 
few immediate causes of death. One of these is aspiration pneumonia, in which food and drink go down 
the windpipe into the lungs (rather than down the esophagus) [5]. This is usually attributed to impaired 
control of basic mouth functions such as swallowing, drinking and coughing. Additional causes include 
blood clots due to immobility as well as dehydration and malnutrition due to difficulty swallowing [3,6].  
 Diagnosis: A critical determinant of prognosis is timely diagnosis. Given the difficulty of obtaining 
brain biopsies, a combination of psychological testing, biomarkers from blood and cerebrospinal fluid (CSF), 
and brain imaging is used. The Mini-Mental State Examination is the standard psychological test where 
patients are given exercises such as basic questions about time and place, simple arithmetic, repeating 
words, language comprehension and basic motor skills. Next come conversations with family members, 
followed by blood tests to rule out other conditions with cognitive symptoms (e.g., type-2 diabetes mellitus, 
T2DM). Another major component of diagnosis is structural and functional brain imaging [7]. If magnetic 
resonance imaging (MRI) and positron emission tomography (PET) suggest reductions in hippocampal 
volume and white matter volume, this would support any indications of AD from the behavioral testing. This 
can be further validated through functional PET with 18-fluorodeoxyglucose (FDG-PET) to assess glucose 
hypometabolism [8] and Aβ tracers to assess increased Aβ lesioning [8–10]. Cerebral single-photon 
emission computed tomography (SPECT) can also be used to test hypoperfusion [11]. Final confirmation 
is often achieved upon observation of elevated Aβ42:Aβ40 ratios as well as Tau and phospho(T181)-Tau 
in CSF [12,13]. Levels of neurofilament light (NFL) protein, an axonal protein that is released upon white 
matter degeneration characteristic of AD, can also be assayed and have demonstrated positive correlations 
with AD status [14]. Of note, these biomarkers are not specific to AD and are also elevated in frontotemporal 
dementia (FTD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) [15–20].  
 Treatment: Following diagnosis, therapeutic options are discussed. Unfortunately, AD has the 
highest clinical trial failure rate of all major disease areas [21], with no new drugs gaining FDA approval in 
over a decade. There are currently four compounds indicated for AD. Donepezil, galantamine and rivastig-
mine are acetylcholinesterase inhibitors; these drugs prevent the degradation of the excitatory neuro-
transmitter (NT), acetylcholine, which is important for cell-cell communication and memory formation. The 




binding to prevent excitotoxicity. Benefits from these therapies are modest and fail to significantly retard 
disease progression [22,23]. The dearth of clinically effective therapies likely results from substantial effort 
in the AD space being directed toward anti-Aβ antibodies aimed at clearing Aβ deposits, none of which 
have passed clinical trials due to lack of consistent results, poor trial design and serious side effects [24,25]. 
The enzymes responsible for Aβ production – β-secretase and ɣ-secretase – have also been directly 
targeted as has tau, a microtubule-stabilizing protein whose hyperphosphorylation is also linked to AD. 
However, similar to anti-Aβ therapies, none have come to market. As a result, combination therapies based 
on drugs already approved are emerging and the first combination therapy for moderate to severe AD 
patients was approved in 2014: the addition of memantine for patients tolerating donepezil [26]. There are 
currently over 600 clinical trials in progress for AD and related dementias, targeting amyloid, inflammatory, 
metabolic and psychosocial aspects of the disease through pharmacological, dietary and lifestyle-based 
approaches (source: www.clinicaltrials.gov). 
 
Genetic and environmental risk factors 
 It is believed that the underlying pathways responsible for AD start to become dysfunctional 20-30 
years before the onset of neurological symptoms [27], partly explaining the high failure rate of clinical trials 
that aim to ameliorate existing symptoms. Thus, effective treatment requires a focus on the prevention, 
rather than the reduction, of symptoms. This necessitates a detailed understanding of AD etiology.  
Familial AD (FAD): As described above, there are two subtypes of AD: familial AD (FAD) and 
sporadic AD (SAD). While they can be distinguished by age of onset, they also have distinct molecular 
causes. FAD is caused by missense mutations in three genes – APP (encoding amyloid precursor protein, 
APP), PSEN1 (encoding presenilin-1, PS1) and PSEN2 (encoding PS2) – that are mostly inherited in an 
autosomal dominant manner and are thus highly penetrant [28]. APP, which has an unknown function, is 
ubiquitously expressed but most highly expressed in the central nervous system (CNS). In AD, cleavage of 
APP by an aspartyl protease called β-secretase (BACE1) to generate the transmembrane 99 a.a.-long C-
terminal fragment, C99, is increased. This is problematic because C99 undergoes cleavage by ɣ-secretase 
(containing PS1 and PS2 as its catalytic subunits) to generate Aβ [29]. To date, 39 mutations in the 




[30,31] that result in the same phenotype: increased production of longer forms of Aβ (≥42 a.a.-long, 
compared to the more common Aβ40) that contain additional hydrophobic residues, conferring increased 
susceptibility to aggregation. Under the amyloid cascade hypothesis, to be discussed in greater detail 
below, increased production of longer forms of Aβ causes amyloid deposits and senile plaques that impair 
neuronal function and communication. This has been the predominant theory of AD etiology for decades.  
Of note, the A673T mutation in APP (in the Aβ domain adjacent to the β-cleavage site) has been 
shown to be protective against AD [32]. This mutation was discovered in an Icelandic population and is thus 
termed the “Icelandic” mutation. This variant was observed to be significantly more common among non-
demented individuals than in AD cases, and reduced Aβ production in experimental models [32,33]. 
Furthermore, the APP gene does not need to be mutated in order to be pathogenic, as increased gene 
dosage is sufficient to cause early-onset AD [34,35]. In fact, Down syndrome patients (carrying a trisomy 
of chromosome 21, which contains APP) develop Aβ plaques and AD-like symptoms by age 30 [36]. 
 Sporadic AD (SAD): Despite the plethora of associated APP/PSEN1/PSEN2 mutations, FAD 
accounts for <1% of all AD cases. The majority of AD cases fall under SAD and develop upon the 
convergence of genetic and environmental factors. Polymorphisms in >20 additional genes have been 
identified to confer increased AD risk and can be grouped into three main processes: cholesterol 
metabolism, brain inflammation and endosomal vesicle cycling [37,38]. Chief among these is APOE, 
encoding apolipoprotein E, the principal component of cholesterol-carrying lipoproteins in the brain [39]. 
Humans express three alleles, which differ by only two residues: ε2 (Cys112/Cys158), ε3 (Cys112/Arg158) 
and ε4 (Arg112/Arg158). Of these alleles, ε3 is the most common (allele frequency in Europeans of ~70-
90% [40]). Expression of the ε4 allele (referred to as APOE4, frequency ~10-30% [40]) increases AD risk 
by 4-fold when heterozygous and by 12-fold when homozygous. Expression of the ε2 allele (~3-12% 
frequency [40]) reduces risk for AD [41,42] but, like APOE4, increases risk for cardiovascular disease [43]. 
Expression of the ε4 allele of APOE is the most common cause of AD and accounts for 37% of cases [44]. 
47% of heterozygous carriers develop AD, a number that is doubled for homozygous carriers [44], making 
APOE4 a major focal point in the AD field. Interestingly, a separate mutation in WT (ε3) APOE, Arg136Ser 
(dubbed “Christchurch”), was shown to delay onset of cognitive symptoms by 30 years in a female member 




common cause of FAD, underlying the important influence the ApoE protein has over AD pathogenesis.  
 ApoE is thought to influence AD risk by modulating Aβ oligomerization and clearance [46,47]. 
However, it is likely that ApoE’s canonical function in mediating lipid transport is also relevant. Indeed, other 
lipid metabolic genes are additional demonstrated SAD risk loci, including ABCA7 (encoding ATP-binding 
cassette transporter A-7), CLU (encoding clusterin, or apoJ), PICALM (encoding PI-binding clathrin 
assembly protein) and SORL1 (encoding sortilin-related receptor-1). Additional pathways constituted by 
known SAD risk genes include inflammation (TREM2, encoding triggering receptor expressed on myeloid 
cells 2; CR1, encoding complement C3b/C4b receptor 1; CLU; INPP5D, encoding inositol polyphosphate-
5 phosphatase), endocytosis (PICALM; SORL1; EPHA1, encoding ephrin type-A receptor 1; BIN1, 
encoding bridging integrator 1), cytoskeletal regulation (CELF1, encoding CUGBP, elav-like family member 
1; NME8, encoding NM23 family member 8) and tau metabolism (BIN1; CASS4, encoding cas scaffold 
protein family member 4; FERMT2, encoding fermitin family member 2) [48].   
 Environmental causes: Although 60-80% of AD risk can be explained by heritable factors [49], 
environmental risk factors have been described in multiple systematic reviews [50,51]. These include 
lifestyle, pre-existing health conditions and toxins. To be discussed in greater detail in a separate section, 
head injury is a major environmental cause of AD and is estimated to increase risk ~1.5-fold [50,52]. 
Depression, diabetes mellitus, pesticides, smoking, air pollution, cognitive inactivity and living close to 
power lines have also been shown to increase risk [50,51,53,54]. Thus, environmental contributors to AD 
risk appear plentiful and broad; however, since genetic factors have proven insufficient in predicting 
sporadic AD susceptibility, the contributions of environmental factors are robust. Twin studies have been 
especially enlightening here, with one study in Sweden showing that only in 45% of identical male pairs did 
both twins have AD [49]. Thus, SAD is largely a result of gene-environment interactions. The same 
approaches that uncovered these correlates also revealed protective factors against AD, including the ε2 
allele of APOE, statin use and the Mediterranean diet [50].  
While the multifactorial etiology of SAD is clear, it is critical to emphasize that the single biggest 
risk factor for AD is aging. There is a sex effect, with two female AD patients for every one male patient 
[55]. Finally, even though non-white ethnicities have been historically underrepresented in AD research, 




to develop AD than non-Hispanic whites, and Hispanics/Latinos are one and a half times as likely [56].  
Altogether, the epidemiological data on AD risk factors and associated conditions shows that the 
pathogenesis of this disease is highly complex, with multiple molecular, genetic and lifestyle factors at play.  
 
Molecular features of AD: hypotheses and evidence 
 Despite the identification of specific mutations as direct causes of AD, our understanding of the 
disease’s molecular mechanism is incomplete. In this section, I will discuss a few widely reported molecular 
features, many of which are considered primary drivers of AD pathogenesis. These include the amyloid 
cascade hypothesis, the tau hyperphosphorylation hypothesis, the inflammatory hypothesis, the calcium 
hypothesis, metabolic alterations, and the mitochondrial cascade hypothesis. I will complete this section by 
describing the MAM hypothesis, which has motivated my studies in traumatic brain injury (TBI). 
 
Amyloid-β deposition: the amyloid cascade hypothesis 
 The amyloid precursor protein (APP) is a highly conserved, single-pass transmembrane protein 
that is predominantly expressed in the CNS [29]. Of the three members of the APP protein family (APP, 
APLP1 and APLP2, each having a different tissue distribution), only APP contains the Aβ domain, making 
APP and its metabolism the subject of intense study. Research into APP was stimulated by the identification 
of the Aβ peptide as the major constituent of senile plaques, and supported by the finding of APP mutations 
and duplications as direct causes of FAD. As a result, most studies have focused on APP’s amyloidogenic 
roles rather than its canonical function, which has yet to be definitively determined. However, knockout 
mouse studies suggest a role for APP in brain development, specifically in neuronal migration [57] and 
synaptic function [58]. Mice lacking one APP family member are viable and fertile but have reduced body 
weight, locomotor activity [59] and axonal development [60]. When the evolution of the APP gene is 
examined, it can be observed that APP appearance coincides not only with the earliest species expressing 
functional synapses [61], but also with the appearance of lipoprotein receptors [62]. Indeed, interactions 
between APP and multiple lipoprotein receptor related proteins (LRPs) have been described, suggesting 






Figure 1-1: The amyloid precursor protein (APP) processing pathway. 
 
 APP cleavage and trafficking: Proteolytic processing of APP, which occurs in both neurons and 
glial cells, is an important aspect of APP pathogenicity (Fig. 1-1). Following synthesis in the endoplasmic 
reticulum (ER), APP traffics through the trans-Golgi network (TGN) to the plasma membrane (PM). In the 
majority of physiological APP cleavage events, APP is cleaved by the ⍺-secretases, a group of membrane-
bound metalloproteinases encoded by the ADAM9/10/17/19 genes (ADAM10 is the predominant ⍺-
secretase). The ⍺-secretases have multiple membrane-embedded substrates and are stimulated upon 
acute neuronal excitation [63–66]. This cleavage generates soluble APP⍺ (sAPP⍺), a secreted product with 
neurotrophic properties [67,68], and the C-terminal fragment of 83 a.a. (C83). This fragment is endocytosed 
and cleaved by the ɣ-secretase aspartyl protease complex, which consists of presenilin-1 (PS1) and 
presenilin-2 (PS2) as the catalytic components alongside nicastrin, anterior pharynx defective (APH)-1a or 
APH-1b, and PS enhancer protein (PEN)-2 [69]. This cleavage event results in the generation of P3, which 
has potential neurotoxic properties [70–73], and APP intracellular domain (AICD), a transcription factor. P3 
is secreted through the Golgi secretory pathway or exocytosis, while AICD which translocates to the nucleus 
to activate transcription of a diverse group of target genes, including p53 (an oncogene), EGFR (encoding 




cleavage site falls within the Aβ domain; thus, cleavage of APP by ⍺-secretase prevents the formation of 
Aβ, leading to this processing pathway being called the “non-amyloidogenic” route.  
While cleavage in this direction predominates under healthy conditions, an alternative pathway is 
stimulated in AD. The “amyloidogenic” pathway is upregulated by increased plasma membrane cholesterol 
concentration [75–77], which promotes APP and β-secretase internalization (albeit through distinct 
endocytic mechanisms [78]) and clustering [79]. β-secretase, or β-site APP cleaving enzyme 1 (BACE1), 
is active at acidic pH and cleaves APP in endosomes to generate sAPPβ (also secreted but not considered 
neurotrophic [67]) and C99. Following trafficking to the ER through unknown mechanisms, C99 is cleaved 
by ɣ-secretase to generate Aβ and AICD. Aβ is secreted from the cell. Of note, through a pathway that is 
still incompletely understood, endocytosed full-length APP can be “recycled” back to the PM through 
trafficking mediated by the retromer multi-protein complex, which antagonizes amyloidogenic processing 
[29,80]. This process has been studied as a potential therapeutic target [81].  
While the inter-membrane trafficking pathway outlined above has been studied for decades and 
validated through numerous studies, the subcellular localization of these events is still a major area of 
research. Particular attention has been devoted to localization of each cleavage event. Cleavage by ⍺-
secretase, while traditionally thought to occur on the extracellular surface of the PM, has also been detected 
in the TGN where it is stimulated by protein kinase C signaling (activated during neuronal excitation) and 
competes with β-secretase for APP [63,82,83]. Indeed, catalytic activity of β-secretase is known to be 
restricted to acidic environments, consistent with reports of APP β-cleavage occurring primarily in 
endosomes and the TGN [29]. Subcellular localization of ɣ-secretase activity has been an especially 
contentious area. The PSs have been reported to be localized in nearly every membrane compartment of 
the cell, including the ER [84], Golgi [84], endosomes/lysosomes [85], the nuclear envelope [86], the PM 
[87], mitochondria [88] and mitochondria-associated ER membranes (MAM domains, discussed in greater 
detail in a later section) [89]. At the same time, it is widely agreed that the PSs and ɣ-secretase activity 
along with APP and C99 are localized in lipid raft (LR) domains [90–92]. LRs are membrane microdomains 
enriched in cholesterol and saturated sphingolipids, making them liquid-ordered and less fluid relative to 
liquid-disordered membrane regions [93]. These detergent-resistant membranes (DRMs) have traditionally 




learned that ɣ-secretase activity is minimal in the PM [89,94]. This underlies a longstanding “spatial 
paradox” in the AD field [95]. Our group was able to resolve this discrepancy through the observation that, 
similar to the PS proteins, ɣ-secretase activity is enriched in MAM domains [89] relative to other cellular 
LRs, which we also validated to be intracellular LRs [96]. The significance of these findings, which relates 
to a further finding of upregulated functionality of MAM activity in AD [96], will be discussed below. 
 Amyloid-β: Wildtype Aβ is 40 a.a. long, with its production, secretion and degradation being 
physiological processes [97–99]. The physiological function of Aβ is not agreed upon but putative roles 
include sealing leaks in the blood-brain barrier (BBB), acting as a microbicidal agent, and promoting 
synaptic activity [100]. In the presence of FAD-linked APP/PSEN1/PSEN2 mutations, ɣ-cleavage of APP 
becomes modified to favor the production of Aβ isoforms with additional C-terminal residues, becoming 42 
a.a., 43 a.a. or even longer, at the cost of Aβ40 [101–106]. The ɣ-secretase complex first carries out endo-
peptidase ε-cleavage of C99, usually at residue 49, followed by sequential carboxypeptidase ɣ-cleavage 
events that “trim” the resultant peptide 3-4 a.a. at a time [107–110]. Many FAD mutations modulate this 
activity by shifting the initial endopeptidase cleavage to residue 48 [111–113]. This alters the “product line” 
of sequential cleavage, and longer peptides are “prematurely” released from the active site [104,113–118]. 
Additionally, PSEN mutations cause alterations in the conformation of presenilins and affect their interaction 
with substrates [119–125]. This has even been observed in heterozygous cases, indicating that these 
mutations can behave in a dominant-negative manner [126]. Finally, since ɣ-secretase cleavage of C99 is 
an intramembrane process [127,128], local membrane lipid composition and thickness affect ɣ-secretase 
activity [129–131]. The net result of these genetic- or lipid-based modulations of ɣ-secretase activity, while 
often lowering overall Aβ production, is an increase in the Aβ42:Aβ40 ratio [132,133]. This is problematic 
because the additional residues have hydrophobic side chains and make Aβ more prone to oligomerization 
and aggregation [134,135]. Interestingly, increases in the Aβ42:Aβ40 ratio are not consistent in SAD [136], 
leading to alternative explanations for Aβ deposition in this predominant form of AD [25]. It is thought that 
SAD-linked mutations can impair Aβ clearance [137,138], modulate Aβ fibrillogenicity [139], alter APP 
endocytic vesicle recycling [140] and increase β-secretase expression [141,142]. In addition, as discussed 
below, multiple SAD risk genes are involved in lipid metabolic pathways, so associated mutations will 




an additional explanation for altered APP processing and Aβ deposition in SAD.  
 Aβ deposition has received considerable attention in the AD field because extracellular Aβ 
aggregates, both in soluble oligomer and insoluble plaque forms, are neurotoxic. At healthy concentrations, 
pre-fibrillar, soluble aggregates are degraded [143]. These pools are generally concentrated in the synapse 
[144] and are cleared through glial-regulated processes that include secreted proteases, protein 
chaperones that promote clearance via the BBB, and internalization through phagocytosis or receptor-
mediated endocytosis [143]. Of note, three lipid transport proteins are important in Aβ clearance: APOE 
and APOJ, which promote Aβ clearance through lipoprotein receptor-related protein (LRP, the third protein) 
family members through direct or indirect interactions [145–147]. As Aβ levels rise, either due to increased 
production or defective clearance mechanisms, synaptic signaling becomes impaired [148]. Synaptotoxic 
effects can be observed at the soluble oligomer level alone, leading to the theory that oligomers may be 
more toxic than plaques. Specifically, treatment of cells and animals with Aβ oligomers reduces dendritic 
spine density, destabilizes glutamate receptors and induces synaptic loss. This impairs neurotransmission, 
manifesting as attenuated long-term potentiation and enhanced long-term depression [149–152]. Despite 
this widely observed toxicity of oligomers, higher-order Aβ aggregates in the form of amyloid fibrils and then 
senile plaques have been historically associated with AD (Fig. 1-2). Plaques are insoluble and readily 
identifiable through histological staining. Perhaps this visibility is why, for decades, plaques were 
considered a principal driver of AD pathogenesis, especially since FAD mutations that cause AD modulate 
the production of monomeric Aβ. Furthermore, upon passage through the BBB, plaques can be deposited 
in cerebral blood vessels, similar to aortic lesions in atherosclerosis. This deposition has been shown to 
correlate with impairments in cerebral blood flow in a phenomenon called “hypoperfusion,” which can 
severely limit nutrient supply to neighboring cells [153–155]. Interestingly, in terms of synaptic toxicity, 
plaques may be relatively inert compared to oligomers, failing to induce alterations in synaptic morphology 
to the same extent [156–160], suggesting that plaques act as reservoirs that sequester oligomeric Aβ. 
Indeed, in one study of AD patients, the ratio of oligomers to plaques successfully distinguished AD and 





Figure 1-2: Amyloid-β (Aβ) plaques in familial and sporadic AD cases. 
Post-mortem human tissues from FAD and SAD subjects were stained for Aβ deposition by 
immunohistochemistry. Aβ is labeled in brown, with blue identifying cell nuclei. Adapted from [161]. 
 
 This debate and the relevant molecular events comprise the amyloid cascade hypothesis. Under 
this hypothesis, Aβ oligomerization and deposition is the primary driver of AD pathogenesis and precedes 
other molecular pathologies characteristic of the disease. This is similar to other neurodegenerative 
diseases that are also associated with aberrant protein aggregation, such as Parkinson’s disease (PD; ⍺-
synuclein), Huntington’s disease (HD; huntingtin) and amyotrophic lateral sclerosis (ALS; SOD1, TDP43 
and FUS, among others [162]) [163]. The oligomeric stage is associated with synaptic dysfunction as 
described above. Subsequent fibrillization and plaque deposition is met with inflammatory responses 
(microglia and astrocyte activation), oxidative stress, tau hyperphosphorylation and cytoskeletal 
destabilization, axonal transport defects and neurofibrillary tangle deposition. Ultimately, neurotransmission 
in affected areas is abolished, leading to the development of cognitive impairments and dementia.  
Pitfalls of the amyloid cascade hypothesis: While this hypothesis appears to address many 
molecular features of AD, it has several shortcomings that bring its validity into question [164]. First, there 
is a major discord between histopathological and clinical AD phenotypes. Specifically, there are several 
reports of aged patients with amyloid pathology (determined through PET or post-mortem histology) that 
did not display cognitive impairment [165–170]. The converse is true as well, as there are dementia patients 
with AD-like cognitive symptoms who are devoid of amyloid plaques [171,172]. Related to this, in AD 
patients who do develop amyloid pathology, biomarkers of Aβ oligomerization can appear years before any 




phenotypes. Additionally, upon onset of cognitive impairment, the degrees of amyloid deposition and 
cognitive impairment do not always correlate [160,173,176–179]. The second major shortcoming of this 
hypothesis can be understood by looking at clinical trials for AD drugs. As mentioned above, AD has the 
highest failure rate for clinical trial drugs of all major disease areas. A handful of these failed drugs directly 
target Aβ, including monoclonal antibodies targeting plaques and inhibitors of ɣ-secretase. These therapies 
successfully reduced amyloid pathology but did not improve (or worsened) cognitive deficits [180–184]. Of 
the four approved AD medications, none target Aβ or the APP processing pathway. Finally, when the 
genetic polymorphisms associated with sporadic AD cases are examined, it can be learned that the affected 
proteins do not directly modulate Aβ production [185,186]; however, the cognitive impairments are identical 
to those in FAD albeit with different ages of onset and timelines of progression. This provides strong 
rationale for the idea that factors outside of Aβ alterations underlie AD pathogenesis.  
 The amyloid cascade hypothesis has provided a valuable framework to guide AD research for 
decades. This has enabled significant advances in our understanding of neurodegeneration and dementia, 
while also unveiling the complexity of this disease. The AD community has not invalidated the hypothesis 
completely, and research into the neurotoxicity of aggregated Aβ is ongoing. It is the responsibility of 
scientists to critically evaluate molecular studies in light of epidemiological data and determine which reports 
reflect the progression of AD in humans and which do not. Indeed, by doing so, several other hypotheses 
have emerged that have advanced the field considerably. These are discussed below.  
Potential roles of C99: Of note, the immediate precursor of Aβ, C99, correlates especially well 
with AD pathologies and is elevated at early disease stages [187–194]. It is known that, in the presence of 
APP/PSEN1/PSEN2 FAD mutations, ɣ-cleavage of C99 is modified. However, the same outcome can occur 
in the absence of these mutations but in the presence of local alterations in membrane lipid composition 
and thickness [129,131]. Such alterations are observable in SAD, explaining the appearance of C99 
pathologies in the absence of genetic ɣ-cleavage modifications. While these lipid alterations generally result 
in increased Aβ42/40 ratio, a less commonly reported outcome is increased “unprocessed” C99 [192], 
consistent with the viewpoint that PSEN1/2 mutations cause loss of ɣ-secretase enzymatic function [195]. 
Increased steady-state levels of C99 have been reported in both FAD and SAD postmortem tissues 




cytotoxic in its own right, capable of inducing endocytic and autophagic dysfunction, mitochondrial 
alterations, hippocampal degeneration and cognitive impairment when elevated via overexpression or ɣ-
secretase loss-of-function [189–191,193,198–203]. Given that early C99 elevations coincide with 
mitochondrial and lipid metabolic alterations, increases in the C99:Aβ ratio have been proposed as early-
stage indicators of AD [192]. The role of C99 in AD pathogenesis is the subject of Chapters 2 and 3. 
 
Tau hyperphosphorylation and tangle formation: the tau hypothesis 
 Protein aggregation is a cardinal feature of multiple neurodegenerative diseases. After disrupting 
basic functioning of their origin cells, these protein aggregates can spread in a prion-like manner throughout 
the brain, expanding pathology [204]. In addition to Aβ, a second protein whose aggregation is characteristic 
of AD is tau [1]. This microtubule (MT)-associated protein promotes the polymerization of tubulin into MTs 
and stabilizes formed MTs [177]. Tau has conventionally been considered an axonal protein, and indeed 
has been observed in growth cones of developing neurons [205], but somatodendritic [206] and synaptic 
[207] localization have also been reported. For reasons that are incompletely understood, tau is 
hyperphosphorylated in AD, causing tau to oligomerize into soluble filaments that can further polymerize 
into insoluble “neurofibrillary tangles” (Fig. 1-3), similar to how Aβ monomers become plaques. However, 
since tau is not secreted, tau pathology is an intracellular phenomenon observable in both neurons and glia 
[208]. The combination of tau aggregates and destabilized MTs impairs several key cellular processes, 
including axonal transport of critical cargo like synaptic vesicles, mitochondria, lipoproteins, proteins and 
other organelles. The end result of this traffic jam is impaired synaptic transmission. 
 
 
Figure 1-3: Tau tangles in a human AD case.  
Brain tissue from an AD subject was stained post-mortem for hyperphosphorylated tau tangles by 




 The cause of tau hyperphosphorylation has not been definitively determined; however, the literature 
points to deregulated activity of a responsible kinase, CDK5 [210] (albeit still under debate [211,212]), and 
phosphatase, PP2A [213–216]. Downregulation of a key tau post-translational modification, O-
GlcNAcylation [217], which inversely correlates with phosphorylation status [218,219], has also been 
proposed as a contributing factor [220–222]. Aβ oligomers have also been proposed as a contributing factor 
because, under the amyloid cascade hypothesis, tau hyperphosphorylation and MT destabilization are 
downstream of Aβ. Even though this temporality has been confirmed experimentally [173,223,224], no 
mechanism has been determined and reports of tau lesions occurring before Aβ deposition have also been 
published [225]. Thus, even though both pathologies often occur in the same disease, the molecular link is 
not understood. That being said, animal and postmortem human studies provide rationale for studying the 
role of tau in AD, as tangles are considered more reliable correlates of neuronal loss and cognitive deficits 
than plaques [178,226,227]. However, this correlation has been challenged [173], with reports of tangles in 
non-demented subjects [166,169,170,228], similar to Aβ. Also, from a genetic approach, mutations in the 
MAPT gene encoding the tau protein do not cause AD but cause frontotemporal dementia with Parkinson-
ism (FTDP), indicating that tau pathology is not specific to AD [229]. Similar to Aβ, no tau-targeted therapies 
have passed clinical trials; however, immunotherapies aimed at diminishing aggregation and spreading, as 
well as small molecules targeting phosphorylation, are under development [230]. Of the 2173 clinical trials 
initiated by 2019, 12.2% targeted tau [231], but none were approved. Thus, similar to the amyloid cascade 
hypothesis, it is likely that tau pathologies do not completely explain AD pathogenesis.  
Activation of inflammatory signaling and glial responses: the inflammatory hypothesis 
 Microglia: Alongside the proteostatic impairments described above, activation of inflammatory 
signaling in the brain is well described [232,233]. While expression of pro-inflammatory mediators is known 
to increase with aging [234], it is believed that chronic neuroinflammation is a substantial contributor to AD. 
The inflammatory hypothesis of AD is a major hypothesis in the field, prompted by the early finding that 
AD tissues express MHC class II [235], which speaks to microglial activation. Indeed, almost 5% of the 
>2000 AD clinical trials initiated thus far have targeted AD-associated inflammatory cascades [231]. Under 
this hypothesis, microglia, the brain’s resident macrophages that constantly patrol their environment for 




activate. This pro-inflammatory environment can be detrimental for neural homeostasis. 
 The predominant trigger of microglial activation in AD is supraphysiological concentrations of Aβ 
deposits [236,237]. Since secreted Aβ can aggregate into plaques and exert synaptotoxicity, efficient 
clearance mechanisms are critical to evade disruption of cognitive circuitry. One such pathway is microglial 
phagocytosis, a process that can become impaired in AD. Microglia bind Aβ through multiple receptors, 
such as TLR2, TLR4 and RAGE, and are subsequently stimulated to express pro-inflammatory mediators 
such as NF-κB, TNF⍺, COX2, and iNOS [232]. This recruits additional microglia to plaques to propagate 
the inflammatory cascade. Indeed, immunohistochemical analysis of AD tissues has shown that activated 
microglia accumulate around Aβ plaques [238]. However, it has been shown that microglial expression of 
Aβ-binding receptors decreases with age, in spite of increased pro-inflammatory cytokine expression [239], 
suggesting that microglial recruitment to plaques may not correlate with increased plaque clearance [240]. 
In sporadic cases of AD, Aβ-mediated stimulation of microglial activity can be supplemented by genetic 
influences. Three genes whose polymorphisms significantly increase SAD risk, TREM2, CD33 and CR3, 
are microglial cell-surface receptors that regulate phagocytosis [241]. It is believed that mutations or altered 
expression of these genes modulate microglial Aβ phagocytic capacity [242]. Additionally, expression of 
the ε4 variant of APOE, the most common genetic cause of AD, has been shown to induce heightened 
inflammatory responses, suggesting yet another potential pathogenic mechanism of the ε4 allele [243–
246]. Finally, microglial activation has been reported in AD mouse models before Aβ deposition is 
detectable (at 1 month of age), indicating that inflammatory activation characterizes asymptomatic stages 
of AD as well [188]. Indeed, microglia are known to be activated by soluble Aβ oligomers, more 
characteristic of early disease stages [247]. It can thus be concluded that hyperinflammation is a consistent 
phenotype in the disease and a likely contributor to AD etiology.  
 There are multiple pathogenic mechanisms through which chronic activation of neuroinflammation 
could lead to cognitive impairments characteristic of AD. First, upon activation glial cells assemble the 
NLRP3 inflammasome, a multi-protein complex that is essential for a complete cellular immune response 
[248]. Not only does the inflammasome trigger the release of additional pro-inflammatory cytokines, but it 
also promotes tau hyperphosphorylation [249]. In fact, a recent report showed that NLRP3 inflammasome 




between these two hallmark AD pathologies while also implicating activation of inflammatory pathways in 
disease progression [249]. A second pathogenic mechanism of hyperinflammation in AD comes from one 
of the most basic microglial roles during development: engulfment of synapses in a neuronal refinement 
process known as “synaptic pruning” [250]. Since Aβ plaques accumulate in synapses, chemotaxis of 
microglia to plaques brings these phagocytic cells in close proximity to neurites. While microglia are critical 
for maintenance of neuronal homeostasis in the presence of AD pathology by removing damaged, 
dystrophic neuronal processes, this function can become hyperactivated in disease conditions to the point 
where healthy axons and dendrites are damaged. Indeed, in AD patients microglial activation [determined 
by (11C)PK11195 PET] was reported to negatively correlate with hippocampal volume (measured by 
volumetric MRI) [251]. This can be profoundly detrimental to neuronal, and therefore cognitive, functioning. 
Finally, the promoter regions of APP, BACE1 and components of the ɣ-secretase complex have been 
shown to have responsive sites for pro-inflammatory cytokines that are upregulated in AD [252–254]. This 
means that AD-associated inflammation can directly promote Aβ production and potentiate AD pathology. 
Through this evidence from the literature, it has been demonstrated that AD microglia display an altered 
polarization toward pro-inflammatory phenotypes, perhaps due to sustained Aβ exposure. Interestingly, 
development of inflammatory phenotypes is modulated by cellular lipid metabolic networks [255], another 
early-stage alteration in AD that is discussed in detail below.  
 Astrocytes: While writing about the role of inflammation in AD etiology, it is important to emphasize 
that microglia are not the only glial cell type involved: astrocytes and oligodendrocytes are also major 
players. By no means is this a surprise, as astrocytes are critical regulators of neuronal homeostasis and 
oligodendrocytes produce myelin, which ensheathes axons to enable action potentials. Astrocytes and 
oligodendrocytes are also responsible for cholesterol and lipoprotein production after development, and 
astrocytes provide neurons with multiple trophic factors and energy precursors. Furthermore, in a concept 
known as the “tripartite” model of synapses, astrocyte projections are present at the synaptic cleft and 
participate in glutamate and ion cycling [256]. As such, astrocytes also respond to synaptic Aβ deposition. 
Specifically, plaques are reported to contain monocyte chemoattractant protein 1 (MCP1), a chemo-
attractant for astrocytes that likely contributes to the reported accumulation of astrocytes, in addition to 




receptor, RAGE, through which astrocytes phagocytose Aβ [258]. Astrocytes also promote Aβ clearance 
by secreting matrix metalloproteinases, which proteolytically degrade Aβ [259], as well as pro-inflammatory 
cytokines, which can recruit additional phagocytic glia [260]. Given these roles of astrocytes in response to 
Aβ plaques, it is no surprise that reactive astrogliosis is an established molecular phenotype of AD.  
Oligodendrocytes: Finally, oligodendrocyte homeostasis is also disrupted in AD. Disrupted myelin 
sheaths, or damaged white matter, is one of the earliest phenotypes of AD, pointing to impaired 
oligodendrocyte function [261,262]. Myelin debris is known to induce microglial recruitment for clearance 
[263], and oligodendrocytes themselves have been shown to upregulate expression of complement 
pathway components in AD [264]. Finally, in vitro studies have shown that Aβ exposure can cause 
oligodendrocytes to begin expressing complement proteins and even undergo cell death [262,265,266]. 
Taking these described alterations in astrocytic and oligodendrocytic behavior in AD into account, it is clear 
that all glial cell types contribute to hyperactivation of neuroinflammatory pathways in AD. Thus, the 
homeostatic disturbances responsible for dementia in AD are not specific to neurons, the cells directly 
responsible for cognition, but afflict the glia supporting neuronal function as well.  
 
Excitotoxicity: the calcium hypothesis 
Ions critically regulate cellular homeostasis. Calcium (Ca2+) is especially important in multiple cell 
types, serving as an enzyme cofactor, a signaling second messenger and a major determinant of 
membrane potentials [267]. Indeed, in neurons, transient elevations in intracellular Ca2+ modulate neuronal 
excitation during action potentials and subsequent neurotransmitter (NT) release. It has been observed that 
intracellular Ca2+ becomes elevated in AD to create a state of excitotoxicity [268]. While this is a known 
correlate of normal aging [269], causes and consequences of Ca2+ dyshomeostasis have been uncovered 
that are closely related to molecular features of AD pathogenesis. Ca2+ abnormalities, specifically increased 
ligand-stimulated release from intracellular stores through ryanodine receptors (RyRs) and inositol-1,4,5-
triphosphate receptors (IP3Rs) [270–274] as well as increased RyR expression [275], have also been 
observed in AD patient cells and cellular and animal models.  
A few possible molecular causes have been proposed. First, non-amyloidogenic APP processing 




reduced non-amyloidogenic processing would attenuate this process. A result of increased amyloidogenic 
APP processing is an increased ratio of Aβ42:Aβ40, as discussed above. Oligomeric forms of Aβ42 have 
been shown to have significant structural similarity to pore-forming bacterial toxins [277], and indeed it is 
believed that one mechanism by which Aβ imparts cytotoxicity is the formation of pores in the PM, which 
allow for supraphysiological Ca2+ influxes [278]. Of course, mutant forms of the PSs can promote 
amyloidogenic Aβ production and direct and indirect interactions have been uncovered between the PSs 
and several Ca2+ regulating proteins, including RyRs, Ip3Rs and smooth ER Ca2+-ATPase (SERCA) pumps 
[279–284]. PSEN mutations have even been shown to impair Ca2+ leak functions of WT PS proteins 
localized in ER membranes, which serve to relieve excessive ER Ca2+ loads [285,286]. Finally, a major 
node of intracellular Ca2+ regulation is ER-mitochondria connections (MAM domains), as Ca2+ is directly 
transferred from the ER to mitochondria through multi-protein channels at these contact sites [287]. To be 
discussed in greater detail below, ER-mitochondria connectivity is upregulated at early stages in AD [96], 
which certainly alters cellular Ca2+ homeostasis. From the data presented here, it is clear that Ca2+ 
dysregulation in AD arises from the convergence of multiple aberrant pathways. 
 The consequences for cellular, and specifically neuronal, functionality are multi-fold. First, and 
directly relevant to MAM-mediated Ca2+ transfer, mitochondria play a major role in buffering cytosolic Ca2+ 
levels by internalizing excess amounts of this ion [288]. While Ca2+ serves as a cofactor for mitochondrial 
metabolic enzymes [pyruvate dehydrogenase (PDH), isocitrate dehydrogenase (IDH) and ⍺-ketoglutarate 
dehydrogenase (⍺KGDH)] and thus drives respiration, excessive intra-mitochondrial Ca2+ can directly 
impair mitochondrial functionality by promoting permeabilization and release of pro-apoptotic factors [288]. 
Another mechanism of Ca2+ toxicity, which is relevant both in the cytosol and in mitochondria, is the ability 
to promote free radical production, which can result in oxidative stress and potent damage to lipids 
constituting membranes [268]. Finally, as neural cells begin degenerating and leaking intracellular Ca2+ into 
the extracellular space, this supports the activation of excitatory NT receptors in neighboring cells to 
propagate excitotoxicity [268]. Indeed, one of the only four FDA-approved drugs for AD is memantine, an 
NMDA receptor antagonist that prevents excitotoxicity. This speaks to the important role of Ca2+-mediated 





Cellular metabolic alterations: glucose and lipids  
Glucose metabolic alterations: As discussed above, Aβ and tau deposits trigger the proliferation 
of glial cells as a mechanism of restoring homeostasis. Indeed, inflammatory signaling and microglial 
activation underlie a major hypothesis for AD etiology. Furthermore, as described in the previous section, 
Ca2+ elevations and excitotoxicity are additional molecular features of the disease. Given the role Ca2+ plays 
in neuronal excitation and as a cofactor for multiple metabolic enzymes, combined with the distinct 
metabolic profile proliferating glial cells adopt (known as the Warburg effect [289]), it is no surprise that AD 
samples display alterations in overall cellular metabolism. Most prominently, this manifests as alterations 
in glucose uptake. PET studies in AD patients using 18-fluorodeoxyglucose (FDG) have revealed 
reductions in brain glucose uptake [290–293], which correlate with a reduced rate of ATP production [294]. 
Furthermore, in a recent study of mitochondrial bioenergetics in a mouse model expressing the most 
common AD risk factor, APOE4, mitochondrial respiration in aged Apoe ε4 allele-expressing mice was 
reduced compared to ε3-expressing homozygotes [295]. Reductions in glucose uptake have also been 
reported in asymptomatic individuals genetically at risk for AD [296–300]. The consistency of this phenotype 
across studies has led some researchers to use reduced glucose utilization, as determined by FDG-PET, 
as a predictive measure of AD risk [301–303].  
A major regulator of cellular glucose uptake is signaling by insulin and insulin-like growth factor 
(IGF), pathways that become disrupted in diabetes. Indeed, AD is sometimes called “type 3 diabetes” 
[304,305] as brain insulin and IGF signaling has been shown to be disrupted at early disease stages to the 
point where brain cells are considered “insulin-resistant” [306]. This could explain reductions in glucose 
uptake by brain cells, similar to the consequences of insulin resistance in peripheral tissues during type-2 
diabetes mellitus (T2DM) [307]. Studies into the mechanism(s) of these phenotypes are limited, but a recent 
report shows that ApoE4 negatively regulates insulin receptor function [308]. Indeed, T2DM as well as 
obesity are known risk factors for AD, with many diabetic patients displaying cognitive symptoms [309–
314]. Conversely, a large proportion of dementia patients also display symptoms of systemic insulin 
resistance [315,316]. Interestingly, intranasal insulin delivery in AD patients recently displayed promising 
results in clinical trials, with improvement of mild cognitive impairment (learning, memory and cognition) 




has also been shown to improve cognitive performance in AD mouse models [319,320] and in a human 
study [321]. This evidence suggests that glucose metabolism is a key aspect of AD pathogenesis, with 
many published reports consistent with expected phenotypes of diabetic conditions.  
 Lipid metabolic alterations: In addition to glucose, lipid metabolic changes are also observable 
in AD at early, asymptomatic stages [322,323]. An especially important lipid species in the brain is 
cholesterol, as 23% of the cholesterol in the body is found in the brain [324], mostly in myelin and 
membranes, where it plays critical roles in cell morphology, axon/dendrite formation, synaptogenesis and 
cell permeability [325]. AD patients display elevations in circulating total cholesterol [326,327], supported 
by a specific elevation in cholesteryl esters (CEs; the uncharged, storage form of cholesterol) in fibroblasts 
[96,328] and brain samples [329] collected from AD patients. The enzyme responsible for the conversion 
of free (membrane-associated) cholesterol (FC) to CE is acyl-coenzyme A: cholesterol acyltransferase 1 
(ACAT1), and both FAD and SAD are characterized by a specific increase in the activity of this enzyme 
[96]. Interestingly, ACAT1 activity has been shown to be involved in, and potentially required for, Aβ 
production [330,331], underlining the intimate link between cholesterol metabolism and AD pathology.  
 Most brain FC in membranes is associated with sphingomyelin (SM). This amphipathic lipid 
electrostatically shields FC’s primarily nonpolar structure from the aqueous outer environment of 
membranes, stabilizing FC [332–334]. Cholesterol esterification and release from membranes is accom-
panied by hydrolysis of neighboring SM [335,336]. Indeed, AD models show reductions in SM levels, and 
AD models and patients display increases in the SM hydrolysis product, ceramide [337–342]. Measurement 
of the specific activity of the enzyme responsible for this reaction, sphingomyelinase (SMase), in AD models 
showed significant increases as well [105], shown to directly correlate with levels of Aβ42 [343,344].  
 To form biological membranes, SM and cholesterol are intercalated in phospholipid bilayers. 
Membrane phospholipids, which comprise ~75% of total lipids in mammalian cells [345], are major 
determinants of membrane structure. The major species is phosphatidylcholine (PtdCho), an uncharged 
phospholipid that is a major reservoir of choline used in neurotransmission, followed by the anionic species, 
phosphatidylethanolamine (PtdEtn), phosphatidylinositol (PtdIns) and phosphatidylserine (PtdSer) [345]. 
Indeed, changes in phospholipid metabolism are also associated with AD, with consistent reductions in 




of PtdCho [64,347,349,350]. Of note, the fatty acid (FA) chains of phospholipids often have independent 
functions that become activated upon their release. This is important because perturbations in FA 
metabolism have also been described in AD. The most abundant FA in the brain is docosahexaenoic acid 
(DHA), critical in brain development and repair following injury. Found predominantly in PtdSer, DHA is 
reduced in AD tissues, potentially relating to cognitive alterations [351,352]. The final lipid class to be 
discussed is gangliosides, which are complex sphingolipids that are critical for the interaction between 
axons and myelin. In AD, total ganglioside levels are reduced [353,354], possibly explaining dementia-
associated deficits in axonal integrity.  
Taking these alterations in all major lipid classes into account, which often occur during pre-
symptomatic stages of the disease, it is probable that altered lipid metabolism is a key component of AD 
etiology, caused by impairment of underlying regulatory pathways. Indeed, as discussed above, multiple 
risk loci for the more common type of AD (SAD) fall within genes involved in lipid metabolism, such as 
ABCA7 (encoding ATP-binding cassette transporter A-7), CLU (encoding clusterin, or apoJ), PICALM 
(encoding PI-binding clathrin assembly protein) and SORL1 (encoding sortilin-related receptor-1). 
Furthermore, hypercholesterolemia is an established risk factor for AD [355,356] and correlates with 
increased Aβ deposition and cognitive dysfunction in mouse models [357–360]. Consistently, increased 
circulating lipoproteins and total cholesterol correlate with cerebral amyloid deposition in humans [361]. 
Cholesterol has even been found in Aβ plaques [362], potentially explaining why lipoprotein receptors such 
as LRP1 are involved in Aβ uptake and clearance [145,363]. This wealth of cholesterol data has led to the 
study of statins (cholesterol synthesis inhibitors) as therapies in AD. Indeed, statin use is associated with 
reduced incidence of AD [364–366] and midlife statin use has been suggested to prevent AD [355,367,368]. 
However, patients who began statin intake after the onset of cognitive deficits did not experience any 
benefits [369–371]. This evidence further supports a substantial dysregulation of lipids during early stages 
of AD pathogenesis. 
 
Mitochondrial dysfunction: the mitochondrial cascade hypothesis 
 Nearly all metabolic pathways in the cell converge at mitochondria, which are responsible for 




powered by reducing equivalents (NADH and FADH2) generated from the oxidation of pyruvate or fatty 
acids. Thus, the alterations in glucose uptake and lipid metabolism described above will certainly affect 
mitochondrial functionality. Indeed, disturbances to mitochondrial homeostasis in AD were first reported 50 
years ago, with the observation of structural abnormalities and reduced oxidative function in postmortem 
AD tissues [372,373]. Numerous follow-up studies in AD mouse models have revealed reduced activity of 
intracellular nutrient metabolic processes. AD mouse models display reductions in the activities of PDH 
(critical for pyruvate entry into the tricarboxylic acid, TCA, cycle) [374], and cytochrome C oxidase (COX,  
the site of oxygen consumption in the electron transport chain) [375,376], as well as in oxygen consumption 
[374] and ATP production [375,377] rates. Concomitant accumulation of reactive oxygen species (ROS), 
leading to oxidative stress, has also been reported [374,375,378]. These phenotypes have been replicated 
clinically in symptomatic AD patients [379–394], confirming their close relationship with AD pathogenesis. 
 It has been found that these functional alterations in mitochondria are accompanied by structural 
changes in AD models and patients. Specifically, mitochondrial dynamics become altered [395,396], with 
fission proteins being upregulated and fusion proteins being downregulated [397–399], resulting in a 
fragmented mitochondrial network [397,398,400,401]. Disturbances in the assembly of respiratory super-
complexes, important for efficient respiratory chain activity [402], have also been observed in AD fibroblasts 
[105]. Finally, axonal trafficking of mitochondria is visibly disrupted (perhaps as a result of tau-mediated MT 
destabilization) [397,398,400], potentially relating to the characteristic deficits in synaptic activity in AD.   
 It is noteworthy that, in AD models, these mitochondrial phenotypes are observable before the 
manifestation of amyloid plaques and behavioral deficits [403]. Indeed, it has been suggested that mito-
chondrial deficits are upstream contributors to these phenotypes. Indeed, APP, Aβ and phospho-tau have 
been reported to localize to mitochondria in AD models and patients [401,404–406], implicating mitochon-
dria in these well-known pathways. These findings underlie the basis of the mitochondrial cascade 
hypothesis of AD etiology, which argues that mitochondrial dysfunction is the primary driver of AD 
[380,407]. This means that either mitochondrial dysfunction is the primary trigger of AD pathogenesis, or 
mitochondrial dysfunction is necessary for the development of the disease [408].  
 Bona fide mitochondrial disorders are characterized by mutations or deletions in the mitochondrial 




been observed in AD tissues [409–414]. Furthermore, multiple studies have shown that COX activity is 
reduced compared to age-matched controls in AD patient platelets, which are enucleated, meaning that the 
mitochondrial genome comprises the entirety of cellular DNA [388,394,415–418]. This suggests that COX 
defects in AD may arise, at least to a significant degree, from alterations in mtDNA. Finally, aside from FAD 
cases arising from generally dominant APP/PSEN1/PSEN2 mutations, AD does not display Mendelian 
inheritance patterns [30]. Epidemiological studies have demonstrated that mothers of AD patients have a 
greater likelihood than fathers of also having dementia [419], and children of mothers with AD display 
reductions in COX activity [420]. Altogether, these studies create a case for mtDNA making critical 
contributions to AD pathogenesis. To test this hypothesis, the field has employed cybrid cell lines, in which 
SH-SY5Y neuroblastoma cells were depleted of their mtDNA (“rho-zero, ⍴0” state) and implanted with AD 
patient platelet mitochondria [421,422]. AD cybrid cell lines display significant reductions in COX activity 
compared to control cybrids [423–426], alongside reductions in glucose utilization [426], oxygen consump-
tion [426] and ATP levels [425,426]. AD cybrid cells also displayed increased mitochondrial fission [427], 
oxidative stress markers [424,428,429] and Aβ [430,431]. COX activity reductions were also observed in 
cybrids generated from MCI (the dementia state that precedes AD) patient mitochondria [426,432,433], 
speaking to contributions of mtDNA to AD phenotypes at early disease stages. In spite of these findings, 
the field has yet to reach consensus regarding which specific features of mtDNA (single-nucleotide poly-
morphisms or haplogroups) increase one’s risk for developing AD. Thus, there is likely more to the story. 
 Mechanisms by which mitochondrial dysfunction can be induced have not been determined for all 
genetic polymorphisms associated with AD. However, pathways have been deduced by which many of 
these polymorphisms can induce Aβ elevations, either through increased production or decreased 
clearance. Interestingly, as mentioned above, multiple publications report mitochondrial localization of APP, 
Aβ and phospho-tau in AD models and patients [401,404–406], underlying the proposed hypothesis that 
Aβ and tau induce cytotoxicity through impairment of mitochondrial function. This idea is supported by data 
showing that mitochondrial localization of these proteins can have multiple consequences for mitochondrial 
homeostasis. Specifically, experiments where cultured cells or isolated mitochondria were treated with 
exogenous Aβ replicated many of the aforementioned mitochondrial phenotypes: reduced COX activity 




and increased fission [442]. This suggests that direct actions of Aβ or tau on mitochondria could also 
account for a significant degree of mitochondrial dysfunction in AD. 
While the results in the studies mentioned just above are indeed compelling and could likely 
represent processes that occur in human AD, it is important to emphasize that a bedrock of the 
mitochondrial cascade hypothesis is that mitochondrial deficits are upstream of Aβ or tau pathogenicity. 
These opposite cause-and-effect relationships are not mutually exclusive; thus, data in support of the latter 
perspective also bear mentioning. First, pharmacological inhibition of respiratory chain function has been 
shown to promote APP processing down the amyloidogenic route versus the non-amyloidogenic pathway 
[443–445], meaning that deficits in respiratory function are capable of promoting Aβ production. Further, 
knockout of the COX10 gene reduced Aβ42 levels [446], implying a regulatory role for mitochondria in Aβ 
production. Similarly, Aβ failed to induce cytotoxicity in ⍴0 cells [447]. Finally, in another model of mtDNA 
depletion, amyloid plaque formation was significantly reduced compared to controls [448], suggesting that 
mitochondria are necessary for an amyloidogenic environment.  
Pitfalls of the mitochondrial cascade hypothesis: In spite of this literature in support of 
mitochondrial dysfunction being a major contributor to AD etiology, there are a number of key studies that 
bring this hypothesis into question. First, mitochondrial dysfunction and oxidative stress are observed in 
many neurodegenerative diseases and metabolic disorders [449,450]. Specifically, deficits in COX activity 
have been observed in neurological disorders that lack Aβ accumulation [451–453], and the AD literature 
itself is inconsistent [454–456]. The literature regarding the specificity of reported mtDNA mutations for AD 
is inconsistent as well [457,458], and robust maternal inheritance patterns (expected for a disease caused 
by mtDNA polymorphisms) are not displayed [459,460]. Of note, the field of bona fide mitochondrial 
disorders (studying those diseases specifically caused by mtDNA abnormalities) has determined a 
threshold for the degree of mitochondrial dysfunction that must be surpassed for a disease to be considered 
a mitochondrial disorder [461,462]. Respiratory deficits in AD do not reach this threshold [455,456], 
eliminating the possibility of AD being a mitochondrial disease. A second arm of this hypothesis is direct 
toxicity of Aβ to mitochondria, bolstered by suggestions that Aβ is imported into mitochondria [463]. 
Recently, substantial doubt has been cast on many of these studies. In many papers, cells were treated 




or genetic models were employed in which Aβ is artificially overproduced, making some of the findings 
arguably artifactual. Furthermore, no group has been able to successfully determine the mechanism by 
which Aβ directly impairs mitochondrial functions. Since mitochondria do not contain the enzymes to 
generate Aβ, the protein needs to be imported into mitochondria, but no mechanism for this has been 
determined. Thus, there are still substantial gaps in the AD-mitochondria field that need to be investigated 
before this hypothesis can be accepted as an explanation for the disease. In spite of this, 17% of the 2173 
initiated AD clinical trials (as of 2019) have targeted the mitochondrial cascade hypothesis [231], including 
inhibitors of Aβ-mitochondria interactions, mitochondrial fission inhibitors, enhancers of mitochondrial 
bioenergetics, antioxidants, and NAD, among others. However, none of these has attained FDA approval. 
It is clear that mitochondria undergo substantial changes throughout the course of AD pathogenesis, but 
we have yet to determine whether these are causes or consequences of the disease.  
 
 Thus far, multiple hypotheses for AD etiology have been discussed. From proteostatic alterations 
characterized by Aβ and tau deposition, to systemic hyperinflammation, to metabolic dysregulation at the 
molecular, organellar and cellular levels, many signaling pathways are implicated in AD pathology. While 
there is compelling evidence for each proposed pathway to be considered a major contributor to AD 
pathology, the respective shortcomings of each hypothesis prevent any from being agreed upon as a 
primary driver of the disease. Criteria for this consideration include appearance at early disease stages, 
consistency across familial and sporadic forms of AD, and ability to explain each of the other phenotypes 
described above. Taking these criteria into account, the literature suggests that upregulated functionality of 
mitochondria-associated ER membranes may be a more consistent, and early, AD phenotype.  
 
Lipid metabolic alterations and upregulated ER-mitochondria connections: the unifying MAM hypothesis 
The most studied protein in the AD field is Aβ, which is observable in higher quantities and/or in 
longer isoforms in AD tissues. As discussed above, the ɣ-secretase complex synthesizes Aβ in lipid rafts 
(LRs) [85,91,466]. Even though LRs were originally thought to be enriched in the PM, ɣ-secretase activity 
is negligible in the PM [96] and, consistent with the discovery of intracellular LRs [467], the presenilins have 




In attempting to determine where ɣ-secretase activity in enriched in the cell, our group discovered that the 
majority of cellular ɣ-secretase activity is carried out in LR subdomains of the ER that are physically and 
functionally tethered to mitochondria [89]. This has been corroborated by other groups and has led to the 
conclusion that Aβ fragments are produced at ER-mitochondria contact sites [469–471].  
 
 
Figure 1-4: Schematic representation of mitochondria-associated ER membranes, from [95]. 
 
These mitochondria-associated ER membranes, or “MAM” domains, form as a result of local 
dynamics in ER membrane lipid composition [472] (Fig. 1-4). In response to cellular lipid metabolic needs, 
MAM formation is initiated by increased delivery of cholesterol to the ER, where the cell’s cholesterol 
regulatory machinery resides. This induces the clustering of SM and saturated phospholipid molecules, 
which together form thicker, more rigid, “liquid-ordered” membrane microdomains. These are known as lipid 
rafts (LRs) [96,473], defined by their resistance to detergent-mediated dissolution. Their formation in the 
ER engages mitochondria through a still-unknown mechanism to promote physical contacts between the 
two organelles. These contacts, while transient, are stabilized through electrostatic interactions as well as 
a number of protein-protein tethering complexes that participate in cargo exchange. In fact, the formation 
of MAM domains is accompanied by the passive segregation of multiple membrane-bound proteins whose 
physical properties render them most stable, and often catalytically active, in LRs. Interestingly, not only do 




In other words, MAM domains regulate cellular lipid metabolism, and form and dissociate based on the lipid 
metabolic needs of the cell. Metabolism of nearly all cellular lipid species can be traced to MAM domains, 
raising the possibility that lipid alterations in AD are a result of MAM dysregulation.   
Indeed, MAM assays in FAD and SAD models have demonstrated consistently upregulated MAM 
functions at early disease stages [96,474], potentially explaining why alterations in lipid metabolism are 
some of the earliest reported events in AD pathology [322,323]. A common initial approach for determining 
MAM levels in a sample is confocal imaging of fluorescently labeled markers of the ER and mitochondria 
[475]. Such experiments have demonstrated increased co-localization of these markers in cellular FAD 
models [476,477], WT cells exposed to oligomeric Aβ [478,479], and FAD and SAD patient fibroblasts [96]. 
Often, the next step is to confirm this through visualization of native structures via electron microscopy. 
Indeed, increased apposition length between the ER and mitochondria has been observed in cellular 
[477,480] and animal [478] FAD models as well as in FAD/SAD patient fibroblasts [96].  
It merits clarifying that MAM is a functional domain, in that proximity and communication between 
the two organelles do not always correlate. In fact, in addition to individual enzymatic activities, most of 
MAM’s notoriety arises from its role in cargo exchange between the two organelles. One of the most 
commonly measured of these activities is the transfer of Ca2+ ions from the ER to mitochondria through a 
complex consisting of the inositol 1,4,5-triphosphate receptor-3 (IP3R3) in the ER, the glucose-regulated 
protein 75 (GRP75) chaperone, and voltage-dependent anion channel-1 (VDAC1) in the mitochondrial 
outer membrane [481]. ER-mitochondria Ca2+ transfer is a physiological process that helps relieve ER Ca2+ 
load, and Ca2+ is a cofactor for key mitochondrial metabolic enzymes. This transfer has been demonstrated 
to be upregulated in AD as well [482].  
While Ca2+ homeostasis is the focus of some AD research groups (discussed above), MAM’s 
quantifiable functions in lipid metabolism and exchange are most relevant to this hypothesis. The first of 
these functions to be described is phospholipid synthesis and transfer, observed by Dr. Jean Vance 30 
years ago to be restricted to subcellular MAM fractions [483]. In addition to de novo synthesis via the 
Kennedy pathway, phospholipids can be synthesized by MAM-resident enzymes. In MAM domains of the 
ER, serine is converted to PtdSer through the action of PtdSer synthase-1 (PSS-1). PtdSer is transferred 




ethanolamine (PtdEtn) through the action of PtdSer decarboxylase (PISD). When crude membrane prepar-
ations from tissue or cellular homogenates are pulsed with radiolabeled serine, the different phospholipid 
species retain the radiolabel. Quantification of labeled PtdSer and PtdEtn is thus indicative of MAM activity 
levels [475,484]. This assay has been published in both FAD and SAD patient fibroblasts, with significant 
increases in radiolabeling of both species indicating upregulation of MAM activity in both forms of AD [96]. 
A second MAM-specific function that can serve as a proxy of overall MAM activity, and is especially 
relevant to AD pathogenesis, is ACAT1-mediated cholesterol esterification [96,475,485]. The majority of 
cellular cholesterol resides in the plasma membrane (PM) and, upon surpassing a concentration threshold, 
traffics to the ER for detoxification in order to prevent severe impairments to membrane functionality 
[333,486,487]. These detoxification pathways are oxidoreductase [cytochrome P450 (CYP) enzymes and 
squalene epoxidase]-mediated conversion to oxysterols, which can be eliminated via passage through the 
BBB due to their greater hydrophilicity, and esterification to CEs via conjugation with a fatty acyl CoA 
[487,488]. These detoxification pathways operate in parallel, are regulated in a cell type-specific manner, 
and are activated by even slight increases in ER cholesterol concentration. Of note, cholesterol ester-
ification in the brain is carried out by ACAT1, the protein and activity of which are enriched in MAM fractions 
[96,485]. Since publication of these findings, cholesterol esterification has emerged as a reliable readout of 
cellular MAM activity levels. This can be measured through radiolabeled substrate tracking, similar to 
phospholipids, or through lipidomics analysis of CEs containing oleate (18:1), the preferred fatty acyl-coA 
substrate of ACAT1 [489–492]. Indeed, upregulated ACAT1 activity has been observed in fibroblasts from 
FAD and SAD patients [96], and specific increases in 18:1 CEs have been reported in human AD samples 
[329]. Following production, CEs are packaged into lipid droplets (LDs) for storage or transport to other 
cells. These cytosolic structures can be identified histologically using uncharged dyes that bind to neutral 
lipid species like CEs that are found in LDs. Indeed, lipid deposition of this sort has also been demonstrated 
in AD, with reports in genetic models [471,493], patient fibroblasts [96,328] and postmortem patient tissues 
[494]. From this evidence, it is can be concluded that upregulated cholesterol metabolism, specifically ester-
ification, is characteristic of both FAD and SAD and, together with upregulated ER-mitochondria physical 





Where AD stands: conclusions and perspectives 
AD is a highly complex chronic disease. With multiple prominent hypotheses, the confounder of 
aging, and silent triggers, it may seem like there is no solution in sight. Pharmaceutical companies are 
abandoning AD at an alarming rate due to lack of profitability, and the few approved drugs are palliative, 
attempting to rescue neurotransmission but acting far from the cause. However, there is substantial reason 
to be hopeful. Research into the molecular pathogenesis of AD is advancing at an alarming rate, aided by 
the advent of -omics technologies, and the past decade has observed considerable shifts in philosophy. 
The prevailing Aβ hypothesis is nearly debunked and lipid metabolism is receiving increased attention by 
the community. Given the wealth of cellular processes that lipids are involved in, much of the existing 
literature is being placed in the context of this new perspective and the potential for these pathways to be 
upstream drivers is emerging. Direct assays of MAM functionality in patient fibroblasts, which display a 
nascent version of what occurs in the brain (likely reminiscent of early disease phenotypes), directly speak 
to this idea. The discovery of MAM domains as a locus of APP processing substantiate this viewpoint. 




Traumatic Brain Injury (TBI) 
Traumatic brain injury (TBI) occurs when sudden trauma by an external force, such as a jolt or a 
blow, damages the brain. The leading cause of death and disability for Americans younger than 45, TBI 
can have multiple causes including falls (most common, especially among the elderly), sports, motor vehicle 
accidents, blasts (common in the military), blunt trauma by an object and assaults. Severity is determined 
by scoring on the Glasgow Coma Scale, which measures eye, verbal and motor responses, conducted 
upon arrival to the emergency room (ER). Most (75-85%) reported TBI cases are on the mild side of the 
severity spectrum, consisting of concussions and blast injuries. According to the CDC, in 2014 2.5 million 
people visited an ER for a TBI, with 56,800 deaths and 80,000 of these patients developing long-term 
disabilities. The annual economic cost of TBI (including relating disabilities) is $76.5 billion, indicating that 
this is a major societal issue (statistics sourced from Brain Trauma Foundation and CDC). 
 
Clinical presentation, treatments and consequences 
Presentation: Neurological TBI symptoms manifest in two phases [495]. In the first (acute) phase, 
which includes the initial hours to weeks following injury, patients can experience confusion, headache, 
memory loss, depression, anxiety, aggression, impulsivity, sensory deficits and/or motor deficits. The extent 
of these symptoms depends on injury severity, quantified using the Glasgow Coma Scale tests along with 
length of loss of consciousness and post-traumatic amnesia. During the acute phase, the brain may suffer 
bruising, a hematoma, hemorrhage, or edema. If the injury was severe (or penetrative), the skull can be 
fractured. In most cases, these acute symptoms will subside and the patient will recover. In some cases, 
especially patients with a history of multiple TBIs (such as athletes who have had multiple concussions or 
military personnel who have been exposed to multiple explosions), symptoms of neurodegeneration can 
manifest years to decades later, constituting the second phase. This is discussed in greater detail below. 
Treatment: Because humans can experience TBI in a variety of forms, it is difficult to institute a 
standard of care apart from treating individual symptoms. For mild cases (comprising the majority of TBI 
cases), it is recommended to rest, avoid activities that require intense concentration (such as reading and 
computer work), and stop doing the activity that caused the injury. In order to assess whether there is 




damage does occur, personalized rehabilitation therapy to regain lost (or gain new) skills is common. This 
can include physical therapy, occupational therapy, speech therapy, cognitive therapy, psychological 
counseling and vocational counseling. In terms of pharmacological treatments, no drugs are directly 
indicated for TBI. However, off-label use of some drugs has been effective in clinical trials and published 
reports, such as amantadine [496], a dopaminergic medication aimed at promoting dopaminergic neuron 
function, as well as the AD drugs, donepezil and memantine [497]. Furthermore, psychiatric medications 
like anxiolytics, antidepressants, stimulants and anti-convulsants are prescribed as necessary to treat the 
respective symptoms, as are anticoagulants to promote blood flow and diuretics to help relieve elevations 
in intracranial pressure. The development of effective therapies to attenuate the secondary sequelae of 
TBI, with the goal of preventing neurodegeneration, is an active area of research that is being bolstered by 
ongoing clinical trials and exploration of off-label uses of existing drugs. 
Clinical consequences: A history of repeated TBI can lead to permanent neurological impairment. 
This was first described in 1927 as “traumatic encephalitis” in concussion patients with sustained symptoms 
[498]. The following year, the term “punch drunk” was coined to describe clumsiness, ataxia and dis-
orientation in professional boxers, with Parkinsonism in severe cases [499,500]. Within a decade, this term 
got revised to the more technical “dementia pugilistica” [501] and, in 1959, the term “chronic post-traumatic 
encephalopathy” began to describe TBI symptoms regardless of cause [502]. Today, lasting TBI symptoms 
are often referred to as “chronic traumatic encephalopathy” (CTE) [503,504], a term that has received 
significant attention by both scientific communities and mainstream media. It is estimated that as many as 
65% of moderate to severe TBI patients develop long-term impairments in cognitive functioning [505].  
CTE encompasses the most common neurological sequelae observed in patients with a history of 
repeated head trauma [495,504]. This includes football players, boxers and military veterans, as well as 
athletes in other high-contact sports. The initial symptoms of CTE are concentration and memory deficits 
alongside disorientation and poor judgement. In severe and advanced cases, patients can also display 
movement, speech and hearing difficulties, as well as tremors and psychotic symptoms. It is important to 
emphasize that, like many neurodegenerative diseases, the field has not agreed upon any reliable 
biomarkers; therefore, CTE can only be definitively diagnosed post-mortem based on histopathological 




pathological features include reduction in brain weight, enlargement of ventricles, and thinning of the corpus 
callosum. The molecular features include neuronal loss and gliosis, as well as tau deposition (as neuro-
fibrillary tangles) in superficial cortical layers. Aβ deposition is also observable but is inconsistent. Based 
on these criteria, 51 cases of confirmed CTE in patients with a history of repeated head trauma have been 
described in the literature, with 90% occurring in athletes [507]. As the neuropathological features indicate, 
there are multiple similarities between CTE pathology and pathologies of defined neurodegenerative 
diseases such as AD, PD, ALS and FTD [508]. Additionally, the described molecular features are not 
present in all cases, with substantial variability that mirrors the heterogeneity of human TBI. Thus, while a 
diagnosis of CTE does sufficiently describe behavioral and histological phenotypes in many patients with a 
history of repeated TBI, some studies indicate that a minority of these cases result in bona fide CTE [507]. 
It can thus be concluded that this chronic syndrome does not explain the entirety of TBI pathogenesis.  
Indeed, epidemiological studies have revealed that TBI can result in the development of the 
aforementioned neurodegenerative diseases [508]. The most common of these is AD, particularly relevant 
to this work. In addition to the cognitive and histopathological similarities described above, multiple 
epidemiological studies have associated TBI with an increased risk of AD [509]. Indeed, a recent systematic 
review that included studies examining both single and repeated TBI events of varying severities calculated 
that TBI significantly increases risk for AD by 51% (relative risk of 1.51, 95% confidence interval of 1.26-
1.80) [52]. While this is encouraging for research into the TBI-AD connection, it merits mentioning that these 
studies largely diagnose AD on the basis of histopathological AD hallmarks (i.e., Aβ and tau), which are 
inconsistent AD features as discussed in previous sections. Indeed, the ability of TBI to increase AD risk 
has been disputed [510], suggesting that the design of these studies may need to be revised. Nonetheless, 
it is undeniable that TBI can result in sustained neurological impairment, but we do not yet understand what 
factors determine which disease develops, and why some patients are spared and not others. These 
questions and relevant molecular mechanisms are an active area of research in the TBI field. 
 
Experimental models 
Developing effective therapies requires an understanding of the molecular pathways activated 




mortem. Multiple models have been developed for rodents, larger mammals and flies [511,512], but no 
model can recapitulate the heterogeneity of human TBI, and thus results need interpreted as such. Many 
of these models penetrate the skull to create a severe injury even though the majority of human TBI is mild 
(i.e., non-penetrative). This is necessary because damage to the brain after human TBI usually manifests 
as minor behavioral deficits that are difficult to detect in animals. Thus, in order to generate a phenotype 
that is assayable under reasonable experimental conditions, a relatively severe injury needs to be 
performed even if clinically irrelevant. Nonetheless, these models are accepted because they recapitulate 
the alterations in histopathology (Aβ/tau accumulation, cell morphology and loss, inflammation), behavior 
(motor/sensory/cognitive functions), metabolism (mitochondrial/glucose/lipid metabolism) and structure 
(gray/white matter damage, ventricular enlargement, edema) characteristic of human TBI.  
Rodents are most commonly used because they are easier to acquire and house than larger 
animals and better mimic human head injury than flies. One of the most common models is controlled 
cortical impact (CCI, employed in the studies of Chapter 4) [513], originally developed by General Motors 
in 1989 to model head injuries from car accidents [514]. During a CCI surgery, an animal is anesthetized 
and secured in a stereotaxic frame. Following an incision on the top of the head, a craniectomy is performed 
to expose the cortical dura mater. An electromagnetic or pneumatic piston (rod) is then accelerated to 
directly impact the exposed brain from above. Animals are sacrificed anywhere from hours to months after 
injury in CCI studies, depending on the question at hand. The primary advantage of this model is the ease 
with which impact depth and velocity, and dwell time of the impactor in the brain (on the scale of 
milliseconds), can be controlled. This allows for substantial reproducibility but plays out as a double-edged 
sword, as this “freedom” in injury design has precluded the establishment of standardized parameters for 
different injury severities. Another limitation of CCI is the lack of diffuse phenotypes (e.g., diffuse axonal 
injury, DAI) due to the highly focal nature of the impact. This is important because, in most human TBI 
cases (concussions and blasts), most of the brain is directly impacted. Thus, in studies where more 
widespread phenotypes are of interest, another animal model may be more appropriate. One of these is 
the weight drop model, in which an accelerating weight of variable mass and shape is dropped onto the 
exposed skull (with or without craniotomy) from a variable height [515]. This model reproduces DAI but 




in which a pendulum is used to strike a reservoir of fluid that rapidly injects a fluid pulse into the epidural 
space (below the skull) [516]. The phenotype is not as diffuse as weight drop but is more diffuse than CCI, 
and the location of the injury can be modulated. The final animal model to be discussed here is blast TBI, 
which can be applied in an open field or via a blast tube [517]. This model is especially applicable to studies 
pertaining to military populations and is characterized by the recapitulation of blast waves experienced 
during combat, as well as of DAI. These models and others are depicted in Fig. 1-5. 
 
 
Figure 1-5: Rodent models of traumatic brain injury (from [511]). 
A, fluid percussion injury. B, controlled cortical impact. C, penetrating ballistic-like brain injury.  




These in vivo models are invaluable in understanding the molecular presentation of brain injury, 
and the potential of any drugs to modulate these phenotypes. However, these models arguably possess 
limited capability to generate mechanistic information about drivers of the activated pathways, and how 
physical injury to the brain leads to these phenomena. This is where in vitro TBI models can be applied, in 
which a physical strain is applied to a tissue isolate or cultured cells [518]. In these systems, specific genes 
and proteins can be more easily targeted in order to determine their contribution to observed pathologies. 
Furthermore, the responses of individual cell types can be assessed without confounding influences from 
other cell types or the circulation; however, this absence of natural environment is also a limitation and 
needs to be taken into account. Samples often used in these models are fresh explants of CNS tissue (brain 
slices or organotypic cultures) or cultured cells. These can be maintained on culture dishes, specialized 
chambers or mesh-like systems, and subjected to physical insults like transection (to model axotomy), 
compression, stretching, or hydrostatic pressure. Through these models, it is possible to gain improved 
insight into molecular mechanisms of TBI pathologies without sacrificing multiple animals; however, these 
results are best used in complementation with in vivo experiments rather than as replacements.  
 
Molecular features of TBI: hypotheses and evidence 
One of the primary goals of TBI research is to prevent the development of neurodegenerative 
disease. This inherently requires an understanding of the molecular mechanisms responsible for TBI 
pathology. Most studies in the TBI field are in in vivo models, making mechanistic studies (e.g., knocking 
down a gene, modulating a specific cell type, expressing a fluorescently-tagged protein, etc.) challenging. 
As a result, much of this information is lacking in the field and is largely hypothesized. Nonetheless, these 
ideas are driven by a multitude of existing reports examining aspects such as energy metabolism, oxidative 
stress, lipid homeostasis and proteostatic alterations after TBI. These studies will be discussed here. 
A cornerstone of this literature is the biphasic nature of TBI pathogenesis [519]. The primary phase 
consists of the mechanical damage incurred by the brain at the time of injury. Stretching and twisting of 
axons results in axonal rupture, damage to blood vessels, loss of nutrient supply, and necrotic cell death. 
Typically, areas where this damage is most severe appear as gross contusions with obvious tissue lesioning 




as soon as minutes after injury and lasting for variable periods of time. Here, unregulated release of 
neurotransmitters (NTs) and other cellular components propagates the injury and has detrimental effects 
on cellular homeostasis. Metabolic and inflammatory pathways are especially affected and can lead to 
apoptotic cell death [520,521]. It is in this phase that neurodegeneration can be initiated.  
 
Cardinal AD features after TBI: APP fragments and tau 
As discussed extensively in the previous section, AD is defined by the deposition extracellular Aβ 
plaques and intracellular hyperphosphorylated tau tangles. While these features are by no means 
consistent across AD cases, nor are they necessary for AD development, their appearance after TBI has 
been the subject of multiple studies. Indeed, deposition of Aβ and tau can be observed in humans after TBI 
[522–524] (Fig. 1-6). However, this phenotype is not consistent and in some studies is present in a minority 
of postmortem tissues [525–527]. Interestingly, similar to AD [187–193], elevations of C99 in TBI have also 
been reported [528,529]. This has been related to elevated expression of APP and BACE1, the starting 
materials for C99 production, in damaged brain areas after injury [524,528,530–533]. Of note, C99 has 
been demonstrated to correlate more strongly with brain damage than Aβ does [187,193,201,534], 
suggesting an early role of C99 in TBI pathology. Through these studies, we have learned that APP 
processing and tau deposition represents points of convergence between TBI and AD pathologies, and 
may relate to the pathogenic mechanism by which head trauma leads to dementia.   
 
Figure 1-6: Aβ and tau deposition in post-mortem TBI patient tissues. 
Aβ plaques are visible as large black clusters (from [522]). Tau deposits are visible as brown staining, with 




Inflammatory signaling after TBI 
Similar to AD, another proposed primary driver of TBI-induced neurodegeneration is neuro-
inflammation. Cellular debris and pro-inflammatory cytokines released at the time of injury trigger the brain’s 
innate immune response [521]. This is characterized by proliferation of microglia and astrocytes, attempting 
to clear molecular lesions and eliminate the injury. In fact, astrocytes participate in clearance of glutamate 
from synapses to help allay excitotoxicity [535] and secrete inflammatory mediators like cytokines and 
chemokines similar to microglia [536]. An entire AD subfield considers AD an inflammatory disorder, 
underlying a strong link between the two diseases. While the contribution of these pathways to the disease 
under discussion is certainly strong and relevant, the remainder of this section will focus on metabolic 
hypotheses for TBI-induced AD, which are most relevant to the findings presented in this thesis.  
 
Excitotoxic cascades and calcium homeostasis 
A well-established TBI pathology that is consistently observed among different animal models is 
excitotoxicity, which is triggered upon cellular shearing [519]. This induces the unregulated release of many 
intracellular contents, including excitatory NTs like glutamate and aspartate [537,538]. These can over-
activate their respective receptors and coupled Na+/Ca2+ channels in nearby neurons, not only propagating 
the injury but also causing a sharp increase in intracellular Ca2+ [539]. This is extremely toxic for the cell, 
as Ca2+-dependent enzymes (including proteases) will become overactivated and induce stress while intra-
cellular systems in place to buffer cytosolic Ca2+ (like the ER and mitochondrial Ca2+ transporters) will also 
exceed capacity. In mitochondria, this manifests as swelling, membrane permeabilization and release of 
apoptosis-inducing proteins [540]. Elevated intra-mitochondrial Ca2+ can also induce formation of reactive 
oxygen species (ROS), which can cause profound oxidative damage to cellular DNA, lipids and proteins 
and disrupt relevant signaling pathways [541–543]. As activity through this excitatory NT-Ca2+ axis 
continues, the cell enters a state of “excitotoxicity” during which apoptotic pathways outcompete recovery 
mechanisms. In many cases, such as after a single mild injury, this balance can be restored and most cells 
will recover. Clinically, this will present as a recovery of cognitive symptoms and return to normal life. In 
contrast, in cases of repeated mild injuries or a single severe injury, it is likely that cells will be deprived of 




possibly reaching a higher peak than before, or the cascade induced by the severe injury will escalate to a 
point of no return. These are the cases that lead to neurodegenerative disease. 
 
Cellular metabolic alterations: glucose and lipids 
Glucose metabolic alterations: Metabolomics studies have been especially valuable in 
understanding the effect of TBI on energy metabolism in the brain. In support of the mitochondria literature, 
decreased ATP levels have been reported in multiple experimental TBI models [544,545]. This is consistent 
with observed impairments in mitochondrial respiration (further discussed below). However, glucose uptake 
is elevated after TBI (often termed glucose “hypermetabolism”), in contrast to AD clinical studies. Glycolytic 
flux is also increased, as measured by glycolytic gene expression and enzyme activities as well as lactate 
levels [544,546–553]. One possible contributor to this is the increase in extracellular glutamate levels 
characteristic of TBI, as discussed above. It has been shown that astrocyte end-feet uptake excess 
glutamate in the synaptic cleft to help allay neuronal overexcitation. Glutamate uptake by astrocytes 
stimulates activity of hexokinase, the first enzyme of glycolysis, to promote glycolytic flux and lactate 
production [554–556]. Through a process known as the astrocyte-neuron lactate shuttle, astrocytes export 
lactate to neurons, which can convert the lactate to pyruvate for oxidation and ATP production [557].  
Interestingly, there have been reports of reduced expression of pyruvate dehydrogenase (PDH) 
complex components after TBI. PDH is responsible for the conversion of pyruvate to acetyl-coA, which 
enters the TCA cycle. Thus, existing TBI literature appears to suggest that, while the brain is still oxidizing 
glucose, it is being routed away from the TCA cycle and the electron transport chain. This metabolic rewiring 
could be explained by the known development of hypoxic conditions after brain injury [558]. The primary 
insult during TBI is crushing of tissue, which not only damages cells but also the blood vessels that supply 
essential nutrients like oxygen. This means that injured cells would enter a hypoxic state, characterized by 
an upregulation of glycolysis and downregulation of mitochondrial pyruvate oxidation. This is not only due 
to reduced availability of oxygen as a terminal electron acceptor in the respiratory chain, but also because 
glycolysis is a more efficient ATP source than mitochondria are (as described by the Warburg effect [289]). 
Related to this, there are also indications of elevated pentose phosphate pathway (PPP) activity [559], 




of cellular stress (like hypoxia) and repair because the PPP generates many NADPH reducing equivalents 
that are critical for anabolic reactions like FA, nucleic acid and aromatic amino acid synthesis. NADPH also 
enables glutathione reduction, a counterbalancing mechanism for oxidative stress [560]. In conclusion, 
while it may appear that changes in glucose metabolism are an aspect of pathology, it is likely that these 
aforementioned alterations speak to repair mechanisms activated by brain cells after injury. 
Lipid metabolic alterations: It would be remiss to discuss cellular repair mechanisms after injury 
without reviewing the fundamental role lipids play in this process. In cells directly impacted by injury, the 
first insult they experience is shearing of the plasma membrane (PM). The major structural unit of 
membranes is lipids, which determine membrane curvature and permeability and also stabilize embedded 
proteins. It is thus no surprise that significant alterations in lipid homeostasis have been reported after TBI. 
To begin, injury stimulates cholesterol trafficking activities. 18:1 CEs and lipid droplets are elevated along 
with expression of the low-density lipoprotein (LDL) receptor (LDLR) and ATP-binding cassette transporter 
A1 (ABCA1), another cholesterol transporter [561–566]. Indeed, lipoprotein delivery to axons has been 
demonstrated as critical for axon regeneration [561,567]. Consistent with this, SMase activity is 
concomitantly upregulated [566], proposed to be a result of excitatory NT release. As a consequence, and 
also due to upregulated de novo synthesis, ceramide levels are elevated and, if not rescued, can be potently 
toxic [566,568–570]. Finally, multiple studies have demonstrated increased activity of phospholipases, 
which hydrolyze phospholipids to release phosphatidic acid (PA) and FAs [571–574]. PA serves as a 
precursor for phospholipids involved in membrane reconstruction, and FAs have implications for cellular 
signaling, synthesis of other lipid species, and inflammatory responses. Thus, similar to AD, TBI stimulates 
lipid trafficking and metabolic activities, many of which mirror those observed in AD tissues.  
 
Mitochondrial dysfunction after TBI 
Many of these affected glucose and lipid metabolic pathways undergo regulation by mitochondria, 
which also buffer cellular excitotoxic cascades. Thus, extensive research has been performed examining 
the effect of brain injury on mitochondrial respiratory parameters in both animal models and human tissues. 
These studies have assayed different injury types, severities and post-injury time-points. A paradigm has 




time- and injury severity-dependent manner [575]. Specifically, respiration through complex I (C-I; which is 
responsive to pyruvate oxidation) can be depressed for up to 24h after TBI, and sometimes longer [576–
579]. There are also indications that respiration through C-II (responsive to FA oxidation) is slightly elevated 
[579,580]. This potentially relates to reported reductions in PDH activity and hypoxic conditions, which 
would reduce mitochondrial pyruvate oxidation and increase reliance on FAs. However, due to the lack of 
standardization of injury parameters and study design across TBI experimental models, this literature is not 
consistent. Thus, the effects of TBI on mitochondrial functionality merit further study.  
 
Where TBI stands: conclusions and perspectives 
TBI and AD are both challenging fields but for different reasons: the AD field is unable to reach 
consensus as to the causative molecular pathway, and TBI’s heterogeneous nature prevents any cause 
from being confidently proposed. The literature regarding TBI’s molecular features is plentiful and spans 
decades but, outside of the excitotoxic cascade, fails to delineate a logical pathway nature would activate 
following physical damage to the brain. Such a pathway would need to be protective when activated to a 
moderate degree (i.e., after a single mild injury), reversible (i.e., in the absence of a second injury), and 
toxic when activated to a severe degree (i.e., after multiple mild injuries or fewer severe injuries). Our lack 
of knowledge in this area underlies a principal gap in the TBI field, necessitating increased research into 
early molecular mechanisms of brain injury. In a hypothesis that is the subject of Chapter 4, we propose 
that MAM functionality is activated upon brain injury to promote lipid synthesis for repair of damaged cellular 
membranes. This is supported by existing literature in the TBI field (discussed in Chapter 4), as well as our 
studies in AD that show that upregulated MAM functionality is an early feature of AD. While activation of 
many pathways can be tested in in vivo TBI models, emerging in vitro models will be especially key to 
validate the mechanistic roles of these pathways in TBI pathogenesis. Through this research, we can 





Chapter 2: Accumulation of C99 at MAM domains upregulates MAM 
functionality in AD 
 
This chapter has been published in its entirety in The EMBO Journal (Pera et al, 2017, DOI: 
10.15252/embj.201796797). I am a co-author on this paper. I helped optimize the C99 western blot protocol. 
This experiment is highly technically challenging because C99 is membrane-bound, has a small molecular 
weight, and is present at a much lower abundance than C83, which has almost the same molecular weight. 
Additionally, C99 and C83 have many residues in common I thus helped conduct the experiments depicted 
in Figs. 2-2B/C, 2-8F/G and the response to reviewers (not included). I also helped conduct the 
sphingomyelinase (SMase) assays depicted in Figs. 2-4D/E and 2-11B. This work is included in this thesis 
because it demonstrates a concept that is foundational for the TBI studies: that increased localization of 
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 In the amyloidogenic pathway associated with Alzheimer disease (AD), the amyloid precursor 
protein (APP) is cleaved by β-secretase to generate a 99-aa C-terminal fragment (C99) that is then cleaved 
by ɣ-secretase to generate the β-amyloid (Aβ) found in senile plaques. In previous reports, we and others 
have shown that ɣ-secretase activity is enriched in mitochondria-associated endoplasmic reticulum (ER) 
membranes (MAM), and that ER-mitochondrial connectivity and MAM function are upregulated in AD. We 
now show that C99, in addition to its localization in endosomes, can also be found in MAM, where it is 
normally processed rapidly by ɣ-secretase. In cell models of AD, however, the concentration of 
unprocessed C99 increases in MAM regions, resulting in elevated sphingolipid turnover and an altered lipid 
composition of both MAM and mitochondrial membranes. In turn, this change in mitochondrial membrane 
composition interferes with the proper assembly and activity of mitochondrial respiratory supercomplexes, 





Familial AD (FAD) is characterized by mutations in presenilin-1 (PS1), presenilin-2 (PS2), and APP. 
APP is first cleaved by either α-secretase or β-secretase (BACE1) to produce C-terminal fragments (CTFs) 
83 aa (C83) or 99 aa (C99) long, respectively. PS1 and PS2 are the catalytic subunits of the γ-secretase 
complex that cleaves C83 and C99 to produce either p3 or β-amyloid (Aβ; ~40 aa), respectively, along with 
the APP intracellular domain (AICD). The accumulation of Aβ , and especially its longer forms (e.g., ~42 
aa), within plaques, together with Tau tangles, are the neuropathological hallmarks of AD. The deleterious 
effects of Aβ deposition during the symptomatic stages of AD are undeniable [581], but the role of Aβ in 
earlier phases of the disease is still debated. 
 During these early stages, AD cells exhibit alterations in numerous metabolic processes [403,582]. 
Among these, perturbed mitochondrial function, including reduced respiratory chain activity and ATP pro-
duction, and increased oxidative stress [438] have been described extensively [583], occurring before the 
appearance of plaques [374,403]. Nevertheless, the cause of mitochondrial deficits in AD is still unknown.  
 In addition to mitochondrial dysfunction, alterations in lipid metabolism are another feature of AD 
[584], but their origin and relationship to APP metabolism are unclear. Among these alterations, abnormal 
sphingolipid metabolism has been reported in AD tissues [585]. Specifically, there is upregulated de novo 
ceramide synthesis [586] and activity of sphingomyelinase (SMase), which catabolizes sphingomyelin (SM) 
into ceramide [340]. These alterations act synergistically to increase ceramide content in AD brains [340]. 
 As these metabolic alterations occur early in AD, they cannot be explained by the accumulation of 
plaques or tangles. Moreover, unsuccessful efforts directed towards modifying Aβ production as a treatment 
for AD [587] have raised the possibility that other aspects of APP cleavage may be contributing to these 
metabolic changes. In this regard, increased levels of the C99 fragment have also been shown to contribute 
to AD pathogenesis [187,200], suggesting a role for C99 in the early stages of pathogenesis. 
 The processing of APP occurs in lipid raft domains (LRs) [588], which are membrane regions 
enriched in cholesterol and sphingolipids [589]. While most of these domains are found in the plasma 
membrane, intracellular LRs have also been described [467]. One of these intracellular LRs is called 
mitochondria-associated ER membranes (MAM), a functional subdomain of the ER located in close 




 We and others have shown that the presenilins and γ-secretase activity localize to MAM 
[89,469,470]. Moreover, MAM functionality [96] and ER-mitochondria apposition [96,478] are increased in 
AD. We now report that the concentration of unprocessed C99 at MAM is increased in cell and animal 
models of AD and in AD patient cells. This increase in MAM-localized C99 is associated with the activation 
of sphingolipid synthesis and hydrolysis, and with a subsequent increase in ceramide levels (a feature ob-
served in AD [338,339], particularly in mitochondrial membranes [590]). Finally, we show that these higher 
levels of ceramide in mitochondria cause reduced respiratory chain activity. We propose that a critical 




Materials and Methods 
Cells, animals, and reagents: AD and control cell lines were obtained from the Coriell Institute for 
Medical Research (Camden, NJ). SH-SY5Y, and COS-7 cells were obtained from the American Type 
Culture Collection. Other PS1-mutant FAD cells were the kind gift of Dr. Gary E. Gibson (Cornell University). 
WT, PS1-KO, PS2-KO, and PS1/2-DKO (called PS-DKO) mouse MEFs were provided by Dr. Bart De 
Strooper (University of Leuven). APP/APLP2-KO (called APP-DKO) [591] and PS1-KIM146V knock-in mice 
[271] were generated as described. All experiments were performed according to a protocol approved by 
the Institutional Animal Care and Use Committee of the Columbia University Medical Center and were 
consistent with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice 
were housed and bred according to international standard conditions, with a 12-h light, 12-h dark cycle, and 
sacrificed at 3, 5, 7, 8, and 12 months of age. Brains were removed and homogenized for Western blot and 
Seahorse analysis. All the experiments were performed on at least three mice per group. 
We used antibodies to ACAT1 (Abcam, ab39327), APP C-terminal (Sigma; A8717, polyclonal), 
APP-C99 (Covance; SIG-39320-200 [6E10], monoclonal), the α-subunit of mitochondrial ATP synthase 
(complex V) (Invitrogen; 459240), the α-subunit of ATPase (Abcam, ab7671),  BACE1 (Cell Signaling; 
D10E5), CANX (Chemicon, MAB3126), complex I subunit NDUFA9 (Abcam; ab14713), complex III subunit 
core-1-ubiquinol-cytochrome c reductase (Abcam; ab110252), OxPhos complex IV subunit IV (COX IV) 
(Abcam; ab14744), Ergic53/p58 (Sigma; E1031), Erlin-2 (Cell Signaling; 2959), ERp72 (Cell Signaling, 
D70D12), FACL4 (Abgent, AP2536b), GM130 (BD Transduction Laboratories, 610822), Lamp2 (Novus 
biologicals; NBP1-71692), Na+/K+ ATPase (Abcam, ab7671), PEMT (a gift of Joan Vance, University of 
Alberta), Presenilin 1 (Calbiochem; PC267; NOVUS biologicals; EP1998Y), Rab5a (NOVUS Biologicals; 
NBP1-58880), Rab7a (Novus Biologicals; NBP1-87174), nSMase (Thermo Scientific; PA5-24614), total 
OXPHOS mouse cocktail (Abcam, ab110413), TOM20 (Santa Cruz; sc-11415), β-tubulin (Sigma; T4026), 
vinculin (Sigma, V4505) and VDAC1 (Abcam; 34726). Thin layer chromatography (TLC) silica plates were 
from EMD Biosciences (5748-7). Ceramide (22244), sphingomyelin (S0756), cholesteryl palmitate (C6072), 
cholesteryl oleate (C9253), lipid markers for TLC (P3817), α-secretase inhibitor TAPI-1 (SML0739), 
cytochrome c from horse heart (C2506), 3, 3’- diaminobenzidine tetrahydrochloride hydrate (D5637), 




(D5942), antimycin A (A8674), FCCP (carbonyl-cyanide p-(trifluoromethoxy)phenylhydrazone) (C2920), 
NADH Grade II, disodium salt (Roche; 10128023001), nitro blue tetrazolium (N5514-25TA1), oligomycin 
(O4876), rotenone (R8875), imatinib mesylate (Gleevecâ, SML1027) and serine palmitoyltransferase 
inhibitor myriocin (M1177) were from Sigma. Fluorescent lipids BODIPY-FL C6 ceramide complexed to 
BSA (N22651) and BODIPY-FL C12-sphingomyelin (D7711) were from Invitrogen. Radiolabeled 3H-serine 
and 3H-cholesterol were from Perkin Elmer; fatty acid-free bovine serum albumin (FAF-BSA) was from MP 
Biomedical (820472). Amyloid β peptides 40-aa and 42-aa were from Biopolymer Laboratory (UCLA) and 
APP intracellular domain (AICD) peptide was from Genescript Corporation (Piscataway, NJ). 
Seahorse analysis: Respirometry of cultured cells was performed using the XF24e Extracellular 
Flux Analyzer (Seahorse Bioscience). Oxygen consumption was measured in basal conditions (Seahorse 
media with 25 mM glucose and 2 mM pyruvate) and after the sequential addition of 1 μM oligomycin 
(complex V inhibitor), 0.75 μM FCCP (uncoupler) and 1 μM rotenone/1 μM antimycin A (complex I and 
complex III inhibitors respectively). All results were averages of ≥5 biological replicates, each consisting of 
three technical replicates. For each technical replicate, we plated an equal number of cells (25,000 cells/well 
for MEFs, and 50,000 cells/well for human primary fibroblasts). The number of cells was also counted after 
every respirometry assay to correct for cell death. All oxygen consumption (OCR) data were normalized by 
the number of viable cells, or by protein quantity when isolated mitochondria were used. 
 For permeabilization assays, the cell culture medium was replaced by the mitochondrial assay 
solution (70 mM sucrose, 220 mM mannitol, 5 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA and 
0.2% FAF-BSA, pH 7.4) containing 10 nM of the XF Plasma membrane permeabilizer reagent XF PMP 
(Seahorse Bioscience 102504-100) and pyruvate/malate (for complex I assays) or succinate/rotenone (for 
complex II assays). Oxygen consumption was measured at States 2, 3, 4, and uncoupling after sequential 
addition of 3 mM ADP, 4 µM oligomycin, 6 µM FCCP and 4.5 µM Antimycin A. 
 To analyze mitochondrial respiration in mouse tissues, mitochondria were isolated from WT and 
PS1-KIM146V mouse brain. Mouse brains were homogenized in ~10 volumes homogenization buffer (210 
mM mannitol, 70 mM sucrose, 5 mM HEPES and 1 mM EGTA) and centrifuged at 900xg for 10 min at 4°C. 
The remaining supernatant was centrifuged at 9000xg for 10 min at 4°C and the resulting pellets were 




FAF-BSA, pH 7.2) and centrifuged again at 8000xg for 10 min at 4°C. The pellets, containing mitochondria, 
were resuspended in mitochondrial assay solution and protein was quantified using the BCA Protein Assay 
kit (Thermo Scientific 23227). For C-I experiments, 8 µg of protein were added to each well and 6 µg for C-
II analysis. Analyses in the Seahorse analyzer were performed as described in the permeabilization assays.  
Culture of primary mouse cortical neurons: Cortexes from four 14-day-old embryos were 
minced and washed in 45% glucose in PBS. The tissues were resuspended in 1 ml trypsin diluted in 45% 
glucose in PBS (1:1 v/v) and incubated at 37°C for 20 min. Samples were added to 500 µl horse serum and 
10 units of DNase and incubated for 10 min at room temperature until debris sank to the bottom of the 
tubes. The non-debris fraction was pelleted at 800 x g for 10 min and resuspended in Neurobasal Medium 
(Life Technologies; 21103-049) supplemented with 200 mM glutamine. Cells were counted and seeded on 
coverslips coated with poly-ornithine and laminin. 
Plasmid constructs and transfections: Plasmids were constructed using standard techniques. 
In brief, APP fragments AICD, and C99 were amplified from pCAX APP-695 [57], using forward primer 5’-
cccgctagcctcgagATGCTGAAGAAGAAA-CAGTACACATCCATTC-3’ for AICD, and 5’-cccggatccATGGAT-
GCAGAATTCCGACATGACTC-3’ for C99, with a single reverse primer 5’-cccggatccaagcttCTAGTTCTGC-
ATCTGCTCAAAGAACTTG-3’ for both; restriction sites for subcloning are underlined and the start/stop 
codons are in bold. The PCR products were cut with XhoI+BamHI (for AICD) or with BamHI (for C99) and 
subcloned into the corresponding sites in pGFP-N3 (Clontech). Plasmid C99-GFP was kind gift of Dr. Albert 
Lleo. For the construction of this plasmid, C99 amplified from APP770 GFP using Forward primer_(Scott): 
(HindIII)   5’ gcaagcttgcagaattccgacatgact-cagga 3’ and reverse primer cw mini LRP 3’ (psectag 2B mini 
LRP GFP primers). The fragment was subcloned into psectag 2B with HindII/Not1. All plasmids were 
verified by restriction analysis and sequencing. Cells were transfected using Lipofectamine™ Transfection 
Reagent (Thermo Fisher Scientific, Life Technologies) according to the manufacturer’s instructions. 
Subcellular fractionation and Western blotting: Purification of ER, MAM, and mitochondria was 
performed and analyzed as described [89]. 
Electron microscopy: Samples were fixed in 2.5% glutaraldehyde in 0.1 M Na-cacodylate buffer, 
enrobed in 4% gelatin, post-fixed with 1% osmium tetroxide (aq) followed by 2% uranyl acetate, dehydrated 




Ultrathin sections were cut onto nickel grids with Leica Ultracut UCT (Leica Microsystems, Wetzlar, Germany). 
Antigen Retrieval Immunolabeling: Sections were etched with saturated sodium metaperiodate for 
1 hour, washed with PBS, blocked with 1% BSA and incubated with primary antibody overnight at 4°. The next 
day, they were washed and then incubated in 6 nm goat anti-rabbit gold (Aurion, NL), for two hours at room 
temperature.  Sections were counter-stained with uranyl acetate and viewed on a JEOL JEM-1400Plus 
transmission electron microscope at 120 kv. 
Inhibition of a-, β- and γ-secretase activity: To inhibit γ-secretase activity, cells were treated with 
10 μM DAPT, a highly specific inhibitor of this enzyme complex. For β-secretase inhibition, cells were 
treated with 100 nM β-secretase inhibitor IV (BI) or different doses of imatinib lysate (Gleevec). To inhibit 
a-secretase, cells were treated with 5 μM of TAPI-2 (Enzo Life Sciences). Inhibition of aSMase and the 
nSMase activities was performed using 10 μM desipramine or 5 μM GW4869, respectively. To inhibit serine-
palmitoyl transferase activity, cells were treated with 5 μM myriocin. All drug Incubations were for 12-16 h. 
Staining of lipid droplets: Staining of lipid droplets was performed using HCS LipidTox™ Deep 
Green neutral lipid stain (Invitrogen H34475) according to the manufacturer's instructions. Lipid droplet 
staining was quantified using ImageJ. The different values represent the product of the intensity and the 
area covered by the fluorescent signal above background in every cell examined. 
Sphingolipid synthesis in cultured cells: Cells were incubated for 2 h with serum-free medium 
to ensure removal of exogenous lipids. The medium was then replaced with MEM containing 2.5 µCi/ml of 
3H-serine for the indicated periods of time. The cells were washed and collected in PBS, pelleted at 2500 x 
g for 5 min at 4ºC, and resuspended in 0.5 ml water, removing a small aliquot for protein quantification. 
Lipid extraction was done in 3 volumes of chloroform:methanol:HCl (2:1:0.5 v/v/v) added to the samples. 
Samples were vortexed and centrifuged at 8000 x g for 5 min; the organic phase was blown and dried under 
nitrogen. Dried lipids were resuspended in 30 μL chloroform:methanol (2:1 v/v) and applied to a TLC plate. 
Sphingolipids were separated using a solvent composed of chloroform/methanol/0.22% CaCl2 (60:35:8 
v/v/v). Development was performed by exposure of the plate to iodine vapor. The spots corresponding to 
the relevant sphingolipids (identified using co-migrating standards) were scraped and counted in a 
scintillation counter (Packard Tri-Carb 2900TR). 




Lipid extracts were prepared via chloroform-methanol extraction, spiked with appropriate internal 
standards, and analyzed using a 6490 Triple Quadrupole LC/MS system (Agilent Technologies, Santa 
Clara, CA) as described previously [329]. Glycerophospholipids and sphingolipids were separated with 
normal-phase HPLC using an Agilent Zorbax Rx-Sil column (inner diameter 2.1 x 100 mm) under the 
following conditions: mobile phase A (chloroform:methanol:1 M ammonium hydroxide, 89.9:10:0.1, v/v/v) 
and mobile phase B (chloroform:methanol:water:ammonium hydroxide, 55:39.9:5:0.1, v/v/v/v); 95% A for 2 
min, linear gradient to 30% A over 18 min and held for 3 min, and linear gradient to 95% A over 2 min and 
held for 6 min. Quantification of lipid species was accomplished using multiple reaction monitoring (MRM) 
transitions that were developed in earlier studies [329] in conjunction with referencing of appropriate internal 
standards: ceramide d18:1/17:0 and sphingomyelin d18:1/12:0 (Avanti Polar Lipids, Alabaster, AL). Values 
are represented as mole fraction with respect to total lipid (% molarity). For this, lipid mass (in moles) of 
any specific lipid is normalized by the total mass (in moles) of all the lipids measured [329]. In addition, all 
of our results were further normalized by protein content.  
Analysis of sphingolipid synthesis in subcellular fractions: Cellular fractions were isolated 
from MEFs as described [89]. Two hundred μg were incubated in a final volume of 200 μL 100 mM HEPES 
pH 7.4, 5 mM DTT, 10 mM EDTA, 50 μM piridoxal phosphate, 0.15 mM palmitoyl-CoA and 3 μCi/ml 3H-Ser 
for 20 min, 37°C. The reaction was stopped by addition of 3 volumes of chloroform/methanol (2:1 v/v). Lipid 
extraction and TLC analysis were done as described above. 
Analysis of sphingomyelinase activity: One hundred μg of protein were assayed in 100 mM of 
the appropriate buffer (Tris/glycine for pH 7.0-9.0 and sodium acetate for pH 4.0-5.0), 1.55 mM Triton X-
100, 0.025% BSA, 1 mM MgCl2, and 400 μM bovine brain sphingomyelin spiked with 22000 dpm of [3H]-
bovine sphingomyelin (1 nCi/sample). Reactions were carried out in borosilicate glass culture tubes at 37°C, 
overnight, followed by quenching with 1.2 ml of ice-cold 10% trichloroacetic acid, incubation at 4°C for 30 
min, and centrifugation at 2000 rpm at 4°C for 20 min. One ml of supernatant was transferred to clean 
tubes, 1 ml of ether was added, the mixture vortexed, and centrifuged at 2000 rpm for 5 min. Eight hundred 
μL of the bottom phase was transferred to scintillation vials, 5 ml of Scintiverse BD (Fisher Scientific, Fair 
Lawn, NJ) was added, and samples were counted. 




in serum-free medium for 2 h to remove all exogenous lipids. 2.5 µCi/ml of 3H-cholesterol was added to 
FBS-free DMEM containing 2% FAF-BSA, allowed to equilibrate for at least 30 min at 37°C, and the radio-
labeled medium was added to the cells for the indicated times. Cells were then washed and collected in 
DPBS, removing a small aliquot for protein quantification. Lipids were extracted in 3 volumes chloroform: 
methanol (2:1 v/v). After vortexing and centrifugation at 8000 x g for 5 min, the organic phase was blown 
to dryness under nitrogen. Dried lipids were resuspended in 30 μL chloroform:methanol (2:1 v/v) and app-
lied to a TLC plate with unlabeled standards. A mixture of hexanes/diethyl ether/acetic acid (80:20:1 v/v/v) 
was the solvent. Iodine-stained bands corresponding to cholesterol and CEs were scraped and counted. 
Analysis of ER-mitochondrial apposition: Cells under were co-transfected with GFP-Sec61-β 
(Addgene plasmid 15108) and DsRed2-Mito (Clontech, 632421) at a 1:1 ratio, with Lipofectamine 2000 
(Invitrogen, 11668-027) in serum-free DMEM. After 12h, cells were analyzed as described [592]. 
Preparation of synthetic Aβ in different states of aggregation and Aβ40/Aβ42 detection: 
Lyophilized Aβ40 and Aβ42 peptides (American Peptide; 62-0-80; UCLA) were equilibrated at room 
temperature for 30 min and then resuspended in hexafluro-2-propanol (HIFP) (Sigma; H8508) to 1 mM 
using a glass-tight Hamilton syringe with Teflon plunger. HIFP was allowed to evaporate in a fume hood 
and dried under vacuum in a SpeedVac (Savant Instruments) and kept at -20°C. Immediately prior to use, 
an aliquot was resuspended to 5 mM in DMSO followed by bath sonication for 10 min. 
 To analyze the effect of Aβ addition, a mix of Aβ40/Aβ42 at a ratio 10:1 was added to the cultured 
cells to a final concentration of 6000 pg/ml for 24 h. For Aβ42 oligomer formation, 5 mM of Aβ42 in DMSO 
was diluted to 100 μM in ice-cold media, vortexed for 30 seconds, and incubated at 4°C for 24 h. Aβ42 
Oligomers were added to the cultured cells to a final concentration of 5 or 10 μM for 24 h. 
Detection of Aβ40/Aβ42 levels in cell media was performed by ELISA following manufacturer’s 
instructions (WAKO ELISA kit 294-64701 for Aβ40 and 292-64501 for Aβ42). 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR): Total RNA was 
extracted from MEFs using TRIzol® Reagent (Invitrogen 15596-018) according to the manufacturer 
instructions, and was quantified by NanoDrop2000 (Thermo Scientific). One μg of total RNA was used to 
obtain cDNA by RT-PCR using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; PN 




System (Applied Biosystems; 4376600). The expression of each gene under study was analyzed using 
specific predesigned TaqMan Probes (PGC-1α, ppargc1a Mm01208835_m1; aSMase, smpd1 
Mm00488319_g1; nSMase, smpd3 Mm00491359_m1). The forward and reverse primers (5'®3') for Cox1 
quantification were, respectively, (TGCTAGCCGCAGGCATTACT; CGGGATCAAAGAAAGTTGTGTTT). 
The expression of each gene under study was analyzed using specific predesigned TaqMan Probes and 
normalized against Gapdh expression (Applied Biosystems, 4352339E) as an internal standard. 
Supercomplex analysis: Analysis and quantification of mitochondrial respiratory complexes by 
western blot and enzymatic in-gel activity were carried out as described [593]. 
Statistical analyses: All averages are the result of 3 or more independent experiments carried out 
at different times with different sets of samples. Tests of significance employed Student's t-test at p<0.05, 
unless indicated otherwise; all error bars in the figures are ±SD. For the determination of ER-mitochondrial 
apposition, all images were taken randomly from a set of multiple fields. The degree of colocalization was 





C99 inhibits mitochondrial respiration in presenilin-mutant cells 
Current hypotheses regarding mitochondrial dysfunction in AD propose that this defect is the 
consequence of the accumulation of Aβ in mitochondria [406], but the mechanism is unclear. To address 
this, we measured mitochondrial respiration in fibroblasts from FAD patients with pathogenic mutations in 
PS1 (M146L and A246E) and in age-matched controls, as well as in mitochondria from the brain of a knock-
in (KI) mouse model expressing the M146V mutation in PS1 (PS-KIM146V) [271]. We observed a reduced 
respiration in FAD patient cells (Figs. 2-1A, 2-7A, and 2-7P) and in mitochondria isolated from PS-KIM146V 
mouse brain (Fig. 2-7B). To understand the consequences of presenilin (PS) mutations and the effect of 
amyloid on mitochondrial function in AD, we measured respiration in mouse embryonic fibroblasts (MEFs) 
ablated for both Psen1 and Psen2 (PS-DKO) [594]. As above, we found decreased respiration in the PS-
DKO cells compared to controls (Figs. 2-1B and 2-7Q). Additionally, measurements of oxygen consumption 
rate (OCR) in permeabilized cultures of PS-DKO cells showed clear defects in respiration (Fig. 2-7D). 
Importantly, the decrease in respiration was not due to reductions in mitochondrial content or biogenesis 
(Figs. 2-7C, 2-7F, 2-7G, and 2-7I). Taken together, these results suggest that, from the mitochondrial 
perspective, cells with pathological mutations in, and ablation of, PSs behave similarly, resulting in loss of 
mitochondrial respiration. Given that PS-DKO MEFs lack γ-secretase, these results suggest that 
mitochondrial dysfunction in these mutant cells does not depend on Aβ production. 
 To determine whether mutations in PSs affect mitochondria via the role of PSs as the catalytic core 
of γ-secretase, we measured mitochondrial respiration in human neuroblastoma SH-SY5Y cells treated 
with 10 µM of the γ-secretase inhibitor, DAPT. This inhibition caused a significant reduction in respiration 
compared to untreated cells (Figs. 2-1C and 2-7R) without altering mitochondrial content or biogenesis 
(Figs. 2-7F, 2-7I, and 2-7J). This result implies that the catalytic activity of PSs is necessary to maintain 
respiratory function. In addition, given that neither PS-DKO nor DAPT-treated cells produce Aβ, our results 
raise the possibility that the mitochondrial deficits in AD are independent of Aβ production. However, it is 
equally possible that alterations in full-length APP (FL-APP) or in any of its cleavage products may play a 
role in regulating mitochondrial respiration. To test this, we measured oxygen consumption in MEFs in 




mutant cells, elimination of APP and APLP2 had no detrimental effects on respiration (Fig. 1D). In fact, the 
oxygen consumption rate in permeabilized APP-DKO cells was slightly but significantly increased 
compared to controls (Figs. 2-1D, 2-7E, and 2-7T). 
 Considering that PS-DKO and APP-DKO cells both lack Aβ and AICD, our results suggest that the 
difference in mitochondrial function was due to the presence or absence of FL-APP or its cleavage products, 
C99 and C83. We therefore measured respiration in PS-DKO cells treated with BACE1 inhibitor IV (BI) (Fig. 
2-1E and 2-7S) and an α-secretase inhibitor (TAPI-1) (Fig. 2-7H) to abrogate the production of C99 and/or 
C83, respectively. As controls, we added back physiological concentrations of Aβ and oligomers of Aβ42 
(Figs. 2-7K, 2-7L, and 2-7M). Remarkably, only the treatment with BI rescued the respiration defects, both 
in PS-DKO cells (Figs. 2-1E and 2-7S) and in FAD fibroblasts (Fig. 2-7N), suggesting that increased levels 
of unprocessed C99, rather than the levels of Aβ, plays a role in the mitochondrial dysfunction seen in AD. 
Supporting this, addition of Aβ oligomers to APP-DKO cells had little effect on respiration (Fig. 2-7M), 
whereas APP-DKO cells expressing C99 suffered a significant decrease in respiration, which was accen-
tuated by adding DAPT (Figs. 2-1D and 2-7T), without changes in the content of mitochondria (Fig. 2-7O). 
 
C99 can be localized in MAM 
APP and its cleavage products have been shown to colocalize with almost every membranous 
compartment in the cell, including mitochondria [596]. Thus, it is possible that in AD cells, C99, as previously 
suggested for Aβ [436], is retained on mitochondrial membranes, disrupting its regulation. 
 To explore C99 and C83 localization, we isolated subcellular fractions from mouse brain [475] (Fig. 
2-8A) and analyzed them by western blot (this was also validated in an identical fractionation of mouse liver 
[Fig. 2-8B]), using specific markers for each compartment. Interestingly, we found that APP-CTF fragments, 
while present in all compartments, were enriched significantly in MAM regions of the ER (Fig. 2-2A).  
 To discriminate between the localization of C83 and C99, we isolated subcellular fractions from 
SH-SH5Y cells treated with DAPT (to prevent cleavage of C99 and C83), or treated with ⍺- and ɣ-secretase 
inhibitors (TAPI-1 and DAPT, to prevent the generation of C83 and the cleavage of C99, respectively, 
thereby revealing the presence only of C99). Notably, western blot analysis of these fractions showed that 




MAM (i.e., fractions from cells treated with TAPI-1 and DAPT) (Fig. 2-2B). 
 Many reports have shown that C99 is localized mainly in endosomes [597,598]. Therefore, it is 
possible that the presence of C99 in MAM regions was the result of cross-contamination of MAM samples 
with endosomes during the process of subcellular fractionation. To eliminate this possibility, we isolated 
cellular membranes from mouse brain and separated them through continuous sucrose density gradients 
(Fig. 2-8C), to purify MAM away from endosomes and other subcellular fractions. After gradient 
centrifugation, we examined the distribution of C83 and C99 compared to markers for other compartments 
(Fig. 2-2C). Consistent with the data of others [598], FL-APP and BACE1 co-migrated partially with a marker 
for endosomes (Rab7), but not with lysosomal, ER-intermediate, or MAM markers (Fig. 2-2C). Similarly, 
the APP-CTFs, C83 and C99, co-migrated with endosomal and lysosomal markers (Rab5, Rab7, and 
LAMP-2) [597,598], whereas PS1 co-migrated with MAM markers, such as FACL4 [89,469,470]. We 
reasoned that the difficulty in seeing APP-CTFs and PS1 together may be due to the rapid cleavage of the 
CTFs by ɣ-secretase once both are in the same compartment. Thus, to circumvent this and determine C99 
localization, we repeated the same analysis using PS-DKO cells [594] in which APP-CTFs are not cleaved 
due to the absence of PSs (Fig. 2-7G). Western blot analysis showed that, in addition to its localization in 
endosomes, a significant fraction of unprocessed C99 co-migrated with MAM markers (Fig. 2-2D). 
 To validate this result by imaging, we transfected wild-type (WT) MEFs and COS-7 cells with 
plasmids expressing fluorescently-tagged C99 and mitochondrial and ER markers, and in the absence (Fig. 
2-8D) or presence (Fig. 2-2E) of γ-secretase inhibitors. Confocal microscopy analysis revealed that C99 (in 
red) was present mainly in the cytosol and in ER membranes (in green), as shown previously by others 
[598]. In addition to those sites, C99 (in red) also colocalized with regions where both ER (in green) and 
mitochondria (in blue) were present (white arrows in Figs. 2-2E and 2-8D). This suggests that, like PSs 
[89], C99 can be localized to areas of the ER apposed to mitochondria (i.e. MAM) and is consistent with 
the fact that g-secretase activity is present in this compartment [89,470].  
 To corroborate this result, we analyzed the localization of unprocessed C99 by immunogold 
electron microscopy (iEM) of PS-DKO cells, using antibodies against C-terminal regions of APP. In 
agreement with the confocal and western blot analyses, iEM images indicated that, when uncleaved, C99 




 We next asked if the increased localization of C99 in the MAM also occurred in the context of AD, 
as tissues from AD patients and animal models show increases in this fragment [196]. We measured C99 
levels by western blot in homogenates from embryonic cortical neurons from WT and PS-KIM146V mouse 
brain [271] (Fig. 2-8F), as well as from cells from AD patients and controls (Fig. 2-8G). Notably, there was 
more C99 in the homogenates of mutant neurons and cells from AD patients, than in those from controls 
(Figs. 2-8F and 2-8G), similar to previous findings in other AD patients and FAD mice [141,534,599]. In 
addition, western blot analysis of subcellular fractions isolated from WT and PS-KIM146V mouse brain also 
showed an increase in the levels of C99 in the mutant samples, and especially in MAM fractions, compared 
to in controls (Fig. 2-8H), while the relative concentration of AICD was not changed significantly (Fig. 2-8H). 
 Taken together, our results suggest that C99, after being produced in endocytic compartments 
[598] is targeted to MAM, via an as-yet unknown mechanism, to be cleaved rapidly by γ-secretase. 
Moreover, both pathogenic mutations in PS1 and reductions in γ-secretase activity cause the retention of 
this fragment in this region of the ER that is in close apposition to mitochondria. 
 
Increased MAM localization of C99 upregulates MAM functionality and ER-mitochondria apposition  
Given that reduced γ-secretase activity causes C99 accumulation at MAM, we asked if elevated 
C99 could be the cause of the upregulated ER-mitochondria apposition and MAM activity in AD [96]. To 
assess apposition, we transfected control and PS-DKO cells with markers of ER and mitochondria, and 
measured their co-localization [96,600] in the absence or presence of BACE inhibitor (BI) to prevent the 
generation of C99; remarkably, incubation with BI rescued upregulated ER-mitochondria apposition seen 
in mutant cells (Figs. 2-3A and 2-3B). 
 To assess the effect of C99 on MAM functionality, we measured the conversion of cholesterol to 
cholesteryl esters (CEs) by ACAT1, a MAM-resident enzyme [96], and monitored the accumulation of 
newly-synthesized CEs in lipid droplets (LDs) [96]. Treatment with BI reduced the incorporation of 
cholesterol into CEs (Fig. 2-3C) and reduced the number of LDs in PS-DKO cells, in AD patient fibroblasts 
(Fig. 2-3D), and in PS1-KIM146V mouse astrocytes and cortical neurons (Fig. 2-9A). Similarly, treatment of 
PS-DKO cells with Gleevec, an anticancer drug that has been shown to reduce APP cleavage by BACE 




SY5Y and HeLa cells treated with DAPT alone (i.e., increasing C99), which was reversed in cells treated 
with DAPT+BI (i.e., preventing C99 formation) (Fig. 2-9C). Supporting these data, and contrary to what we 
observed in ɣ-secretase-deficient cells but in agreement to what we saw in the DAPT+BI cells, MEFs in 
which BACE1 had been knocked-out [602] were essentially devoid of LDs in the cytosol (Fig. 2-9D). 
 Taken together, these results show that the increase in, and retention of, uncleaved C99 in the 
MAM induces both a physical and functional enhancement of ER-mitochondria connections. 
 
Sphingolipid metabolism is perturbed in AD-mutant cells 
Given that MAM is a lipid raft [96], we speculated that C99 could have a role in MAM activity and 
ER-mitochondrial connectivity through changes in MAM lipid composition [93]. We performed lipidomic 
analyses of total homogenates (THs), mitochondrial fractions, and isolated MAM from PS-DKO MEFs and 
controls. We found significantly increased ceramide (Figs. 2-4A and 2-10A, left panel) and a parallel 
decrease in sphingomyelin (SM) in mutant cells (Figs. 2-4B and 2-10B, right panel), more pronounced in 
the mitochondrial (Figs. 2-4A, 2-4B, and 2-10B) and MAM (Figs. 2-4C and 2-10C) fractions than in THs. To 
confirm the PS-dependent nature of these lipid alterations, we transfected the PS-DKO cells with plasmids 
expressing either PS1WT or PS1A246E (Figs. 2-10D and 2-10E). Notably, expression of PS1WT, but not 
PS1A246E, was capable of partially rescuing the altered sphingolipid content in PS-DKO cells (Fig. 2-10F).  
 Moreover, there was an inverse relationship between the amounts of individual SM species present 
and those of the corresponding ceramide species (Fig. 2-10G). This latter result suggested that there was 
an increase in the hydrolysis of SM by sphingomyelinases (SMases), and subsequent upregulation of the 
de novo synthesis of SM to replace its loss (Fig. 2-4D). In agreement with this, PS-DKO cells showed 
significantly higher synthesis of both ceramide and SM vs WT (Fig. 2-4D). In addition, acidic (aSMase) and 
neutral (nSMase) SMase activities were increased in the PS-DKO cells (Fig. 2-4E), with a more dramatic 
upregulation of nSMase activity, correlating with increased expression of nSMase 2 (gene Smpd3) (Fig. 2-
10H). We also observed increases in both acid and neutral SMase activities in PS1-KIM146V mouse brain 
(Fig. 2-10I). Likewise, we replicated the increase in SMase activity in SH-SY5Y cells by inhibiting γ-
secretase activity (Fig. 2-10J), suggesting that mutated PSs modulate sphingolipid metabolism via their 




but not PS1A246E, significantly blunted the upregulation of nSMase activity in PS-DKO cells (Fig. 2-10K).   
 To understand whether these effects were direct or were mediated by APP and/or its cleavage 
products, we measured SMase activity in APP-DKO cells. Contrary to what we found in PS-DKO and DAPT-
treated cells, APP-DKO cells showed significant decreases in both sphingolipid synthesis (Fig. 2-10L) and 
SMase activities (Fig. 2-10M). As mentioned previously, both PS-DKO and APP-DKO cells lack Aβ and 
AICD. Therefore, any difference in sphingolipid regulation between the two cell types must be due to the 
presence or absence of full length-APP and/or C88 and C99. We therefore measured SMase activities in 
PS-DKO cells treated with α- and ɣ-secretase inhibitors to test the effect of C83 and C99, respectively, as 
well as in PS-DKO cells in which Aβ and AICD were added back (Fig. 2-10N). Interestingly, only the 
inhibition of C99 production (by BI) resulted in an attenuation of sphingolipid synthesis and hydrolysis by 
SMases (Fig. 2-4E). These results indicate that it is the increase in C99 that causes the upregulation of 
sphingolipid metabolism, resulting in the previously described elevations in ceramide in AD [340]. However, 
they did not clarify why ceramide is particularly elevated in MAM and mitochondrial membranes. 
 
MAM participates in the regulation of sphingolipid metabolism 
Previous reports have suggested that MAM is involved in sphingolipid metabolism, affecting 
mitochondrial activity [603]. In fact, mitochondria contain ceramide, likely generated at MAM [604]. Taking 
these and our data into account, we hypothesized that increased ceramide synthesis and SMase activity 
at ER-mitochondria connections could explain the increased ceramide in mitochondrial membranes in AD. 
 To address this, we analyzed ceramide synthesis and SMase activity in vitro, using subcellular 
fractions from WT and PS-DKO cells. The results indicate that MAM indeed participates in regulating 
sphingolipid metabolism (Figs. 2-5A and 2-11A). Moreover, SMase activities were upregulated significantly 
in subcellular fractions from PS-DKO cells compared to controls (Fig. 2-5A), as well as in MAM from PS1-
KIM146V mouse brain (Fig. 2-11B). In agreement with these results, western blot analysis revealed a 
remarkable increase in the localization of nSMase to MAM in mutant cells compared to WT (Fig. 2-5B), 
suggesting higher recruitment of SMase to these ER-mitochondria contacts. 
 To explore this further, we incubated PS-DKO and control cells with fluorescent SM and analyzed 




a substantial decrease in fluorescent SM intensity (Fig. 2-5C), paralleled by an increase in fluorescent 
ceramide (Fig. 2-5C), implying that upregulated SMase activity may be responsible for this inverse behavior. 
Remarkably, the elevated deposition of ceramide in mitochondria disappeared when mutant cells were 
treated with BI (Fig. 2-5C). These data suggest that BACE1 inhibition may enhance mitochondrial 
respiration (Figs. 2-1E and 2-7N) by attenuating sphingolipid metabolism in mutant cells. 
 Why is there an increased recruitment of nSMase to these ER regions in PS-mutant cells? It is well 
known that SMase activity is modulated by membrane characteristics and lipid composition [605]. Notably, 
SMase activity is higher in LR-like domains, such as MAM, where liquid-ordered and -disordered phases 
coexist [606]. In addition, nSMase shows increased affinity for membranes enriched in anionic phospho-
lipids [607]. In particular, the activity of nSMase2 is stimulated upon its binding to phosphatidylserine 
(PtdSer) [607]. To see whether elevated PtdSer might be behind the increased recruitment of nSMase 
activity to MAM in mutant cells, we analyzed the content of PtdSer in WT and PS-DKO homogenates and 
in subcellular fractions. In agreement with our hypothesis, we found a significant increase in the amount of 
PtdSer in PS-DKO membranes, which was most pronounced in the MAM domains of the ER (Fig. 2-11C). 
This result also supports the idea that increases in PtdSer due to C99-mediated upregulation of MAM is 
driving the increased SMase activity in these ER regions. Consistent with this proposed mechanism, 
inhibition of C99 production (with BI) reduced the PtdSer content of PS-DKO membranes to control levels 
(Fig. 2-11D), while reversing the alterations in both SM (Fig. 2-11E) and ceramide (Fig. 2-11F). 
 Taken together, we conclude that retention of uncleaved C99 in MAM in PS-deficient cells up-
regulates both the synthesis and catabolism of SM in these regions of the ER, likely accounting for the 
increased ceramide in mitochondrial membranes (Fig. 2-4A) via ER-mitochondrial connections.  
 
Mitochondrial dysfunction in AD is caused by upregulated sphingolipid turnover 
The detrimental effects of ceramide on mitochondrial functionality have been shown extensively 
[604]. Thus, we speculated that the upregulation of SM turnover at MAM and the subsequent local increase 
in ceramide could be the underlying cause of the respiratory deficits seen in AD [438,583]. To test this idea, 
we measured respiration in PS-DKO mutant cells treated with 5 μM myriocin, a specific inhibitor of serine-




Inhibition of sphingolipid synthesis by myriocin resulted in slight decreases in SM (Fig. 2-12A) but in 
significant reductions in ceramide content (Fig. 2-12B) in our cell models, with changes in the latter more 
pronounced in PS-DKO cells (Fig. 2-12B). In agreement with our hypothesis, this reduction in ceramide 
rescued the bioenergetic defect in these mutant cells (Fig. 2-6A). 
 Ceramide has been shown to provoke changes in mitochondrial lipid composition, altering its 
membrane potential and permeability [604]. Notably, the lipid composition of mitochondrial membranes is 
crucial for the stabilization and assembly of mitochondrial respiratory complexes into supercomplexes (SCs; 
also called respirasomes) necessary for optimal respiratory chain function [608]. Therefore, it is possible 
that ceramide interferes with bioenergetics by destabilizing or preventing SC assembly. To assess this, we 
used blue-native gel electrophoresis [593] to examine the activity (Figs. 2-6B and 2-6C) and assembly 
status (Figs. 2-12C and 2-12D) of SC in mitochondria from WT and PS-DKO cells, from DAPT-treated WT 
cells, and from PS-DKO cells incubated with BI and myriocin (Fig. 6B). Measurements by in-gel staining of 
the activities of respiratory chain complexes I and IV (Figs. 2-6B and 2-6C) and western blotting to detect 
subunits of complexes I and III from PS-DKO and DAPT-treated WT cells (Fig. 2-12C and 2-12D) showed 
a decrease in the activity of SCs I+III+IV, I+III, and III+IV, which could be rescued after treatment with BI 
and myriocin (Fig. 2-6D and 2-6E). Importantly, these changes in SC activities and assembly were not due 
to alterations in the expression of individual complex subunits (Fig. 2-12E).  
 To corroborate these results in vivo, we analyzed mitochondrial respiration and SC activity in brain 
mitochondria from PS1-KIM146V mice of various ages (Figs. 2-13A/B). Interestingly, while MAM defects were 
already present in fetal cortical neurons (Fig. 2-9A), decreases in mitochondrial respiration became 
significant only at 3 months (Fig. 2-13A). In agreement with our previous results, this bioenergetic defect 
correlated with significantly decreased SC activity in mutant samples compared to controls (Figs. 2-13C/D). 
 Taken together, these results indicate that the bioenergetic defects in AD are likely to be the 
consequence of upregulated sphingolipid turnover and increased ceramide content in mitochondria, 
triggered by the retention of C99 at the MAM. This elevation in ceramide levels alters mitochondrial 
membrane properties, likely hindering the assembly and activity of respiratory SCs. Moreover, these data 
suggest that while mitochondrial dysfunction is an early and significant defect in AD, it is not a primary insult 





In previous reports we showed that g-secretase activity is localized in MAM [89], and alterations in 
g-secretase activity result in upregulation of MAM function and increased ER-mitochondria apposition [96]. 
We now show that the g-secretase substrate C99, in addition to its endosomal localization, is also present 
in MAM domains. Thus, both g-secretase enzymatic activity (presenilins; PSs) and its direct substrate (C99) 
are located in the same compartment, where the former can cleave the latter. Moreover, chemical and 
genetic alterations of g-secretase activity provoke a significant increase in the amount of this APP 
processing fragment in MAM regions. The increased presence of C99 in MAM causes upregulation of MAM 
functionality (as measured by ACAT1 activity) and greater apposition between ER and mitochondria. In 
addition, the higher concentration of MAM-localized C99 induces the recruitment of SMase to this ER 
domain and subsequent deregulation of sphingolipid homeostasis, followed by mitochondrial dysfunction.  
 These results support a model in which, in addition to Aβ, increased C99 plays an early role in AD 
pathogenesis, via altered MAM function. Of course, our results do not exclude the possibility that C99 has 
other roles in AD pathogenesis. In fact, increases in C99 were already shown to contribute to other aspects 
of the pathogenesis of the disease [135,187], including endosomal dysfunction [193], hippocampal degen-
eration [187], and altered Tau proteostasis [609]. In addition, elevations in C99 are toxic to neurons [198], 
correlating with symptoms of the disease [201,534]. Importantly, we note that although much of our data is 
from FAD models and cells from FAD patients containing PS mutations, alterations in g-secretase activity 
and increased levels of C99 have been detected in sporadic AD patients as well [141,142,197,610]. 
 We propose that, while the majority of C99 resides in endosomes, C99 can traffic to MAM regions 
in the ER, where it is cleaved rapidly by g-secretase to produce Aβ and AICD [89,470]. We note that 
although the mechanism by which C99 translocates to ER-MAM is unknown, recent work has demonstrated 
the existence of ER-endosome contacts [611] where lipid and protein exchange may occur [612]. Thus, it 
is possible that C99 is delivered to ER via a similar mechanism, where it regulates the interaction between 
ER and mitochondria. Furthermore, the localization of C99 at MAM clarifies why C99, an ER-localized 
protein [613], was also detected in mitochondria [596]. Similarly, since C99 processing occurs at MAM, this 
could explain why Aβ has been found to co-localize with mitochondria [614,615]. 




unprocessed C99 in MAM. This, in turn, provokes the recruitment of SMase activity to MAM and the up-
regulation of sphingolipid turnover at these sites. These findings have mechanistic implications. Specifically, 
one of the MAM functions that is increased in AD is the synthesis of PtdSer by phosphatidylserine synthases 
1 and 2 (PTDSS1/2) [96,472,616,617], resulting in higher levels of this phospholipid in MAM and other 
membranes in AD cells and tissues. Considering the affinity of nSMase for PtdSer [607], we believe that 
the activation of nSMase by C99 is due, at least in part, to upregulation of PTDSS1/2 in MAM, triggered by 
increased concentration of this APP fragment. The details of this mechanism will require further study. 
 These results also help clarify a number of previous observations. First, as MAM contains γ-
secretase and SMase activities, our data help explain why changes in APP processing can induce 
alterations in sphingolipid regulation [340,618]. Second, upregulation of SMase and the resulting increase 
in ceramide are known to alter the size and composition of lipid raft domains [619], such as MAM. Therefore, 
an increased localization of C99 in MAM in AD may explain the upregulation of ER-mitochondria 
connections and MAM functionality seen in the disease [96,478]. Finally, given the detrimental effect of 
ceramide on mitochondrial SC assembly and respiratory chain activity [620], we conclude that its 
accumulation is likely to be a primary cause of mitochondrial dysfunction in AD. 
 This last conclusion disagrees with proposals that the accumulation of Aβ42 oligomers in 
mitochondria triggers the mitochondrial defects seen in AD [406]. Rather, our results show that PS-DKO 
and DAPT-treated cells, in which Aβ production is inhibited, can nevertheless recapitulate the mitochondrial 
deficits seen in AD. This finding suggests that mitochondrial deficiencies are due to increased levels of C99 
rather than to elevated production of longer Aβ species, since bioenergetic deficiency can occur in the 
absence of Aβ. We believe that the discrepancy between our results and those of others showing reductions 
in mitochondrial respiration after incubation with Aβ [436] is due mainly to the use of unphysiologically high 
concentrations of this peptide [436]. Thus, we propose that MAM and mitochondrial alterations are caused 
by an increased ratio of C99:Aβ, rather than by an increased ratio of Aβ42:Aβ40. In agreement with this, the 
increase of C99 in mitochondria in AD has been described before, correlating with mitochondrial respiratory 
defects that could be rescued by partial deletion of BACE1 [596]. Finally, our results linking C99, rather 
than higher levels of Aβ42, to mitochondrial dysfunction help explain how mitochondrial alterations can occur 




 In summary, our data demonstrate that increased levels of unprocessed MAM-localized C99 is a 
fundamental cause of mitochondrial dysfunction in AD, mediated by the loss of sphingolipid homeostasis 
at ER-mitochondria connections. Equally important, while the toxicity of Aβ is undeniable, our work supports 
a role for elevated C99 [534] and MAM deregulation [95,622] in the pathogenesis of the disease, thus 
providing a new framework for understanding the link between alterations in APP processing and lipid 
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Figure 2-1: Mitochondrial respiration (oxygen consumption rate, OCR) in ɣ-secretase-deficient 
cells.  
(A) AD fibroblasts. (B) PS-DKO MEFs. (C) SH-SY5Y cells treated with DAPT. (D) APP-DKO cells before 
and after overexpression of C99. (E) PS-DKO MEFs treated with BACE inhibitor (all experiments are the 






Figure 2-2: Localization of C99 to MAM. 
WB of fractions from mouse brain (Tot, Total homogenate; PM, plasma membrane; CM, crude membrane 
fractions) probed with the indicated antibodies (30 µg of protein per lane). (B) WB of subcellular fractions 
from SHSY5Y cells treated with α- and γ-secretase inhibitors to reveal the differential localization of APP-
CTF fragments. Note that C99 is predominantly in the MAM fraction (30 µg of protein per lane). (C) The CM 
fraction from mouse brain was treated with detergent, purified on a continuous sucrose gradient, and 
gradient fractions were analyzed by WB (two parallel gels [dotted line]), probing with antibodies to detect 
the indicated marker proteins. (D) The same analysis using CM fractions from PS-DKO MEFs to reveal the 
differential distribution of C83 vs C99. (Average of n>5 independent experiments ±SD. * p<0.05). (E) 
Representative confocal image of a DAPT-treated COS-7 cell shows that uncleaved C99 (red) and mito-
chondria (blue) can colocalize only in those areas where ER (green) is also present (i.e. MAM). Note how 
C99 colocalizes with areas where mitochondria and ER are apposed (white arrows in Merge [boxed], also 
shown in the expended view [Merge-Zoom shown in bottom panel]). Size bars=20 μm (F) Representative 
iEM image of PS-DKO cells incubated with antibodies against APP-CTF conjugated with immunogold 
particles, showing retention of C99 in MAM areas of the ER. The ER is in green and the mitochondrial outer 






Figure 2-3: ER-mitochondrial apposition is regulated by C99. 
Localization of ER (green) and mitochondria (red) in the indicated MEFs without and with BACE1 inhibitor 
(inhibiting C99 formation; see western in panel B). Large boxes in the Merge are enlargements of the small 
boxes. Size bars=20 μm (average of n=4 independent experiments ± SD. * p<0.05). (B) Quantitation by 
ImageJ analysis of the colocalization of ER and mitochondrial signals from experiments like the one shown 
in (A). The western blot indicates the APP-CTF levels in the indicated cells (average of n=4 independent 
experiments ± SD; * p<0.05) (30 µg of protein per lane). (C) ACAT1 activity in WT and PS-DKO MEFs in the 
presence and absence of a-, b-, and/or g-secretase inhibitors (average of n=4 independent experiments ± 
SD. * p<0.05). (D) Staining of the indicated cells with LipidTox Green to detect lipid droplets. Size bars=20μm 





Figure 2-4: Sphingolipid metabolism in PS-DKO MEFs. 
(A, B) Ceramide (A) and sphingomyelin (B) levels in total homogenate and in crude mitochondrial fractions 
in WT and PS-DKO MEFs. Lipid units are represented as molar mass over total moles of lipids analyzed 
(mol%) (average of n=5 independent experiments ± S.D. * p<0.05). (C) Ceramide and sphingomyelin levels 
in MAM isolated from WT and PS-DKO MEFs. Lipid units are represented as nmol per mg of protein over 
total nmoles of lipids analyzed (average of n=3 independent experiments ± S.D. * p<0.05). (D) De novo 
synthesis of ceramide (Cer) and sphingomyelin (SM) in WT and PS-DKO MEFs (average of n>5 
independent experiments ± S.D. * p<0.05). (E) Activities of acid (aSMase) and neutral (nSMase) 






Figure 2-5: MAM participates in the regulation of sphingolipid metabolism. 
(A) Distribution of SMase activity in the indicated subcellular compartments in WT and PS-DKO MEFs. Note 
the overall increase in nSMase levels in the PS-DKO cells (average of n=5 independent experiments ± SD 
* p<0.05). (B) Western blot of the indicated fractions from WT and PS-KO MEFs (probed with antibodies 
against the indicated markers) to detect the levels of nSMase protein in the indicated compartments (30 µg 
of protein per lane). TH, total homogenate; CM, crude membrane fraction (C) Sphingolipid levels in 
mitochondrial membranes extracted from the indicated cells after addition of fluorescent sphingomyelin 
(left, detection in TLC plates; right, quantitation) (average of n=5 independent experiments ± SD * p<0.05 





Figure 2-6: Mitochondrial dysfunction is the consequence of increased sphingolipid turnover. 
Respiratory chain deficiency (as measured by initial oxygen consumption rate [OCR]) in PS-DKO cells was 
rescued after treatment with myriocin (inhibitor of the de novo sphingolipid synthesis pathway) (average of 
n=3 independent experiments ±S.D. * p<0.05). (B, C) In-gel complex I (B) and complex IV (C) activity 
staining in mitochondria from WT and PS-DKO cells after the indicated treatments. (D, E) Quantification of 
specific bands shown in (B) and (C).  Note that chemical or genetic inhibition of γ-secretase results in 
decreased supercomplex I+III+IV activity. This effect can be rescued by inhibition of C99 production (with 
a BACE1 inhibitor [BI]) or by inhibition of ceramide production with myriocin (Myr). Dotted lines denote 












Figure 2-7 (Supplemental Figure 1): Mitochondrial bioenergetics in ɣ-secretase-deficient cells. 
All respiratory chain assays (OCR) were performed using the Seahorse XF24 Flux Analyzer. (A) Fibroblasts 
from FAD and SAD patients, (B) Mitochondria from PS1-KIM146V brain. (C) Western blot from homogenates 
from the indicated cells probed against mitochondrial markers (VDAC and TOM20) and the tubulin loading 
controls (30 µg of protein per lane). (D, E) Complex I and II activities in which malate-pyruvate or succinate-
rotenone, respectively, were added to permeabilized PS-DKO MEFs (D) and to APP-DKO MEFs (E). Note 
significant decrease in OCR in PS-DKO MEFs but an increase in APP-DKO MEFs. (F) qRT-PCR to 
measure mRNA levels of mitochondrial encoded Cox1 as a measure of mitochondrial DNA in WT and PS-
DKO cells before and after addition of DAPT and BI. n.s.=not significant. (G) Western blot from total 
homogenates of WT, PS-DKO, and PS-DKO cells treated with BACE1 inhibitor (BI); 30 µg of protein per 
lane). Note that BI treatment eliminates the accumulation of APP C-terminal fragments in PS-DKO MEFs, 
without changes in mitochondria (VDAC, TOM20). (H) OCR in WT or PS-DKO cells is unaffected by 
treatment with the ɣ-secretase inhibitor TAPI-1. (I) qRT-PCR to measure mRNA levels of PGC-1⍺, a master 
regulator of mitochondrial biogenesis, in WT and PS-DKO cells before and after addition of DAPT and BI 




deficient cells. n.s., not significant. (J) Western blot from total homogenates of SHSY5Y cells treated with 
DMSO and ⍺-, β-, and ɣ-secretase inhibitors probed with the indicated antibodies. Note that none of the 
treatments change the levels of mitochondria (VDAC). Loading control in the right panel (30 µg of protein 
per lane). (K, L) Addition of monomers of Aβ40 and Aβ42 (added at a ratio of 10:1 Aβ40:Aβ42, total 
concentration of Aβ was 6 ng/ml) to PS-KO cells (K), or to APP-DKO cells (L) did not affect mitochondria 
respiration. (M) Addition of 0, 5, and 10 μM of Aβ42 oligomers to WT and APP-DKO cells shows that only at 
a high-non-physiological concentration (10 μM) of Aβ42 oligomers, mitochondrial respiration is slightly 
decreased. (N) Respiratory chain deficiency in fibroblasts from an FAD patient (AG06840. PS1A246E) was 
rescued following treatment with a BACE1 inhibitor. (O) Western blot showing how transient transfection of 
C99 in APP-DKO cells did not affect mitochondrial levels (TOM20). (P-T) Seahorse graphs of representative 
experiments shown in Figure 1. All experiments represent the average of n³4 independent experiments; 

















Figure 2-8 (Supplemental Figure 2): Localization of C99 to MAM in PS1-KIM146V mice. 
Scheme showing the protocol followed to isolate the subcellular fractions analyzed by Western blot. (B) 
Example of western blot analysis of subcellular fractions from mouse liver obtained using the protocol 
shown in panel S2A, probed against specific markers for each indicated compartment (30 µg of protein per 
lane). (C) Scheme showing the protocol followed to purify subcellular fractions by continuous sucrose 
gradients analyzed by Western blot as shown in Figure 2C. (D) Representative confocal images from WT 
MEFs non-treated with DAPT and transfected with C99 (red), Sec61β to label ER (green), and mitochondria 
(blue). White arrowheads indicate areas of contact between ER and mitochondria where C99 is present. 
Red signal in the nucleus corresponds to the APP intracellular domain (AICD) produced after the γ-
secretase cleavage of the transfected C99-red construct (compare to DAPT-treated COS-7 cells in Figure 
2E, where no AICD is produced after γ-secretase inhibition). (E) Representative electron microscopy 
images of PS-DKO cells incubated with antibodies against APP-CTF conjugated with immunogold particles 
show significant labeling in MAM regions (brackets). (F, G) Western blots of total homogenates of 
embryonic cortical neurons explanted from WT and PS1-KIM146V mice (F) and of fibroblasts from AD patients 
(G) show higher levels of C99 in mutant samples vs. controls (30 µg of protein per lane). Quantifications of 
western blot bands normalized to the loading controls (tubulin and vinculin) are shown in the panels at right. 
(H) Western blot of subcellular fractions isolated from WT and PS1-KIM146V shows increased levels of C99 
in total homogenates (TH), crude membranes (CM), ER, and MAM fractions. Note that AICD levels are not 










Figure 2-9 (Supplemental Figure 3): Cholesteryl ester and lipid droplet formation in ɣ-secretase-
deficient cells. 
Staining with LipidTox Green to detect lipid droplets in the indicated explanted astrocytes (size bar=20 μm) 
and cortical neurons (size bar=25 μm) from WT and PS1-KIM146V mice. (B) Staining of LDs as in (A) of PS-
DKO cells untreated and treated with 10 μM of Gleevec. Quantitation of lipid droplets after incubation of 
PS-DKO cells with increasing concentrations of Gleevec is shown at right. All values represent the average 
of n=3 independent experiments ± SD; * p<0.01. (C) Staining of SH-SY5Y cells (upper panels) or HeLa 
cells (lower panels) treated with DAPT (to increase C99 accumulation) or with DAPT+BI (to inhibit C99 
production) (size bar=20μm). Quantitation of lipid droplets is shown at right. All values represent the 
average of n=3 independent experiments ± SD; * p<0.01. (D) Staining of BACE1-KO cells. Quantitation of 
lipid droplets is shown at right. All values represent the average of n=3 independent experiments ± SD; * 










Figure 2-10 (Supplemental Figure 4): Acid (aSMase) and neutral (nSMase) sphingomyelinase 
activities in various cell types. 
(A-C) Ceramide and sphingomyelin levels in total homogenates (A), mitochondria (B), and MAM (C) from 
WT and PS-DKO cells, represented as nmol per μg of protein. (D) Western blot of WT and PS-DKO cell 
homogenates to reveal PS1 levels after transfection with the indicated plasmids. (E) Ratio of Aβ42:Aβ40 
produced by cells shown in (D). Note the increase in the ratio of Aβ42:Aβ40 in cells transfected with mutant 
PS1A246E. (F) Ceramide and sphingomyelin levels in PS-DKO cells transfected with the indicated plasmids. 
Note partial “rescue” of ceramide levels after transfection with WT-PS1, but not with PS1A246E, plasmids. 
(G) Molecular species of ceramide and sphingomyelin in mitochondrial fractions from WT and PS-DKO 
MEFs. (H) Transcription of a gene encoding neutral sphingomyelinase 2 (nSMAse2; [SMPD3]), in WT and 
PS-DKO MEFs, by qRT-PCR. (I) Acid (aSMase) and neutral SMase (nSMase) activities in brain from PS1-
KIM146V mice. Note increased SMase in the mutant cells compared to WT. (J) SMase activities in SH-SY5Y 
cells. Note significantly increased SMase activities following inhibition of ɣ-secretase activity (and increased 
C99) with DAPT. (K) Neutral SMase (nSMase) activities in PS-DKO cells transfected with the indicated 
plasmids. Note decreased SMase in the mutant cells transfected with WT-PS1, but not with PS1A246E, 
plasmids. (L) Sphingomyelin (SM) synthesis in APP-DKO MEFs. (M) Sphingomyelin hydrolysis or 
sphingomyelinase activities in APP-DKO MEFs (lacking C99). (N) Both aSMase (aSM) and nSMase (nSM), 
but particularly nSMase activity, are increased significantly in PS-DKO MEFs (containing C99 but lacking 
both A� and AICD) vs WT cells. These activities are essentially unchanged in the presence of either A� 
(monomers of Aβ40 and Aβ42 added to the medium at a ratio of Aβ40:Aβ42 of 10:1; 6 ng/ml total Aβ 
concentration) or AICD (expressed transiently from a plasmid). All experiments represent the average of 






Figure 2-11 (Supplemental Figure 5): Analysis of sphingolipid metabolism in WT/PS-DKO MEFs. 
Approximate distribution of steady-state levels of sphingomyelin (SM) and ceramide (Cer) in cell 
compartments in WT MEFs (numbers in boxes denote % of the total present in the indicated compartment). 
The "Other" value was derived from subtracting the MAM+ER+Mito values from those in the total 
homogenate. (B) Increased nSMase activity in MAM isolated from PS1-KIM146V brain compared to WT brain 
(data represent the average of 4 independent experiments ±S.D. * p<0.05; n.s., not significant). (C) 
Phosphatidylserine (PtdSer) content in fractions isolated from WT and PS-DKO cells. Lipid values are 
represented as nmol normalized per unit of protein and total lipid extracted. Note the increase in PtdSer in 
MAM fractions (values represent the average of n=3 independent experiments ±S.D. * p<0.05; n.s., not 
significant). (D) PtdSer content in membranes isolated from WT, PS-DKO, and PS-DKO cells treated with 
BACE inhibitor. Note the decrease in PtdSer content in mutant cells after inhibiting the production of C99 
with BI. Values represent the average of 3 independent experiments ±S.D. * p<0.05; n.s., not significant. 
(E, F) Sphingomyelin (E) and ceramide (F) levels in membranes isolated from WT, PS-DKO, and PS-DKO 
cells treated with a BACE1 inhibitor. Note that BI treatment rescues sphingolipid homeostasis in mutant 









Figure 2-12 (Supplemental Figure 6): Supercomplex assembly is altered in γ-secretase deficient 
cells. 
(A, B) Sphingomyelin (A) and ceramide (B) levels in total homogenates, mitochondria, and MAM 
membranes from WT and PS-DKO cells untreated and treated with myriocin. Note significant reductions in 
sphingolipid levels after de novo synthesis of sphingolipids by myriocin. (C, D) Western blot of blue-native 
PAGE gels to detect complex I (C), and complex III (D) to reveal respiratory supercomplexes in 
mitochondria from WT and PS-DKO cells after the indicated treatments. Note that chemical or genetic 
inhibition of γ-secretase results in decreased supercomplex I+III+IV assembly. Inhibition of C99 production 
by BACE inhibitor (BI) or inhibition of ceramide production by myriocin (Myr) increases the assembly of 
supercomplexes I+III and I+III+IV as measured by anti-complex I antibodies, and of supercomplex III+IV as 
measured by anti-complex III antibodies. All values represent the average of n=3 independent experiments 
± SD; * p<0.05; n.s., not significant. (E) Western blot of WT and PS-DKO cells after the indicated treatments 
to reveal individual subunit complexes. (F) As a loading control, the samples from (A) and (B) were analyzed 
by Coomassie staining or western blot to reveal TOM20 (a protein localized in the mitochondrial outer 
membrane). Note that chemical or genetic inhibition of γ-secretase results in decreased supercomplex 
I+III+IV assembly. Inhibition of C99 production by BACE1 inhibitor (BI) or inhibition of ceramide production 
by myriocin (Myr) increases the assembly of supercomplexes I+III and I+III+IV as measured by anti-
complex I antibody, and of supercomplex III+IV as measured by anti-complex III antibodies. All experiments 







Figure 2-13 (Supplemental Figure 7): Mitochondrial dysfunction in PS1-KIM146V mice. 
(A, B) Oxygen consumption in mitochondria isolated from brain homogenates from PS1-KIM146V mice 
analyzed at various ages (indicated in months) compared to that in the corresponding WT mice (set as 
100%; dotted lines). In each assay, respiration is first measured at baseline; this is State 2 (i.e. initial 
respiration in the presence of added substrates [e.g. malate+pyruvate to measure complex I; 
succinate+rotenone to measure complex II]). ADP is then added; this is State 3 (i.e. maximum respiration 
in the presence of substrates). Oligomycin is then added to inhibit ATP synthase; this mimics State 4 (i.e. 
respiration after added ADP has been consumed). Finally, the uncoupler FCCP is added; this is State 3U 
(i.e. state 3 "uncoupled," [also called "noncoupled" respiration]. Note the steady decline in OCR that 
appears to accelerate at 8 months of age, correlating with (C) a decrease in supercomplexes activity, as 
measured by in-gel staining complex IV activity in mitochondria isolated from brain samples from 8 months 
old mice (upper left panel). As loading control, same membranes were analyzed by Coomassie staining 
(right panel), and the same samples were examined by western blot to detect Tom20 (bottom left panel). 
(D) Quantification of bands from (C) by densitometry. All experiments represent the average of n=3 




Chapter 3: C99 upregulates MAM functionality by promoting 
cholesterol trafficking to MAM domains 
 
This chapter in its entirety has been published in its entirety in The EMBO Journal (Montesinos, 
Pera, Larrea et al, 2020; DOI: 10.15252/embj.2019103791).  I am a co-author on this paper and helped 
conduct the C99 western blot shown in Fig. 3-7L and the sphingomyelinase (SMase) assay shown in Fig. 
3-9F. I also was extremely involved in the editing of this manuscript, and helped write some sections. This 
work is included in this thesis because it illustrates a concept that is foundational to the TBI studies: the 
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The link between cholesterol homeostasis and cleavage of the amyloid precursor protein (APP), 
and how this relationship relates to Alzheimer’s Disease (AD) pathogenesis, is still unknown. Cellular 
cholesterol levels are regulated through crosstalk between the plasma membrane (PM), where most cellular 
cholesterol resides, and the endoplasmic reticulum (ER), where the protein machinery that regulates 
cholesterol levels resides. The intracellular transport of cholesterol from the PM to the ER is believed to be 
activated by a lipid-sensing peptide(s) in the ER that can cluster PM-derived cholesterol into transient 
detergent-resistant membrane domains (DRMs). When formed, these cholesterol-rich domains in the ER 
maintain cellular homeostasis by inducing cholesterol esterification as a mechanism of detoxification while 
attenuating its de novo synthesis. In this manuscript, we propose that the 99-aa C-terminal fragment of APP 
(C99), when delivered to the ER for cleavage by g-secretase, acts as a lipid-sensing peptide that forms 
regulatory DRMs in the ER, called mitochondria-associated ER membranes (MAM). Our data in cellular AD 
models indicates that increased levels of uncleaved C99 in the ER, an early phenotype of the disease, 
upregulates the formation of these transient DRMs by inducing the internalization of extracellular cholesterol 
and its trafficking from the PM to the ER. These results suggest a novel role for C99 as a mediator of 







The lipid composition of cellular membranes undergoes continuous modulation to regulate 
processes such as signal transduction and trans-membrane ion gradients [623]. To support these events, 
a network of enzymes interconnects the metabolism of all lipids and promotes the remodeling of 
membranes into functional subregions [473]. Often, these domains display the characteristics of lipid rafts, 
or detergent-resistant domains [473]. Lipid rafts are transient membrane subregions formed by local 
increases in free or unesterified cholesterol, shielded from the aqueous phase through interaction with 
sphingomyelin (SM) and saturated phospholipids [473]. These local elevations in cholesterol create highly 
ordered membrane microdomains that passively segregate and enrich for lipid-binding proteins, facilitating 
protein-protein interaction(s) and the regulation of specific signaling pathways [473]. The formation of these 
domains is enabled by “lipid-sensing” proteins that possess the capacity to bind and cluster cholesterol 
[624]. If these lipid-sensing proteins were to be eliminated, local cholesterol clusters would disperse, 
dissolving lipid rafts into the liquid-disordered state. A critical event in this process is the activation of 
sphingomyelinases (SMases), which hydrolyze SM to ceramide [625]. As opposed to SM, ceramide creates 
an electrostatically unfavorable environment for cholesterol [626] and makes cholesterol accessible for 
removal from the membrane via, for example, esterification [625]. Hence, the turnover of lipid raft domains 
and their capacity to regulate signaling pathways are tightly linked to the regulation of cholesterol 
homeostasis. Thus, alterations in cholesterol metabolism would affect lipid raft formation, and vice versa. 
 Cellular cholesterol is either synthesized de novo in the endoplasmic reticulum (ER) or taken up as 
cholesterol esters (CEs) from lipoproteins [625]. The de novo synthesis of cholesterol is activated by the 
transport of the sterol regulatory element binding protein isoform 2 (SREBP2, gene SREBF2) from the ER 
to the Golgi and its subsequent activation by proteolytic cleavage [627]. The processed form of SREBP2 
translocates to the nucleus and induces the transcription of cholesterol-synthesizing genes and SREBF2 
itself [627]. When cellular cholesterol supply is sufficient, SREBP2 is retained in the ER in its uncleaved 
form, preventing activation of de novo cholesterol synthesis [627]. When taken up from extracellular 
lipoproteins, the internalized CEs are hydrolyzed in endolysosomes to unesterified free cholesterol, most 
of which is transferred to the plasma membrane (PM) [333,628]. Once the PM cholesterol concentration 




A:cholesterol acyltransferase 1 (ACAT1; gene SOAT1), as a means of detoxifying excess cholesterol [333]. 
The resultant CEs are stored in lipid droplets in the cytosol before being secreted [333]. Thus, to preserve 
cholesterol homeostasis, the cell maintains crosstalk between the PM, where the bulk of cholesterol 
resides, and the ER, where the enzymatic activities that regulate cholesterol levels reside [629]. This 
crosstalk is believed to be controlled by an as-yet-unknown sensor in the ER that triggers communication 
between the PM and the intracellular ER regulatory pool of cholesterol containing ACAT1 [486,628]. 
 The regulation of lipid metabolism (especially cholesterol) is particularly critical within the nervous 
system [630]. It is therefore not surprising that lipid dysregulation has been described in multiple neuro-
degenerative diseases, including in Alzheimer’s disease (AD) [631]. Specifically, cholesterol abnormalities 
in AD have been widely reported [631], but the field currently lacks consensus as to their cause(s).  
 The “amyloid cascade hypothesis” of AD pathogenesis states that increases in the levels of the β-
amyloid peptide (Aβ), derived from APP processing, triggers neurodegeneration [1]. In addition to these 
higher levels of Aβ, AD samples also present with increases in the cleavage of endocytosed full-length APP 
by β-secretase (BACE1) to produce the immediate precursor of Aβ, the 99-aa C-terminal domain of APP 
(C99) [1]. These alterations in APP metabolism are due to mutations in the PSEN1 [presenilin-1 (PS1)], 
PSEN2 [presenilin-2 (PS2)], and APP genes in familial AD (FAD), or by unknown causes in sporadic cases 
(SAD) [1]. Further linking AD and cholesterol, processing of APP C-terminal fragments (APP-CTFs) occurs 
in detergent-resistant membranes (DRMs) [588]. Notably, elevations in C99 have been shown to contribute 
to AD pathology [195], causing endosomal dysfunction [193] and hippocampal degeneration [187,194].  
 Previously, we and others found that C99, when delivered to the ER for cleavage by g-secretase, 
is not distributed in the ER homogeneously but is concentrated in mitochondria-associated ER membranes 
(MAMs) [89,105,469–471]. MAM is a DRM/lipid raft subdomain within the ER [96,632], involved in the 
regulation of lipid homeostasis [472]. We showed that, in AD cell and animal models, there is an increase 
of C99 at MAM [105] that results in the upregulation of MAM activities [96,478], including SMases, and 
cholesterol esterification by ACAT1 [105], a known MAM-localized enzyme [633]. Remarkably, inhibition of 
C99 production caused the inactivation of these MAM functions [105]. 
 We now report that in AD, by means of C99’s affinity for cholesterol [634], the pathogenic 




Trafficking of this excess cholesterol from the PM to the ER results in the continuous formation, activation, 
and turnover of MAM domains, previously observed in cells from AD patients [96,105]. Altogether, our data 
suggest a pathogenic role for C99 elevations in AD, via upregulation of cholesterol trafficking and MAM 
activity, which in turn disrupt cellular lipid homeostasis and cause the alterations in the membrane lipid 






Materials and Methods 
Cells: WT and PSEN1/2-DKO (called PS-DKO) mouse embryonic fibroblasts (MEFs) were 
provided by Dr. Bart De Strooper (University of Leuven). APPWT and APP/APLP2-KO (called APP-DKO) 
mouse embryonic fibroblasts (MEFs) [591] were a kind gift from Dr. Huaxi Xu (Sanford Burnham Institute). 
SH-SY5Y and Neuro-2a cell lines were obtained from the American Type Culture Collection. AD and control 
fibroblasts were obtained from the Coriell Institute for Medical Research (Camden, NJ, USA). Other PS1-
mutant FAD cells were kind gifts from Dr. Gary E. Gibson (Cornell University).  
Human induced pluripotent stem cells (hiPSCs) in which the APPV717I (London) mutation was 
knocked into both alleles of the control IMR90 cl.4 iPSC line (WiCell) were generated by Dr. Andrew 
Sproul’s lab, as described previously for the heterozygous knock-in of this mutation [635]. APPV717I knock-
ins and the isogenic parent line were maintained feeder-free in StemFlex media (Life) and Cultrex substrate 
(Biotechne). Cortical neurons from WT or PS1M146V-KI mice were cultured from P0 pups as reported [636]. 
Plasmid constructs and transfections: Plasmids were constructed using standard techniques. 
Construction of C99, AICD and C99-GFP (a kind gift of Dr. Albert Lleo) plasmids were described in [105].  
C99MUT was constructed using a megaprimer method. First, a PCR was performed using the pCAX 
APP-695 plasmid (Addgene #30137) as a template, forward primer: 5’-GTTCAAACAAAGCTGCAATCGCT-
GCACTCATGGTGGG-3’ and reverse primer: 5’-CCCGGATCCAAGCTTCTAGTTCTGCATCTGCTCAAA-
GAACTTG-3’, to obtain a megaprimer with the mutations (in bold). The product of this PCR was used as a 
reverse primer, with forward primer: 5’-ATACGAAGCTTGCAGAATTCCGACATGACTCA-3’ and the pCAX 
APP-695 plasmid as a template. The final PCR product was digested using HindIII/BamHI (restriction sites 
underlined) and ligated into pGFP-N3. 
C99MUT-GFP was generated by PCR using the C99MUT plasmid as a template, the forward primer 
5’-ATACGAAGCTTGCAGAATTCCGACATGACTCA-3’ and the reverse primer: 5’-AGGTGGATCCCGTT-
CTGCATCTGCTCAAAGAACTTG-3’. The PCR product was ligated into the C99-GFP plasmid previously 
digested with HindIII/BamHI.  
C83 was amplified from the pCAX APP-695 plasmid (Addgene #30137) using the forward primer: 
5’-CCCGAATTCATGTTGGTGTTCTTTGCAGAAGATGTG-3’ and the reverse primer: 5’- CTAAAGCTTCT-




EcoRI/HindIII (restriction sites underlined). 
All plasmids were verified by restriction analysis and sequencing. Cells were transfected using 
Lipofectamine™ 2000 in serum-free DMEM for 4-6h according to the manufacturer’s instructions. The 
transfection and expression efficiency for C99WT and C99MUT were found to be similar (data not shown).  
Ab42 treatment and Ab40 and Ab42 detection: APP-DKO cells were incubated for 16h with 5 µM 
of Ab42 oligomers prepared as in [105]. To detect Ab40 and Ab42 in cortical neuron media, commercial ELISA 
kits were used following manufacturer instructions (WAKO ELISA KIT 290-62601 and 294-62501). 
Analysis of ER–mitochondria apposition: Cells were co-transfected with BFP-Sec61b 
(Addgene, #49154), MitoDsRed (Clontech, #632421) and C99WT-GFP or C99MUT-GFP at a 1:1:3 ratio. 
Twelve hours post-transfection, images of triple-transfected cells were acquired and ER-mitochondria 
apposition was analyzed as described [592]. For C99 colocalization over ER or mitochondria, the same 
approach was applied using the respective signals. 
Subcellular fractionation and sucrose density gradient ultracentrifugation: Purification of ER, 
crude membranes (CM) and MAM was performed and analyzed as described [475]. 1 mg CM was 
incubated at 4°C for 1h in 0.2% Triton X-100 and loaded onto a continuous sucrose density gradient (10-
40%). Upon 16h centrifugation at 100,000g at 4°C, 24 fractions (200 μL each) were sequentially collected 
from the top without disturbing the gradient. Equal volumes (40μL) were used for WB.  
Silencing of PSEN1/2: To knock down mouse Presenilin-1 and -2 in Neuro-2a cells, shRNAs 
against Psen1 (Sigma SASI_Mm01_00048853) and Psen2 (Sigma SASI_Mm02_00310708) were 
transiently transfected together, according to manufacturer instructions, as in [96,329]. Briefly, cells plated 
at low confluence were transfected with each shRNA to a final concentration of 30 nM, using 
Lipofectamine™ 2000 (Invitrogen, 11668-027), at a 1:1 ratio in serum-free DMEM. After 5h, medium was 
changed to 2% FBS DMEM and cells were incubated for 12h. Successful silencing was determined by WB. 
Western blotting: For C99 detection, samples were boiled in NuPAGE™ LDS Sample Buffer with 
10% b-mercaptoethanol and run in 4-12% Bis-Tris gels (Criterion XT Precast Midi Gels, Bio-Rad) in XT 
MES buffer. Other proteins were detected using the antibodies listed in Table 3-1. 
Inhibitors: Cells were treated with either 100 nM b-secretase inhibitor IV (BI) or 10 µM DAPT to 




performed using 10 µM desipramine or 5 µM GW4869, respectively. To inhibit cholesterol esterification, 20 
µM 3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenethyl] propanamide (Sandoz 58-035) was used. All 
drugs were incubated for 12–16h and DMSO was used as vehicle. 
Cholesterol trafficking and esterification assays: Cholesterol trafficking and esterification were 
measured as previously described [105]. Cells were incubated for 2h in serum-free medium to ensure 
removal of exogenous lipids. 2.5 µCi/mL of 3H-cholesterol was added to serum-free DMEM containing 2% 
FAF-BSA, allowed to equilibrate for at least 30 min at 37°C, and the radiolabeled medium was added to the 
cells for the indicated periods of time. Cells were then washed and collected in PBS. For some experiments, 
cells were subjected to subcellular fractionation, removing a small aliquot for protein quantification. Equal 
protein amounts were used to extract lipids by using three volumes of chloroform:methanol (2:1 v/v). After 
vortexing and centrifugation at 8,000 g for 5 min, the organic phase was blown to dryness under nitrogen. 
Dried lipids were resuspended in 30 µL of chloroform:methanol (2:1 v/v) and applied to a TLC plate along 
with unlabeled standards. A mixture of hexanes/diethyl ether/acetic acid (80:20:1 v/v/v) was used as 
solvent. Iodine-stained bands corresponding to cholesterol and CEs were scraped and counted.  
Cholesterol efflux: Cells were incubated with 2.5 µCi/mL of 3H-cholesterol prepared as indicated 
above. 1 h after incubation, cells were washed to remove the excess of exogenous radioactive cholesterol 
and incubated in unlabeled media. After the indicated post-incubation times, media was recovered, briefly 
centrifuged at 4000rpm 5min to remove any debris, transferred to scintillation vials with 5 mL of Scintiverse 
BD (Fisher Scientific) and measured in a Scintillation Counter (Tri-Carb 2819TR, Perkin Elmer).  
Phospholipid transfer: Performed as in [96,475,484]. 
HMGCR activity assay: HMGCR activity was measured following manufacturer’s instructions 
(HMG-CoA Reductase Assay Kit CS1090, Sigma-Aldrich). 
Cholesterol and lipid droplets staining and immunofluorescence: Fluorescent cholesterol 
analog, NBD-cholesterol (Thermo Fisher Scientific N1148), was used to determine cholesterol uptake. 
Filipin staining was performed by incubation with 50 µg/mL of filipin complex in 10% FBS in DPBS 
for 2h at room temperature. For neurons, the concentration of filipin was 0.5 mg/mL. After extensive 
washes, coverslips were mounted with Fluoromount-GTM (Thermo Fisher Scientific) and visualized by 




excitation, 40 nm dichroic, 430-nm long pass filter).  
For immunofluorescence, prior to filipin staining, cells were permeabilized using saponin 0.05%, 
BSA 5% in PBS for at least 45 min, extensively washed and incubated with primary antibodies, as listed in 
Table A, for 1h at room temperature. After extensive washes, 1h incubation with secondary antibodies 
conjugated to Alexa fluorophores was performed before starting filipin staining. 
Staining of lipid droplets (LDs) was performed using HCS LipidToxTM Deep Green or Red neutral 
lipid stain according to manufacturer instructions. Staining was quantified using ImageJ. Reported 
fluorescence intensity represents the product of intensity and area covered by the fluorescent signal above 
background in every cell examined. For some experiments, the no. of cells containing LDs or filipin-positive 
punctae was counted and reported. In some experiments, DAPI or NucRed® was used to visualize nuclei. 
Sphingomyelinase activity: Sphingomyelinase activity was assayed as previously described 
[105]. 100 µg protein was assayed in 100 mM of the appropriate buffer (Tris/glycine for pH 7.0–9.0 or 
sodium acetate for pH 4.0–5.0), 1.55 mM Triton X-100, 0.025% BSA, 1 mM MgCl2, and 400 µM bovine 
brain sphingomyelin (SM) spiked with 22,000 dpm of [3H]-bovine SM (1 nCi/sample). Reactions were carried 
out in borosilicate glass culture tubes at 37°C overnight, followed by quenching with 1.2 mL ice-cold 10% 
trichloroacetic acid, incubation at 4°C for 30 min, and centrifugation at 2,000 rpm at 4°C for 20 min. 1 mL 
supernatant was transferred to clean tubes, 1 mL ether was added, the mixture vortexed, and centrifuged 
at 2,000 rpm for 5 min. 800 µL of the bottom phase was transferred to scintillation vials with 5 mL of 
Scintiverse BD (Fisher Scientific) and measured in a Scintillation Counter (Tri-Carb 2819TR, Perkin Elmer).  
Lipidomics analysis: Lipids were extracted from equal amounts of material (30 µg 
protein/sample). Lipid extracts were prepared via chloroform–methanol extraction, spiked with appropriate 
internal standards, and analyzed using a 6490 Triple Quadrupole LC/MS system (Agilent Technologies, 
Santa Clara, CA) as described previously [329]. Cholesterol and CEs were separated with normal-phase 
HPLC using an Agilent Zorbax Rx-Sil column (inner diameter 2.1 Å~ 100 mm) under the following 
conditions: mobile phase A (chloroform:methanol:1 M ammonium hydroxide, 89.9:10:0.1, v/v/v) and mobile 
phase B (chloroform:methanol:water:ammonium hydroxide, 55:39.9:5:0.1, v/v/v/v); 95% A for 2 min, linear 
gradient to 30% A over 18 min and held for 3 min, and linear gradient to 95% A over 2 min and held for 6 




that were developed in earlier studies [329] in conjunction with referencing of appropriate internal standards. 
Values are represented as mole fraction with respect to total lipid (% molarity). For this, lipid mass (in moles) 
of any specific lipid is normalized by the total mass (in moles) of all the lipids measured [329].  
PhotoClick cholesterol assay: To study cholesterol interaction with C99, a method developed by 
[637] was used. Briefly, 24h after transfection, cells were incubated in serum-free medium for 2h to remove 
all exogenous lipids. 5 µM Photo-Click cholesterol (Hex-5'-ynyl 3β-hydroxy-6-diazirinyl-5α-cholan-24-oate), 
previously complexed with an aqueous saturated solution of MβCD (38 mM), was added to the cells and 
incubated for 4h. Upon washes with DPBS, PhotoClick cholesterol was crosslinked under 365nm-UV (0.75 
J/cm2, UVC 500 Ultraviolet Crosslinker, Amersham Biosciences), washed again, collected and used for 
subcellular fractionation. 500 µg (adjusted to final 150 µL volume with PBS containing protease inhibitors) 
of TH, ER and MAM fractions were briefly sonicated and subjected to click chemistry by addition of 500 µM 
biotin-azide, 100 µM Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), 1 mM CuSO4 and 1 mM 
Tris(2-carboxyethyl)phosphine (TCEP) and incubation for 15 min at room temperature in the dark. Samples 
were diluted in 50 mM Tris pH 7.4 with protease inhibitors (removing an aliquot as input), and incubated 
overnight under rotation at 4°C with streptavidin beads. Upon several washes with Tris 50 mM pH 7.4, 
beads were collected by centrifugation at 2,000 rpm for 1min, boiled with NuPAGE™ LDS Sample Buffer 
(1X) 95 °C for 5min and used for immunodetection. A diagram is presented in Figure 3-5A. 
Statistical analysis: Data represent mean ± SEM. All averages are the result of three or more 
independent experiments, as listed in the figure legends, carried out at different times with different sets of 
samples. No statistical test was used to pre-determine sample size. Data distribution was assumed to be 
normal although this was not formally tested. The statistical analysis was performed using GraphPad Prism 
v5.01 (GraphPad Software Inc., CA, USA). Statistical significance was determined by either t-test, one-way 
ANOVA or (repeated measures) two-way ANOVA, followed by the Newman-Keuls’ post hoc test as 
reported in each figure legend. Values of p < 0.05 were considered statistically significant. The investigators 







Accumulation of C99 in the ER triggers cellular cholesterol uptake and trafficking to MAM 
 Recently, we found that increases in the levels of uncleaved C99 at MAM causes the co-activation 
of SMase(s) and of cholesterol esterification via ACAT1 [105], a mechanism by which cells “detoxify” 
membranes from an excess of cholesterol [486]. In light of these data, we hypothesized that the 
upregulation of sphingolipid turnover and cholesterol esterification in cell models of AD could be caused by 
elevated membrane cholesterol levels, which would activate this detoxification pathway. 
 To test this, we measured the concentration of cholesterol in homogenates and subcellular fractions 
from mouse embryonic fibroblasts (MEFs) null for PSEN1 and PSEN2 (PS-DKO) [594] (these cell display 
high levels of C99 in MAM [105]) (Fig. 3-1A) and from homogenates of AD fibroblasts (Fig. 3-7A) by liquid 
chromatography-mass spectrometry (LC-MS) [329]. We found that these models displayed increased levels 
of free cholesterol (FC) compared to controls. This increase in membrane-bound cholesterol was highly 
significant in total homogenates and MAM membranes (Fig. 3-1A) which, in light of previous data [96], could 
indicate that the upregulation of cholesterol esterification in AD cell models is the result of cholesterol 
buildup in membranes, and its subsequent elimination by esterification. We were able to recapitulate this 
result in MEFs in which both APP and its paralog, APLP2, were knocked out (APP-DKO) [595] and a 
plasmid expressing C99 was transiently transfected (Fig. 3-1B). Conversely, APP-DKO cells expressing 
either APP-C83 (produced by the cleavage of APP by a-secretase), AICD (produced by cleavage of C99 
by g-secretase) or incubated with amyloid Aβ42 oligomers did not show these cholesterol elevations, 
suggesting that C99 affects cholesterol homeostasis but other APP fragments do not (Fig. 3-1B). 
 Increases in FC levels could be a result of upregulated de novo synthesis, upregulated uptake or 
decreased removal. To determine whether cholesterol increases in AD cells occurred via upregulation of 
the de novo cholesterol synthesis pathway, we quantified the activity of the 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR), the rate-limiting enzyme in the synthesis of cholesterol, in g-secretase-deficient cells 
and in controls. HMGCR activity was reduced significantly in PS-DKO MEFs, in WT cells treated with g-
secretase inhibitors (DAPT) (Fig. 3-1C), and in AD fibroblasts (Fig. 3-7B), in agreement with previous 
observations [638]. Consistent with this, the levels of both uncleaved and mature SREBP2 protein were 




 Ruling out upregulated de novo synthesis as a cause of increased cellular cholesterol, we 
measured the rate of cholesterol uptake in PS-DKO cells and controls through pulse-chase analysis of 3H-
cholesterol internalization. PS-DKO cells showed an enhanced rate of cholesterol uptake when compared 
to controls (Fig. 3-1D), also observed in AD fibroblasts (Fig. 3-7D), and in neuronal cells silenced for PS1 
alone or for both PS1+PS2 (Fig. 3-7E). Interestingly, the increases in the uptake were abrogated upon 
BACE1 inhibition, suggesting a role for C99 in the regulation of cholesterol internalization.  
As mentioned before, internalized cholesterol is transported to MAM domains in the ER for 
esterification by the enzyme, acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1; gene SOAT1). To 
confirm that the internalized cholesterol trafficked to MAM domains in our cell models, we tracked the 
uptake of 3H-cholesterol, and its delivery to MAM and/or bulk ER, by pulse-chase analysis and subcellular 
fractionation in PS-DKO cells (Fig. 3-7F). We found that in PS-DKO cells the rate of cholesterol 
incorporation into MAM (Fig. 3-1E) was higher when compared to that in controls or in bulk ER fractions 
(Fig. 3-1F) and was abrogated upon BACE1 inhibition, confirming an elevated rate of cholesterol influx and 
mobilization towards the MAM in cells with elevated C99. This enhanced uptake and internalization of 
extracellular cholesterol was also reflected in the elevated ratio of cholesteryl esters:free cholesterol 
(CE:FC) [335,628] in PS-DKO cells (Fig. 3-7G) and in cells from AD patients (Fig 3-7H). 
To assess whether reductions in the removal of cellular cholesterol in our cell models of AD also 
contributed to these alterations in cholesterol dynamics, we also measured the levels of radiolabeled 
cholesterol secreted from the cell after the indicated post-incubation times (Fig. 3-7I). Our data indicates 
that cholesterol efflux correlates with increased cholesterol uptake, suggesting that, rather than reduced 
removal, these phenotypes are caused by an increase in cholesterol internalization, esterification and 
subsequent efflux from the cell, triggered by increases in C99. Supporting this result, the uptake of 
fluorescently labeled cholesterol was also increased in both DAPT-treated WT or PS-DKO cells compared 
to controls (Fig. 3-1G, upper panel), and was abrogated upon BACE1 inhibition, suggesting a role for C99 
in the regulation of cholesterol internalization.  
 To confirm that these results were not an artifact of exposure to exogenous cholesterol and indeed 
represent upregulated activity of cellular uptake machinery, we stained WT and PS-DKO MEFs cells with 




markedly different in both DAPT-treated WT or PS-DKO MEFs (Fig. 3-1G, lower panel), as well as in AD 
fibroblasts vs. controls (Fig. 3-7J), showing a higher degree of cholesterol puncta in the cytosol. Our images 
also showed that these filipin-positive bodies co-localized with markers of late endosomes (Rab7) and 
lysosomes (LAMP1), suggesting that these are indeed cholesterol-rich endolysosomes (Fig 3-7K).  
 To extend our observations to neuronal cell models of AD, we measured cholesterol uptake and 
esterification in WT cultured cortical neurons treated with DAPT, as well as in cultured cortical neurons from 
a knock-in mouse model carrying a familial mutation in PS1 (PS1M146V-KI mice) [271]. As reported previously 
[105], cortical neurons from PS1M146V-KI mice showed increased C99 levels (Figs. 3-7L and 3-7M) and 
higher Aβ42:Aβ40 ratios (Fig. 3-7N), as well as significant upregulation of MAM activity vs controls (Fig. 3-
7O). Similar to PS-DKO cells, neurons from PS1M146V-KI mice showed higher uptake of exogenous 
fluorescently- and radio-labeled cholesterol (Fig. 3-1H upper panel, and 3-1I), an increased number of 
filipin-positive bodies and lipid droplets (stained by LipidTox) in the cytoplasm (Fig. 3-1H, middle and lower 
panels) and a higher level of cholesterol esterification (Fig. 3-1I). Confirming a role for C99 in the regulation 
of cholesterol metabolism, these alterations were reversed by inhibition of BACE1 (Fig. 3-1H).  
 Finally, we were able to recapitulate these alterations in cholesterol metabolism in induced pluri-
potent stem cells (iPSCs) in which a pathogenic mutation in APP (London mutation; APPV717I) was knocked 
into both alleles using CRISPR/Cas9. In agreement with our hypothesis, this cell model presented with 
significant increases in C99 (Fig. 3-7P), upregulated cholesterol uptake and esterification (Fig. 3-7Q-R), 
and elevated ratio of CE:FC compared to isogenic controls (Fig. 3-7S). Altogether, our data indicates that 
cell models of AD present with increased intracellular cholesterol turnover, triggered by elevations in C99. 
 
Upregulation of cholesterol uptake induced by elevated C99 results in the activation of 
sphingomyelinase (SMase) activity 
 In cellular membranes, a “regulatory” pool of cholesterol is complexed with SM to shield cholesterol 
from water and prevent its mobilization [333,334]. Over a certain threshold of cholesterol concentration, 
SMases become activated and hydrolyze SM to produce ceramide, releasing the membrane-bound 
cholesterol for trafficking to the ER [335]. Our previous data revealed that increases in MAM-localized C99 




ER. Therefore, we asked whether the increase in cholesterol mobilization observed in our AD cell models 
might be a consequence of sustained SMase activity provoked by increases in MAM-C99. To test this idea, 
we incubated DAPT-treated WT cells and PS-DKO MEFs, both of which have an accumulation of C99 at 
MAM [105], with SMase inhibitors and analyzed cholesterol distribution and esterification by staining with 
filipin and LipidTox Green, respectively. Interestingly, incubation with SMase(s) inhibitors resulted in a sig-
nificant reduction in both cholesterol esterification by ACAT1, as evidenced by the amount of lipid droplets 
(LDs), in PS-DKO cells (Fig. 3-2A), in DAPT-treated SH-SY5Y cells (Fig. 3-8A), and in fibroblasts from AD 
patients (Fig. 3-8B). Therefore, we concluded that the increases in ACAT1 activity and LD production 
associated with elevated C99 were facilitated by activation of SMase(s), consistent with previous findings 
[335]. However, inhibition of SMase activity was not capable of reducing the internalization of extracellular 
cholesterol in g-secretase deficient cells (Fig. 3-2B-C), which presented with increased numbers of 
cytoplasmic filipin-positive punctae. This result suggests that SMase upregulation in AD models is likely a 
consequence, rather than the cause, of increased uptake and enrichment of cholesterol in membranes. 
 We were able to recapitulate this phenotype in DAPT-treated WT mouse cortical neurons treated 
with SMase inhibitors, which, as before, reduced lipid droplets (LDs) but failed to rescue the increased 
uptake of cholesterol, as measured by incubation with fluorescent cholesterol analogs (NBD-cholesterol) 
and filipin staining (Fig. 3-2D). Remarkably, treatment with BI was able to rescue the sustained uptake and 
internalization of cholesterol in our AD models (Fig. 3-2D), again supporting a role for C99 in this pathway. 
 Taken together, our results suggest that C99 accumulation in g-secretase-deficient cells suffer from 
a sustained upregulation of extracellular cholesterol uptake, internalization, and delivery to ER-MAM, where 
its esterification by ACAT1 is facilitated by SMase(s)-mediated SM hydrolysis [105].  
 
Localization of C99 to MAM is dependent on its cholesterol binding domain 
 The C99 fragment of APP contains a cholesterol binding motif within its transmembrane domain 
[634] that could promote its localization to lipid rafts [639], such as MAM [96,105]. To test whether C99’s 
cholesterol binding domain (CBD) is necessary for its localization to MAM, we transfected APP-DKO cells 
with plasmids expressing WT-C99 and a mutant C99 construct with reduced affinity for cholesterol 




DAPT to impede C99 cleavage by endogenous ɣ-secretase. After this, we analyzed the subcellular 
localization of WT and mutant forms of C99 by running membrane homogenates from these same 
transfected cells through a continuous sucrose density gradient and compared their comigration with 
compartment-specific markers by WB (Fig. 3-3A). As shown previously [105], C99WT comigrated with endo-
some (Rab5) and MAM (Acsl4) markers (Fig. 3-3B), while C99MUT showed markedly reduced comigration 
with MAM markers (Fig. 3-3C). As expected, flotillin, another protein with affinity for cholesterol, also 
comigrated with MAM markers in cells transfected with C99WT (Fig. 3-3D). On the other hand, flotillin showed 
reduced comigration with MAM markers in C99MUT-expressing cells (Fig. 3-3E). In addition, and contrary to 
its WT counterpart, C99MUT also showed reduced comigration with ER (Sec61b) or mitochondria (ATP5A1) 
markers (Fig. 3-3F-G), suggesting that the C99 CBD is required for its proper localization to MAM domains.  
To substantiate these results, we conducted confocal imaging by transfecting APP-DKO cells with 
GFP-tagged C99 constructs, alongside fluorescent mitochondrial (MitoDsRed) and ER (Sec 61b-BFP) 
markers (Fig. 3-4A). While C99WT showed a perinuclear pattern of colocalization with ER and mitochondria, 
C99MUT presented a less marked perinuclear localization and decreased association with mitochondria 
(Figs. 3-4A-B). Moreover, and as shown before [105], while overexpression of C99WT resulted in significant 
increases in the apposition between ER and mitochondria (Fig. 3-4C-D), APP-DKO cells expressing C99MUT 
showed no changes in ER-mitochondria connections (Fig. 3-4C-D), and perhaps in MAM formation and 
activation. This suggests that cells expressing C99MUT are deficient for MAM functionality [105]. 
To test this idea, we measured MAM activity and ER-mitochondria crosstalk by quantification of 
phosphatidylserine (PS) synthesis and its conversion to phosphatidylethanolamine (PE), a known MAM-
resident function [472,484]. As shown previously [105], MAM activity was significantly increased in APP-
DKO cells expressing C99WT in contrast to those expressing C99MUT, which showed significant reductions 
in MAM activity (Fig. 3-4E). Taken together, these results suggest that C99 binding to cholesterol is 
important not only for its localization to MAM, but also for the proper formation and activation of MAM itself. 
 
The cholesterol binding domain of C99 is required for the formation of MAM domains in the ER 
 As a lipid raft, MAM [96] is a transient functional membrane domain formed by local increases in 




coalesces into a rigid, lipid-ordered domain [624]. Thus, in light of our results, we hypothesized that C99, 
when delivered to the ER, docks to cholesterol via its CBD, thereby helping form MAM domains. To test 
this, we decided to analyze C99’s affinity for cholesterol using a click chemistry approach (Fig. 3-5A). 
PhotoClick-cholesterol is a cholesterol analog conjugated to a photoreactive alkyne that faithfully mimics 
native cholesterol, and can serve as a tool to determine protein affinity for cholesterol [637]. We incubated 
APP-DKO cells transiently expressing C99WT or C99MUT with this trans-sterol probe. Subcellular fractions 
from these cell models were then conjugated to an azide-biotin tag by click chemistry, followed by a pull-
down assay using streptavidin beads (Figs. 3-5A and 3-9A-B). As a proof of principle, we were able to 
detect increased levels of C99WT bound to cholesterol in MAM fractions from PS-DKO cells (Fig. 3-9C). 
The levels of click-cholesterol in homogenates of APP-DKO cells expressing C99WT or C99MUT were 
comparable (Fig. 3-5B-C). However, pull-down of the added PhotoClick-cholesterol revealed that the 
amount of C99MUT bound to this lipid was significantly reduced when compared to that of C99WT (Fig. 3-5B-
C) confirming that, as reported [634], the C99 residues G700, I703 and G704 are crucial for C99 cholesterol 
binding. Moreover, cells transfected with C99MUT exhibited significant reductions in the amount of click-
cholesterol that was transferred to MAM (Fig. 3-5B and 3-5D). Similarly, pull-down of the click cholesterol 
present in MAM fractions from cells transfected with C99MUT displayed lower levels of bound C99 (Fig. 3-
5C & Fig. 3-9D). In support of this, lipidomics analysis of isolated MAM fractions from these cell models 
showed reduced levels of cholesterol in cells expressing C99MUT when compared to controls (Fig. 3-5E).  
Consistently, transfection of APP-DKO cells with C99WT constructs resulted in the upregulation of 
cholesterol uptake (Fig. 3-5F), cholesterol esterification by ACAT1 (Fig. 3-5G), increased cholesterol efflux 
(Fig. 3-9E) and the concomitant activation of SMase(s) (Fig. 3-9F), whereas cells transfected with C99MUT 
showed no differences in these parameters when compared to controls. In agreement with these data, 
APP-DKO cells expressing C99WT showed a higher ratio of CE:FC (Fig. 3-5H) and a significant increase in 
lipid droplets (Fig. 3-9G) when compared to its C99MUT counterpart and to relevant controls. 
 Altogether, our results suggest that C99’s capacity to recruit and cluster cholesterol in the ER 
triggers the formation and activation of MAM domains. Moreover, accumulation of uncleaved C99 in AD 
cells induces the continuous/uninhibited/persistent/chronic turnover of MAM domains by activating the 





In previous reports, we and others found that g-secretase activity is localized in the ER but is not 
homogeneously distributed throughout this compartment; rather, this functionality is enriched in MAM 
domains, a transient DRM within the ER [89,470]. Moreover, alterations in g-secretase activity result in the 
functional upregulation of this ER subregion and in increased ER-mitochondria apposition [96,478]. 
 Recently, we showed that the g-secretase substrate, C99, predominantly localizes to MAM. Further-
more, we observed that alterations in g-secretase activity induce an accumulation of this APP fragment in 
MAM membranes, causing upregulation of MAM activities - such as cholesterol esterification and 
sphingolipid turnover – as well as mitochondrial dysfunction [105]. We now show that these phenotypes 
are consequences of the continuous uptake of extracellular cholesterol and its delivery to MAM, triggered 
by increased C99 levels in AD cells. Altogether, we suggest a pathogenic role for C99 elevations in AD, via 
upregulated cholesterol trafficking and MAM activity and subsequently disrupted cellular lipid homeostasis. 
 Our data supports a model (Fig. 3-6) in which C99 at MAM induces the uptake and transport of 
cholesterol from the PM to the ER [629], via an as-yet unknown mechanism, resulting in inhibition of the 
SREBP2-regulated pathway(s) [627]. We propose that, under normal circumstances (Fig. 3-6, upper panel), 
C99 - via its CBD - causes cholesterol to cluster in the ER, resulting in the formation of MAM domains. As 
this MAM-cholesterol pool expands, it activates the hydrolysis of sphingomyelin by SMases, exposing 
cholesterol to ACAT1 for esterification, decreasing the concentration of membrane-bound cholesterol and 
resulting in dissolution of lipid rafts [625]. In this way, C99 promotes a self-regulating feedback loop to help 
maintain intracellular cholesterol levels. Under this point of view, the failure to cleave C99 [195] (Fig. 3-6, 
lower panel) would result in a futile cycle of continuous uptake of cholesterol and its mobilization from the 
PM to the ER, resulting in the upregulation of MAM formation and activation, which in turn would cause the 
upregulation of SMases, ACAT1 activity, and lipid droplet deposition. Closing the cycle, this accumulation 
of cholesterol in the PM would also induce APP internalization, its interaction with, and cleavage by, BACE1 
[76,640], and downregulation of α-secretase activity [641]. Interestingly, increases in exogenous chol-
esterol can mimic this scenario, resulting in APP internalization and elevations in C99 [79], increases in the 
Ab42:40 ratio [77], Tau phosphorylation [642], and hippocampal atrophy and cognitive impairment [643].  




there is a substantial increase in the production of amyloid, which originates from elevated levels of C99 
fragments [187]. Thus, the buildup of C99 in AD could be considered an early pathological hallmark that 
may elicit many of the molecular symptoms of the disease, including endosomal dysfunction [193], cognitive 
impairment, and hippocampal degeneration [187]. Interestingly, others have found that changes in C99, 
rather than in Aβ or AICD, could be behind some dementia symptoms [194,201]. In light of these reports 
and our own data, we believe that C99 toxicity in AD is mediated by its role in cholesterol metabolism. 
 Consistent with previous data [638], our results show that the buildup of C99 in MAM correlates 
with significant decreases in HMGCR and SREBP2 and in the de novo synthesis of cholesterol, in an Aβ- 
and AICD-independent fashion. Thus, while the specific pathway still needs to be elucidated, these data 
suggest that the accumulation of C99 prevents SREBP2 activation, impeding its function as a transcription 
factor [627]. We note that one of the SREBP2-regulated genes is the LDL receptor, whose expression 
would also be reduced by SREBP2 downregulation in a feedback mechanism to control cholesterol levels 
[627]. Paradoxically, our results also reveal that cholesterol uptake is highly induced in g-secretase-deficient 
cells in which C99 levels are increased. The intriguing failure of a negative feedback mechanism to 
downregulate C99-mediated cholesterol import suggests that the continuous uptake of cholesterol might 
occur through one of the SREBP2-independent cholesterol receptors expressed in the cell [644,645].  
 As mentioned above, when in excess, “accessible” cholesterol in the PM cholesterol pool will be 
proportionally transported to the ER cholesterol pool, where it will trigger feedback responses to maintain 
homeostasis [333,628,629]. It has been suggested that this trafficking is regulated by cholesterol-sensing 
proteins and/or a specific cholesterol-sensing membrane domain in the ER associated with ACAT1 [486]. 
Based on previous studies [646] and the results presented here, we propose that C99, via its CBD [634], 
acts as such a cholesterol sensing protein, and that the MAM acts as a signaling platform in the regulation 
of cholesterol homeostasis. Thus, it is possible that, via this affinity domain, the accumulation of C99 
generates the cholesterol-rich areas needed for its cleavage by the γ-secretase complex [466]. Hence, in 
the context of deficient γ-secretase activity, uncleaved C99 will continue to recruit cholesterol to MAM, 
which helps explain the upregulation in MAM activity and in ER-mitochondria connections found in cells 
from AD patients [96,478]. In agreement with this idea, C99MUT that is defective in cholesterol binding failed 




 C99 is not alone in harboring a cholesterol binding domain with the capacity to modulate the 
formation and activation of lipid raft domains. This has also been shown for the sigma-1 receptor, a MAM-
resident protein [647] that, via its capacity to bind cholesterol, triggers the remodeling of lipid rafts and the 
regulation of the signaling molecules that are present in them [648]. Thus, such cholesterol sensing proteins 
might represent a natural mechanism of regulating dynamic lipid rafts like MAM domains. 
 In summary, in our hypothesis we propose a potential mechanism to explain the fundamental role 
of cholesterol in AD, underscored by the multiple genetic studies that have identified polymorphisms in 
genes related to cholesterol metabolism and the incidence of AD [649], including, most prominently, APOE. 
Moreover, our data helps clarify the interdependence between cholesterol and APP metabolism [79] and 
the controversial association between cholesterol levels in AD [650], which we believe may be rooted in the 
fact that defects in neuronal transmission could be caused by alterations in the distribution of subcellular 
cholesterol, rather than in overall changes in cholesterol concentration.  
Taken together, we propose a model in which C99 accumulation and increased cholesterol uptake 
occurs early in the pathogenesis of AD. Such a model would help create a framework to understand not 
only the role of cholesterol as both a cause and a consequence in the pathogenesis of AD, but also the 
participation of many genetic loci associated with lipid metabolism, and specifically cholesterol regulation, 
in the pathogenesis of AD. In addition, this model supports the idea that the APP C-terminal fragment acts 
as a cholesterol sensing protein in the membrane [646], whose cleavage regulates lipid homeostasis in the 
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Figure 3-1: C99 accumulation promotes cholesterol uptake and trafficking to MAM. 
(A) Quantification of free cholesterol (FC) levels by lipidomics analysis of total homogenates (TH), ER or 
MAM fractions isolated from WT and PS-DKO cells. Lipid units are represented as molar mass over total 
moles of lipids analyzed (mol %). Graphs represent fold change over controls. (B) Quantification of FC 
levels in TH of APP-DKO cells transiently expressing C99, C83 or AICD peptides, or treated with 5 µM Aβ42 
oligomers for 16h. Cholesterol levels of WT cells are control. Lipid units are represented as molar mass 
over total moles of lipids analyzed (mol %). Graphs represent fold change over controls. (C) Quantification 
of HMGCR enzymatic activity showed a decreased rate of de novo cholesterol synthesis in PS-DKO and 
DAPT-treated WT cells. (D) Quantification of cholesterol uptake by incubating WT and PS-DKO cells, 
treated or untreated with BACE inhibitor IV (BI, 100 nM), with 2.5 µCi/mL 3H-cholesterol for the indicated 
times. Graph represents radioactivity levels in TH. (E-F) Quantification of 3H-cholesterol delivery to MAM 
(E) or bulk ER (F) after the indicated times. Control and BI-treated/untreated PS-DKO cells were incubated 
with 2.5 µCi/mL 3H-cholesterol for the indicated times, before subcellular fractionation. MAM fractions were 
assessed by WB (shown in Fig. S1F). Cholesterol delivery to MAM was calculated by quantification of 
radioactivity levels in the isolated fractions. Note that the increased rate of cholesterol delivery to MAM in 
PS-DKO cells is abrogated by inhibition of C99 production. (G) Measurement of cholesterol uptake in the 
indicated cells as measured by internalization of a fluorescent cholesterol analog [NBD-cholesterol (2 µM; 
upper panel, nuclei in blue)]. Endogenous FC was stained with filipin (lower panel). Graphs on the right 
represent fluorescence intensity (using ImageJ) and the percentage of cells with filipin punctae. Scale bar 
= 20 µm. (H) Representative confocal images of cultured cortical neurons from WT or PS1-KI mice treated 
with DAPT or BI, as indicated. Cholesterol uptake was analyzed by incubation with NBD-cholesterol as 
before (upper panel, nuclei in blue was stained by DAPI). Endogenous cholesterol (no exogenous 
cholesterol added) was stained with filipin (middle panels), and cholesterol esterification and subsequent 
lipid droplet (LD) quantification (no exogenous cholesterol added) was visualized by staining with LipidTox 
(lower panel, nuclei in blue). Graphs on right represent fluorescence intensity quantified by ImageJ. Scale 
bar = 20 µm. Arrows indicate filipin punctae or LDs. (I) Quantification of cholesterol uptake and esterification 
by assessing the radioactivity levels in TH from cultured cortical neurons from WT and PS1-KI mice after 





Figure 3-2: SMase inhibition prevents lipid droplet generation but fails to rescue the increase in 
cholesterol uptake caused by C99 accumulation. 
(A) Representative confocal images of WT and PS-DKO cells treated with the indicated SMase inhibitors 
(10 µM desipramine or 5 µM GW4869) or DMSO (VEH) for 12-16h. Endogenous levels of lipid droplets 
(LDs) were visualized by incubation with LipidTox. Endogenous levels of free cholesterol revealed by filipin 
staining of (B) WT or (C) PS-DKO cells under the indicated treatments. (D) Representative confocal images 
of cortical neurons from WT mice, incubated with the indicated inhibitors. Cholesterol uptake was assessed 
by internalization of fluorescent cholesterol analog (NBD-cholesterol 2 µM; upper panel, nuclei in blue); 
endogenous free cholesterol levels are shown by filipin staining (middle panel, nuclei in red); and 
cholesterol esterification and LD formation were revealed by LipidTox staining (lower panel). Arrows 
indicate the presence of filipin punctae or LD. Scale bar = 20 µm. Graphs on the right represent fluorescence 





Figure 3-3: The cholesterol binding domain of C99 is necessary for its localization to MAM. 
(A) Crude membrane fractions from APP-DKO cells expressing C99WT or C99MUT were treated with 0.2% 
Triton-X-100, loaded onto continuous density sucrose gradients and centrifuged for 16h. Fractions from 
these gradients were analyzed by western blot to determine the migration of the indicated proteins [two 
parallel gels (bold vertical line)]. (B-G) Graphs represent the relative abundance of the indicated proteins 
in each fraction of the gradient, as measured by densitometry analysis of western blot signals (ImageJ). 










Figure 3-4: C99’s cholesterol binding domain facilitates MAM formation and activation. 
(A) Representative confocal images of APP-DKO cells expressing GFP-tagged C99WT or C99MUT (in green) 
and fluorescent markers of mitochondria (MitoDsRed, in red) and ER (Sec61β-BFP, in blue), and treated 
with DAPT to prevent C99 cleavage. Note the different distribution of C99WT or C99MUT forms. Scale bar = 
10 µm. Insets show 5X amplifications of individual (C99 in green, and mitochondria in red) and merged 
images. Black and white bottom panels represent the areas where C99 and mitochondria signals colocalize. 
Upon thresholding each channel, a mask for mitochondria was generated and the C99 channel was 
superimposed on the mitochondria mask, so the positive pixels found in both channels are shown in black. 
(B) Quantification of the degree of colocalization of C99WT or C99MUT forms with mitochondria or ER 
measured by ImageJ. Note the significantly decreased colocalization between C99MUT and mitochondria, 
when compared to that of C99WT. (C) Representative confocal images of APP-DKO cells expressing GFP-
tagged C99WT or C99MUT and ER and mitochondria markers as in (A) (upper panel). Individual zoomed 
single channels (middle panel) as well as areas of ER-mitochondria colocalization (bottom panel) are shown 
for each condition. (D) Quantification of ER-mitochondria colocalization per cell analyzed. Upon 
thresholding each channel, a mask for ER was generated and the mitochondria channel was superimposed 
on the ER mask, so the positive pixels found in both channels were quantified and referenced over the total 
area of the ER mask. The number of cells analyzed is indicated in white text within each column. Levels of 
ER-mitochondria colocalization in APP-WT cells are shown for reference as a dashed line. (E) 
Quantification of MAM activity by measurement of phospholipid synthesis and transfer between ER and 
mitochondria in the indicated cells [484]. Graphs represent the levels of 3H-serine incorporation into 
phosphatidylserine (PS) and its subsequent conversion into phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC) over the indicated time periods. EV, empty vector. * p<0.05, ** p<0.01, *** 





Figure 3-5: C99’s cholesterol binding domain is necessary for cholesterol trafficking to MAM. 
(A) Scheme of PhotoClick cholesterol methodology to detect C99 interaction with cholesterol. (B) 
Representative immunoblot to reveal C99 levels in total homogenate (TH) and MAM fractions of APP-DKO 
cells expressing C99WT or C99MUT before (input) and after cholesterol pull-down. Acsl4 was used as a MAM 
marker. Streptavidin-HRP was used to detect total biotinylation (biotin conjugated to PhotoClick 
cholesterol). (C) Quantification of pulled-down C99 levels versus input from the experiment in B. (D) 
Immunoblot showing the levels of pulled-down PhotoClick Cholesterol (streptavidin-HRP) in ER and MAM 
fractions. Note how the levels of pulled-down C99 in the ER are negligible when compared to those from 
MAM. Isolated MAM and ER fractions were assessed by western blot (shown in Fig. S3D). (E) 
Quantification of free cholesterol levels (FC) analyzed by lipidomics after subcellular fractionation to obtain 
MAM from the indicated cells. Lipid units are represented as molar mass over total moles of lipids analyzed 
(mol%). Graphs represent fold change over controls. (F-G) Quantification of cholesterol uptake and 
esterification in the indicated cells was measured by 4h incubation with 3H-cholesterol and subsequent 
analysis of radiolabel incorporation. The dashed line indicates control levels. Treatment with Sandoz 58-
035, a specific ACAT1 inhibitor, caused a ~95% reduction in cholesterol esterification. EV, empty vector. 






Figure 3-6: Schematic representation of the potential role of C99 in the regulation of cholesterol 
trafficking, and its relevance to AD. 
By means of its affinity for cholesterol, uncleaved C99 at the ER induces the uptake and retrograde transport 
of cholesterol from the PM to the ER, resulting in the formation of a lipid raft domain, or MAM. These C99-
dependent lipid rafts passively segregate and organize lipid-binding proteins, thereby facilitating their 
interaction and the regulation of specific signaling pathways. Failure to cleave C99 completely would result 
in a futile cycle of continuous uptake of extracellular cholesterol and its mobilization from the PM to the ER, 
resulting in the upregulation of MAM formation and activation, which in turn would cause the upregulation 
of SMases, ACAT activity, and LD deposition. Closing the cycle, this accumulation of cholesterol in 
membranes also induces APP internalization and its interaction and cleavage by BACE1, and the 










Figure 3-7 (Supplemental Figure 1) 
(A) Quantification of free cholesterol (FC) and cholesteryl ester (CE) levels in total homogenates from 
fibroblasts from familial (FAD) and sporadic (SAD) AD patients by lipidomics analysis. Lipid units are 
represented as molar mass over total moles of lipids analyzed (mol%). Graphs represent fold change over 
controls (WT). (B) Quantification of HMGCR enzymatic activity showed a decreased rate of the de novo 
synthesis of cholesterol in fibroblasts from FAD patients. (C) Measurement of SREBP2 levels by WB 
showed reductions in its mature/active form in DAPT-treated WT cells, and a reduction in both the full-
length/precursor and mature forms in PS-DKO cells. Note how reductions in SREBP2 levels in mutant cells 
were abrogated upon BACE1 inhibition (BI). Coomassie staining is shown as a loading control. (D-E) 
Quantification of cholesterol uptake in (D) FAD fibroblasts and (E) in neuroblastoma cell lines (Neuro-2a) 
where PS1, or both PS1 and PS2, had been transiently silenced. Dashed line indicates control levels. (F) 
WB of isolated MAM and ER fractions used in Fig. 1E-F, respectively. Erlin-2 and ERp72 were used as 
MAM and ER markers, respectively. (TH: total homogenate, CM: crude membrane). (G) CE:FC measured 
by lipidomic analysis of WT and PS-DKO cells homogenate, and in (H) AD fibroblasts. (I) Cholesterol efflux, 
at 2, 4 and 6h, upon 1h pulse-chase with 3H-cholesterol was assayed in WT or PS-DKO cells previously 
treated for 16h with DAPT or a BACE inhibitor (BI), respectively. DMSO was used as a vehicle. (J) 
Endogenous levels of cholesterol were detected by filipin staining in the indicated FAD cell lines and age-
matched controls. Scale bar = 20 µm. (K) Representative confocal images of PS-DKO and DAPT-treated 
WT cells where the distribution of FC was analyzed by co-staining with filipin (blue) and the indicated 
markers (labeled in red) of endosomes (Rab7), ER (Sec61β), lysosomes (LAMP1) and Golgi (GM130). 
Scale bar = 20 µm. Zoom images are 5X. (L) WB showing the levels of APP, C99 and C83 in homogenates 
of cortical neurons explanted from WT and PS1KIM146V mice. Upper panel shows a shorter exposure of the 
blot to reveal unsaturated signal of APP. Tubulin-β was used as a loading control. Graphs showing the 
quantification for each APP fragment (M); and the ratio Aβ42 and Aβ40 levels (N) in WT and PS1KIM146V 
cortical neurons. (O) Quantification of MAM activity by measurement of phospholipid synthesis and transfer 
between ER and mitochondria in WT and PS1KI cultured cortical neurons [484]. Graphs represent the 
levels of 3H-serine incorporation into phosphatidylserine (PS), and its subsequent conversion into 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC) during the indicated times. Dashed line 
indicates the WT levels. (P) WB of homogenates from APPV717I cells and isogenic controls to reveal APP, 
C99 and C83 levels. TH of C99-transfected APP-DKO cells were used as a control for C99 signal. Tubulin-
β is shown as a loading control. (Q) Quantification of cholesterol uptake and esterification in APPV717I and 
isogenic control cell lines measured by incubation with 2.5 µCi/mL 3H-cholesterol and tracking of its 
internalization and (R) incorporation into 3H-CE at the indicated time points. (S) Ratio of CE:FC measured 







Figure 3-8 (Supplemental Figure 2) 
(A) Confocal images of human neuroblastoma cells (SH-5YSY) incubated with the indicated treatments for 
12-16h or DMSO (VEH) before staining with LipidTox to visualize lipid droplets (green). Treatment with 
Sandoz 58-035, a specific ACAT1 inhibitor, caused a ~95% reduction in cholesterol esterification. Nuclei 
are shown in blue (DAPI). Scale bar = 20 µm. Graphs show the percentage of cells containing lipid droplets 
(LDs) and the quantification of fluorescent intensity/cell (ImageJ). Note how elevations in cholesterol 
esterification can be induced by DAPT and rescued by incubation with either 100 nM BACE inhibitor (BI) or 
the SMase inhibitors, desipramine (DESIP, 10 µM) or GW4869 (5 µM). (B) Confocal images of control and 
FAD fibroblasts incubated with SMase inhibitor, GW4869, for 12-16h and stained with LipidTox to detect 








Figure 3-9 (Supplemental Figure 3) 
(A) Biotinylation levels were detected using streptavidin-HRP to optimize CLICK chemistry conditions. Note 
that the specific biotinylation of PhotoClick cholesterol can be detected 15 min after initiation of the click 
reaction. (B) APP-DKO cells expressing the C99 construct were incubated with PhotoClick cholesterol and 
exposed to UV for crosslinking. PhotoClick cholesterol was biotinylated using CLICK chemistry before using 
streptavidin beads to pull down the biotinylated cholesterol. In parallel, either PhotoClick cholesterol, UV or 
CLICK reagents were omitted to assess the specificity of the approach. The presence of C99 interacting 
with the pulled-down PhotoClick cholesterol was analyzed by immunoblotting for each condition. Note that 
C99 levels are undetectable when either PhotoClick cholesterol, UV or CLICK reagents are not added. 
Streptavidin-HRP treatment was used to reveal endogenously biotinylated proteins (used as loading 
control). (C) MAM fractions from WT or PS-DKO cells incubated with PhotoClick cholesterol were used to 
assess if endogenous C99 was detected upon pull-down of biotinylated PhotoClick cholesterol, thus 
corroborating the feasibility of this technique for analyzing C99-cholesterol interaction. (D) Western blot of 
subcellular fractions isolated in Fig. 5B-D. Erlin-2, ERp72 and ATP5A1 were used as MAM, ER and crude 
membrane (CM) markers, respectively (TH: total homogenate). (E) Cholesterol efflux, measured 4h after 
completion of 1h pulse-chase with 3H-cholesterol was assayed in APP-DKO or WT (APP-WT) cells 
transfected with an empty vector (EV) or the C99WT or C99MUT constructs. (F) Quantification of neutral and 
acidic SMase activities in the indicated conditions. (G) Representative images of APP-DKO cells expressing 
C99WT-GFP or C99MUT-GFP and stained with LipidTox (in red) to detect lipid droplets (white arrows). Scale 
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Chapter 4: MAM functionality is upregulated in a mouse model of 
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Traumatic brain injury (TBI) is a major cause of death and disability in the United States. A history 
of TBI can lead to neurodegenerative diseases, such as Alzheimer’s disease (AD), in a severity- and 
frequency-dependent manner. We previously reported that early stages of AD are characterized by 
alterations in lipid metabolism due to upregulated functionality of mitochondria-associated endoplasmic 
reticulum (ER) membranes (“MAM” domains of the ER), a cellular hub of lipid metabolic regulation. This 
can be caused by increased localization of the amyloid precursor protein (APP) 99-aa C-terminal fragment 
(C99) at MAM, which promotes the uptake of cellular cholesterol and its trafficking to the ER. Through this 
mechanism, MAM-localized C99 can stimulate MAM functionality. In this study, we recapitulated these 
phenotypes in the controlled cortical impact (CCI) model of TBI in adult mice. Specifically, we observed 
increases in phospholipid synthesis, sphingomyelinase activity and cholesterol esterification in the cortex 
and hippocampus 1, 3, and 7 days after injury. These responses were predominant in microglia, and 
coincided with increased levels of MAM-localized C99. Based on these findings, we propose that 
upregulation of MAM functionality could contribute, at least in part, to the epidemiological connection 






In the United States, traumatic brain injury (TBI) is the leading cause of death and disability for 
people under the age of 45, and incurs an annual economic cost of $76.5 billion. According to the Centers 
for Disease Control and Prevention (CDC), in 2014, 2.5 million people visited the emergency room following 
a TBI, with 56,800 deaths; approximately 80,000 of these patients developed long-term disabilities 
(statistics sourced from Brain Trauma Foundation and CDC). A large subset of TBI cases is characterized 
by the development of neurodegenerative diseases, especially in patients who have had multiple TBIs 
[508]. Even though these downstream consequences are usually grouped into a condition known as chronic 
traumatic encephalopathy (CTE) [495], a large percentage is clinically equivalent to Alzheimer’s Disease 
(AD) [52]. Generally, physical damage is restricted to the outer, cortical layer of the brain; however, the 
most common neurological symptoms relate to hippocampal functions [651], which is also where AD 
pathogenesis is thought to originate [652,653]. Thus, the relationship between TBI and AD is a growing 
field of research. While the epidemiological connection is established, the molecular mechanism by which 
a history of TBI can lead to permanent AD-like neurodegeneration is unknown. 
Current understanding of TBI pathogenesis derives largely from studies in rodent models where 
injury parameters can be well controlled. A major focus of TBI research is the recapitulation of AD 
phenotypes in order to find shared aberrations in signaling cascades. Indeed, cardinal AD features such as 
amyloid-β (Aβ) deposition, tau hyperphosphorylation, and neurofunctional deficits, have been reported in 
TBI models [654,655]. These studies suggest that TBI induces alterations in the cleavage of amyloid 
precursor protein (APP) similar to those found in AD, but analyses in port-mortem TBI tissues have failed 
to demonstrate a correlation between Aβ/tau burden and disease progression [527].  
An important aspect of TBI pathogenesis is its biphasic nature [519]: a primary phase of necrotic 
cell death at the site of injury is followed by a secondary phase of metabolic dysfunction in the surrounding 
area, including Ca2+ elevations, mitochondrial alterations and hypoxia [656]. The magnitude and duration 
of this latter phase are dependent on the severity of the injury. In most cases, these alterations will 
normalize; however, it is believed that, following multiple injuries, these metabolic alterations will be 
sustained and become chronically dysregulated. Since the likelihood of developing AD is highest among 




pathways underlies the connection between TBI and AD pathogenesis. 
In relation to these metabolic alterations, our group and others have observed dysregulation of lipid 
metabolism during early stages of AD [657] that resemble the lipid metabolic alterations reported in neural 
injury models [566,658]. Specifically, we have observed that alterations in the activity of ɣ-secretase, which 
cleaves the amyloid precursor protein (APP) C-terminal fragment of 99 a.a. (C99) to generate Aβ, in AD 
samples result in increased ER-localized C99 [105]. Via its capacity to directly bind cholesterol, C99 can 
induce cholesterol trafficking to the ER and the formation of intracellular lipid rafts known as mitochondria-
associated ER membranes (“MAM” domains of the ER) [493]. The formation of MAM domains activates the 
recruitment of specific lipid-binding enzymes to facilitate protein-protein interactions and the modulation of 
their activities [472]. Therefore, MAM formation changes the lipid milieu of the ER, resulting in a “signaling” 
platform for the regulation of metabolic pathways. Increased MAM-localized C99 leads to upregulated 
functionality of MAM domains, which we have observed in both familial (FAD) and sporadic (SAD) AD 
samples [96]. This causes the dysregulation of overall cellular lipid homeostasis due to increased synthesis 
and turnover of specific lipid species, such as cholesterol, sphingomyelin and phospholipids [472]. Given 
the lipid metabolic alterations reported in TBI models, and the known activation of lipid synthesis and 
trafficking for the repair of damaged membranes after brain injury [659], we hypothesized that TBI induces 
the activation of MAM functionality. While cellular lipid homeostasis may be restored after a single TBI 
episode, multiple TBIs would lead to chronic metabolic alterations that resemble AD, leading to AD-like 
cellular phenotypes.   
In this work, using the controlled cortical impact (CCI) model of TBI in adult mice, we report 
upregulated functionality of MAM domains during the acute phase following a single, moderate injury. This 
correlates with increased localization of C99 to MAM domains, and results in relevant alterations in the 
lipidome of brain tissues and of purified microglial, astrocytic and neuronal populations. Through this 
preliminary study, we propose a novel pathway that could underlie the relationship between TBI and AD. 




Materials and Methods  
Mouse husbandry: All animal husbandry was conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals published by the National Institutes of Health. Specific procedures 
were approved by the Institutional Animal Care and Use Committee at Columbia University (protocols AC-
AAAO5307 and AC-AAAY6450). WT male, C57BL/6J mice (12-16 weeks in age) were ordered from 
Jackson labs and housed under a 12h light/12h dark cycle. Following CCI injury (described below), the 
mice were placed in post-procedure housing and monitored daily for wellness. General analgesic (5 mg/kg 
carprofen) was delivered via intraperitoneal (IP) injection 20 min before injury as well as 1 day (1d) and 2d 
after injury. Mice were sacrificed 1, 3 or 7 days after injury via cervical dislocation or transcardial perfusion.  
Controlled cortical impact (CCI) injury: Twenty minutes following IP injection of general anal-
gesic (5 mg/kg carprofen), the mouse was placed in an induction chamber and exposed to 4% isoflurane 
for general anesthesia (supplied via an Isoflurane Vaporizer, Summit Anesthesia Solutions) supplemented 
with oxygen at a flow rate of 1 liter per minute (LPM). Once breathing was stabilized and there was no 
response to toe pinch, head fur was clipped and the mouse was secured in a stereotactic frame to initiate 
surgery. Anesthesia was maintained during surgery through a nose cone supplying isoflurane (eventually 
reduced to 2%) and oxygen (maintained at 1 LPM), verified via toe pinch every 2 min. Body temperature 
was maintained at 37°C by keeping the mouse on a heating pad (Adroit Medical Systems, Loudon, TN) 
throughout the procedure. The scalp was disinfected by swabbing 3 times with fresh Prevantics antiseptic 
3.15% chlorhexidine gluconate/70% isopropanol (Henry Schein, Melville, NY) wipes. Local analgesic (2 
mg/kg bupivacaine) was injected subcutaneously at the injury site and 1 drop of Puralube ophthalmic 
ointment (Dechra Pharmaceutics, Northwich, United Kingdom) was applied to each eye. A midline incision 
was made to the scalp using a scalpel and a craniectomy was performed to create a 5 mm X 5 mm hole in 
the skull between the bregma and lambda to the left of the sagittal suture. A single cortical contusion was 
made to the exposed dura mater using the Impact One instrument (Leica Biosystems, Buffalo Grove, IL) 
with the following parameters: 4.5 m/s velocity, 1.2 mm depth, 0.3 sec dwell time. Following injury, the 
incision was closed with sutures and Neosporin topical antibiotic ointment was applied. The mice were 
monitored during recovery from anesthesia.  




injury (alongside age-matched naïve controls) by cervical dislocation. The brain was extracted and 
immediately snap-frozen in isopentane at -40°C for 35 sec. Following storage at -80°C, the brains were 
sectioned at 8 μm thickness using a CM3050S cryostat (Leica Biosystems, Buffalo Grove, IL). The sections 
were stored at -80°C until ready for staining, at which point they were placed at RT for 25 min before 
beginning the staining protocol. The staining solution consisted of 5.2 mM 3,3-diaminobenzidine, 0.09 mM 
cytochrome C from equine heart, and 1.4 μM catalase in 5 mM phosphate buffer, pH 7.4, filtered through 
Whatman paper. The stain was applied to the tissue for 25 min at 37°C in the dark, followed by 3 gentle 
and quick washes with ddH2O. The slides were coverslipped using warmed glycerin jelly as mounting 
medium. Images were collected the next day using a Nikon Eclipse 80i brightfield microscope. 
 Fluoro-Jade C staining: Mice were euthanized 1, 3 or 7 days after CCI injury (alongside age-
matched naïve controls) via transcardial perfusion with 40 mL 1X phosphate-buffered saline (PBS) followed 
by 80 mL 4% paraformaldehyde (PFA, Sigma) in 1X PBS at a rate of 10 mL/min. The brain was removed 
and post-fixed in 4% PFA overnight (ON) at 4°C with gentle agitation. The brains were embedded in 3% 
agarose gel in a cubic cryomold and coronally sectioned at 50 μm thickness using a VT1000S vibrating 
blade microtome (Leica Biosystems, Buffalo Grove, IL). The sections were rinsed in PBS ON at 4°C, 
mounted onto slides and stained using the Fluoro-Jade C (FJC) Ready-to-Dilute Staining Kit for Identifying 
Degenerating Neurons (Biosensis, Thebarton, South Australia) following manufacturer instructions. The 
slides were coverslipped using DPX mounting medium (Sigma) and imaged using an Olympus IX73 
inverted microscope with an X-Cite Series 120 fluorescent lamp (Lumen Dynamics, Ontario, Canada). 
 Lipidomics analysis (bulk): At the indicated time-points after CCI injury, mice were euthanized 
(alongside age-matched naïve controls) via cervical dislocation and the brain was immediately extracted. 
The ipsilateral cortex and hippocampus (and corresponding regions in naïve animals) were microdissected 
on ice and homogenized in a Dounce homogenizer in Vance buffer (225 mM D-mannitol, 25 mM HEPES-
KOH, 1 mM EGTA, pH 7.4) with cOmplete Mini EDTA-free protease inhibitor cocktail (Sigma) added at the 
time of use. Protein concentration was determined using the Quick Start Bradford 1x Dye Reagent (Bio-
Rad) and Quick Start BSA Standard (Bio-Rad) in a Tecan Infinite F200 PRO spectrophotometer. Equal 
protein amounts of each sample (100 μg) were used for lipid extraction. Lipid extracts were prepared via 




Triple Quadrupole LC/MS system (Agilent Technologies, Santa Clara, CA) as described previously [329]. 
Cholesterol and CEs were separated with normal-phase HPLC using an Agilent Zorbax Rx-Sil column 
(inner diameter 2.1 Å~ 100 mm) under the following conditions: mobile phase A (chloroform:methanol:1 M 
ammonium hydroxide, 89.9:10:0.1, v/v/v) and mobile phase B (chloroform:methanol:water:ammonium 
hydroxide, 55:39.9:5:0.1, v/v/v/v); 95% A for 2 min, linear gradient to 30% A over 18 min and held for 3 min, 
and linear gradient to 95% A over 2 min and held for 6 min. Quantification of lipid species was accomplished 
using multiple reaction monitoring (MRM) transitions that were developed in earlier studies [329] in 
conjunction with referencing of appropriate internal standards. Values are represented as mole fraction with 
respect to total lipid (mole percentage). Lipid mass (in moles) of any specific lipid was normalized by the 
total mass (in moles) of all the lipids measured [329]. 
 Magnetic-activated cell sorting (MACS) isolation of microglia, astrocytes and neurons: At 
the indicated time-points after CCI injury, mice were euthanized by transcardial perfusion with 50 mL 1X 
Hanks’ Balanced Salt Solution ++ (HBSS with Ca2+ and Mg2+, without phenol red or Na2CO3), pH 7.4, at a 
rate of 10 mL/min. The brain was extracted and the ipsilateral cortex and hippocampus (and corresponding 
regions in naïve animals) were microdissected on ice. This step was not done in the validation experiments 
shown in Fig. 4-10 as those were conducted in cells isolated from the whole brain (to have enough material 
for all of the qPCRs). For the remainder of the protocol, MACS+ Buffer (1X HBSS++, 15 mM HEPES and 
0.5% BSA in ddH2O, pH 7.4) was the primary buffer in all steps. The tissue was dissociated using the 
Neural Tissue Dissociation Kit – Postnatal Neurons (Miltenyi Biotec, Bergisch Gladbach, Germany) 
following manufacturer instructions with modifications: a 37°C oven with tube rotator was used instead of 
the GentleMACS dissociator, enzymes and buffer volumes were doubled (per gram tissue); trituration was 
conducted with a trimmed P1000 pipet tip, and a 70-μm Falcon cell strainer (Thermo Fisher Scientific) was 
used instead of the MACS SmartStrainer. For the validation qPCR experiments, a 200 μL aliquot of this 
suspension was taken as the “unsorted” sample. 
 For myelin removal, Myelin Removal Beads II (Miltenyi Biotec) were used. Per 0.5g starting material 
weight, the pellet from dissociation was resuspended in 3.6 mL MACS+ buffer to which 400 μL beads were 
added. The sample was incubated at 4°C for 15 min with agitation every 5 min. The reaction was suspended 




The pellet was resuspended in 6 mL MACS+ buffer and evenly distributed between two LS columns 
(Miltenyi Biotec) in the presence of a magnetic field (generated by the QuadroMACS magnetic separator, 
Miltenyi Biotec). After washing the columns with 3 mL MACS+ buffer three times, the flow-through was 
centrifuged at 300g for 10 min at 4°C. 
 For microglia isolation, the resultant pellet was resuspended in 875 μL MACS+ buffer in a 5-mL 
epitube, to which 125 μL CD11b microbeads (Miltenyi Biotec) was added. The sample was placed on a 
rotating wheel at 4°C for 30 min, after which the tube was filled with buffer and centrifuged at 300g for 10 
min at 4°C. The pellet was resuspended in 4 mL MACS+ buffer and divided evenly between two LS columns 
(Miltenyi Biotec) in the presence of a magnetic field. The columns were washed 3 times each with 3 mL 
MACS+ buffer, and the total flow-through was set aside for astrocyte isolation. The microglia were collected 
by removing the columns from the magnetic field, applying 5 mL MACS+ buffer, and using the plunger to 
elute the captured cells. Both the eluent and flow-through were centrifuged at 300g for 10 min at 4°C.  
 For astrocyte isolation, the pellet of the flow-through was resuspended in 700 μL MACS+ buffer, to 
which 150 μL FcR Blocking Reagent (Miltenyi Biotec) was added. The sample was placed on a rotating 
wheel at 4°C for 30 min, followed by addition of 150 μL Anti-ACSA-2 microbeads. The sample was placed 
on a rotating wheel at 4°C for 30 min, after which the tube was filled with buffer and centrifuged at 300g for 
10 min at 4°C. The pellet was resuspended in 4 mL MACS+ buffer and divided evenly between two LS 
columns (Miltenyi Biotec) in the presence of a magnetic field. The columns were washed 3 times each with 
3 mL MACS+ buffer, and the total flow-through was set aside as the “neurons.” The astrocytes were 
collected by removing the columns from the magnetic field, applying 5 mL MACS+ buffer, and using the 
plunger to elute the captured cells. Both the eluent and flow-through were centrifuged at 300g for 10 min at 
4°C. The supernatants were removed and the pellets were stored for downstream applications. 
 Lipidomics analysis (MACS-sorted populations): Following MACS isolation of cell type-specific 
populations, the final pellets were snap-frozen on dry ice and stored at -80°C until lipid extraction. 
Lipidomics analysis was conducted as described above; however, since protein concentration was not 
determined (due to the high concentration of BSA in the isolation buffer), quantities (moles) of the extracted 
lipid species were normalized by quantity (moles) of total lipid extracted to determine mole percentage. 




after CCI injury (alongside age-matched naïve controls) by cervical dislocation. The brain was extracted 
and the ipsilateral cortex and hippocampus (and corresponding regions in naïve animals) were 
microdissected on ice. The tissues were homogenized in a Dounce homogenizer in Vance buffer (225 mM 
D-mannitol, 25 mM HEPES-KOH, 1 mM EGTA, pH 7.4) with cOmplete Mini EDTA-free protease inhibitor 
cocktail (Sigma) added at the time of use. Protein concentrated was quantified, and equal protein amounts 
(200 μg) were used for each sample. Following digestion with proteinase K (1 mg/mL), DNA was extracted 
using a standard phenol-chloroform extraction protocol with isopropanol for precipitation and ethanol for 
cleaning. RNA was digested using RNase A/T1 mix (Thermo Fisher Scientific EN0551) and DNA 
concentration was measured using a Nanodrop 1000. Quantitative PCR was conducted under standard 
conditions using the reaction composition in Table 4-1. 
Oil Red O staining: Mice were euthanized 3d after CCI injury (alongside age-matched naïve 
controls) via transcardial perfusion with 40 mL 1X phosphate-buffered saline (PBS) followed by 80 mL 4% 
paraformaldehyde (PFA, Sigma) in 1X PBS at a rate of 10 mL/min. The brain was removed and post-fixed 
in 4% PFA overnight (ON) at 4°C with gentle agitation, cryo-protected in 30% sucrose for 2-3d at 4°C with 
gentle agitation (until brains sink), snap-frozen in isopentane at -40°C for 35 sec, embedded in OCT medium 
(Thermo Fisher Scientific) and sectioned at a thickness of 16 μm using a CM3050S cryostat (Leica 
Biosystems, Buffalo Grove, IL). Following storage at -80°C, the slides were allowed to equilibrate at RT for 
30 min and placed in a humidified chamber. 10% formalin (Thermo Fisher Scientific) was applied for 1 min. 
The slides were dipped in ddH2O for 30 sec and allowed to air-dry. In the humidified chamber, Oil Red O 
0.5% solution in propylene glycol (Poly Scientific R&D Corp. s1848) was applied for 1h, followed by three 
5-min dips in ddH2O. The slides were air-dried and coverslipped using Fluoromount-G (Thermo Fisher 
Scientific). Images were immediately collected using a Nikon Eclipse 80i brightfield microscope. 
Quantitative polymerase chain reaction (qPCR; bulk): Mice were euthanized 3d after CCI injury 
(alongside age-matched naïve controls) and the brain was immediately extracted. The ipsilateral cortex and 
hippocampus (and corresponding regions in naïve animals) were microdissected on ice and immediately 
homogenized by pipetting and vortexing in TRIzol (Thermo Fisher Scientific). Total RNA was extracted 
using manufacturer instructions and tested for purity by measuring A260/A280 and A260/A230 ratios via a 




bands corresponding to 28S and 18S ribosomal RNA (rRNA). Following digestion with RQ1 RNase-free 
DNase (Promega), reverse transcription was performed with the High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific). qPCR was conducted in triplicate in a StepOne Plus real-time 
PCR machine (Applied Biosystems) using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific). 
The expression of each gene was analyzed using pre-designed TaqMan Probes (Thermo Fisher Scientific), 
with Gapdh (assay ID Mm99999915_g1, VIC-MGB_PL) serving as the housekeeping gene. The assay IDs 
of the probes used for the experimental genes tested, all conjugated to the FAM-MGB fluorophore, are 
listed in Table 4-2. Data was analyzed using the ΔΔCt method.  
 qPCR for cell type-specific markers in MACS-sorted populations: Following collection of 
pellets, total RNA was immediately extracted using the RNeasy Plus Micro Kit (Qiagen). Lysis was 
conducted by vortexing the pellet in 350 μL Buffer RLT Plus containing β-mercaptoethanol (BME) for 1 min. 
No carrier RNA was used. Purity was determined by measuring A260/A280 and A260/A230 ratios via a Nanodrop 
1000 (Thermo Fisher Scientific). Because the RNeasy Plus kit includes gDNA eliminator columns, DNase 
digestion was not conducted as a separate step. Reverse transcription was performed using the High 
Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). qPCR was conducted in triplicate with 
TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) in a StepOne Plus real-time PCR machine 
(Thermo Fisher Scientific). The expression of each gene under study was analyzed using pre-designed 
TaqMan Probes (Thermo Fisher Scientific), with Rn18s/Rn45s (encoding 18S rRNA and 45S pre-rRNA; 
assay ID Mm03928990_g1, VIC-MGB_PL) serving as the housekeeping gene. The assay IDs of the 
experimental genes tested are listed in Table 4-3. All probes were conjugated to the FAM-MGB fluorophore. 
Data from each mouse was analyzed separately. Grubbs’ test (⍺=0.05) was used to identify outliers, which 
were then removed. GOI = gene of interest. 
 Phospholipid transfer assay: This assay was conducted as described in [475,484]. Briefly, mice 
were euthanized 3 days after CCI injury (alongside age-matched naïve controls) by cervical dislocation. 
The brain was extracted and the ipsilateral cortex and hippocampus (and corresponding regions in naïve 
animals) were microdissected on ice. The tissues were homogenized with a Dounce homogenizer in Vance 
buffer (225 mM D-mannitol, 25 mM HEPES-KOH, 1 mM EGTA, pH 7.4) with cOmplete Mini EDTA-free 




described in [475,660], protein concentration was quantified and 100 μg protein was brought to a volume 
to 50 μL in phospholipid transfer assay buffer (10 mM CaCl2, 25 mM HEPES-KOH, 0.01% Triton X-100, 
0.04 mM 3H-serine). The reactions were incubated at 37°C for 45 min and stored at -20°C as needed. Lipids 
were extracted and resolved through thin layer chromatography (TLC), followed by excision of relevant 
spots and scintillation counting as described in [475,660]. For each experiment, the average of each species 
in the CCI group was divided by the average in the naïve group in order to generate the fold change over 
naïve. These numbers are represented in the graph and were used for statistical analysis.  
 Seahorse analysis of mitochondrial respiration: Mitochondrial oxygen consumption rate (OCR) 
was determined as previously described [661]. In summary, mice were euthanized 1, 3 or 7 days after CCI 
injury (alongside age-matched naïve controls) by cervical dislocation. The brain was extracted and the 
ipsilateral cortex and hippocampus (and corresponding regions in naïve animals) were microdissected on 
ice. The tissues were homogenized in ~10 volumes homogenization buffer (210 mM mannitol, 70 mM 
sucrose, 5 mM HEPES and 1 mM EGTA) and centrifuged at 900xg for 10 min at 4°C. The remaining 
supernatant was centrifuged at 9000xg for 10 min at 4°C and the resulting pellets were resuspended in 
washing buffer (210 mM mannitol, 70 mM sucrose, 5 mM HEPES, 1 mM EGTA, and 0.5% FAF-BSA, pH 
7.2) and centrifuged again at 8000xg for 10 min at 4°C. The pellets, containing mitochondria, were 
resuspended in mitochondrial assay solution and protein concentration was measured. For C-I 
experiments, 8 µg of protein were added to each well and 6 µg for C-II analysis. Oxygen consumption was 
measured at States 2, 3, 4, and uncoupling after sequential addition of 3 mM ADP, 4 µM oligomycin, 6 µM 
FCCP and 4.5 µM Antimycin A, respectively.  
Stimulated Raman Scattering imaging: Mice were euthanized 7 days after CCI injury (alongside 
age-matched naïve controls) via transcardial perfusion with 40 mL 1X phosphate-buffered saline (PBS) 
followed by 80 mL 4% paraformaldehyde (PFA, Sigma) in 1X PBS at a rate of 10 mL/min. The brain was 
removed and post-fixed in 4% PFA overnight (ON) at 4°C with gentle agitation. The brains were embedded 
in 3% agarose gel in a cubic cryomold and coronally sectioned at 50 μm thickness using a VT1000S 
vibrating blade microtome (Leica Biosystems, Buffalo Grove, IL). The sections were rinsed in PBS ON at 
4°C, mounted onto slides and coverslipped.  




throughput and a 25X water objective (XLPlanN, 1.05 N.A., MP, Olympus) with high near-IR transmission 
for SRS imaging. A picoEMERALD system (Applied Physics & Electronics) supplied synchronized pulse 
pump beam (with tunable 720-990 nm wavelength, 5-6 ps pulse width, and 80-MHz repetition rate) and 
Stokes (with fixed wavelength at 1064 nm, 6 ps pulse width, and 80 MHz repetition rate). Stokes is 
modulated at 8MHz by an electronic optic modulator. Transmission of the forward-going pump and Stokes 
beams after passing through the samples was collected by a high N.A. oil condenser (N.A. = 1.4). A high 
O.D. bandpass filter (890/220, Chroma) is used to block the Stokes beam completely and to transmit only 
the pump beam onto a large area Si photodiode for the detection of the stimulated Raman loss signal. The 
output current from the photodiode is terminated, filtered, and demodulated by a lock-in amplifier (Zurich, 
HF2LI) at 8 MHz to ensure shot-noise-limited detection sensitivity. The demodulated signal is fed into 
analog channel of FV1200 software FluoView 4.1a (Olympus) to form image during laser scanning at a rate 
of 100us per pixel. For multi-channel SRS imaging, the pump wavelength was tuned so that the energy 
difference between pump and Stokes matched with the vibrational frequency as described below. λpump= 
1/(1/1064+10-7*v) where v is the vibrational frequency in cm-1. CH channels were acquired at 2845 cm-1 
and 2940 cm-1 and unmixed according to an earlier report [662]. 
 Sphingomyelinase (SMase) assay: Mice were euthanized 3 days after CCI injury (alongside age-
matched naïve controls) by cervical dislocation. The brain was extracted and the ipsilateral cortex and 
hippocampus (and corresponding regions in naïve animals) were microdissected on ice. The tissues were 
homogenized in a Dounce homogenizer in Vance buffer (225 mM D-mannitol, 25 mM HEPES-KOH, 1 mM 
EGTA, pH 7.4) with cOmplete Mini EDTA-free protease inhibitor cocktail (Sigma) added at the time of use. 
Sphingomyelinase activity was assayed as previously described [105]. Following protein concentration 
quantification, 100 µg protein was assayed in a buffer containing 100 mM tris/glycine (pH 7.4), 1.55 mM 
Triton X-100, 0.025% BSA, 1 mM MgCl2, and 400 µM bovine brain sphingomyelin (SM) spiked with 22,000 
dpm of [3H]-bovine SM (1 nCi/sample). Reactions were carried out in borosilicate glass culture tubes at 
37°C overnight, followed by quenching with 1.2 mL ice-cold 10% trichloroacetic acid, incubation at 4°C for 
30 min, and centrifugation at 2,000 rpm at 4°C for 20 min. 1 mL supernatant was transferred to clean tubes, 
1 mL ether was added, the mixture vortexed, and centrifuged at 2,000 rpm for 5 min. 800 µL of the bottom 




measured in a Scintillation Counter (Tri-Carb 2819TR, Perkin Elmer). 
Subcellular fractionation: Mice were euthanized 3 days after CCI injury (alongside age-matched 
naïve controls) via cervical dislocation and the brain was immediately extracted. The ipsilateral cortex and 
hippocampus (and corresponding regions in naïve animals) were microdissected on ice and homogenized 
in a Dounce homogenizer in Vance buffer (225 mM D-mannitol, 25 mM HEPES-KOH, 1 mM EGTA, pH 7.4) 
with cOmplete Mini EDTA-free protease inhibitor cocktail (Sigma) added at the time of use. Subcellular 
fractionation was conducted as previously described [660]. 
 Succinate dehydrogenase (SDH) activity staining: Mice were euthanized 1, 3 or 7 days after 
CCI injury (alongside age-matched naïve controls) by cervical dislocation. The brain was extracted and 
immediately snap-frozen in isopentane at -40°C for 35 sec. Following storage at -80°C, the brains were 
sectioned at 8 μm thickness using a CM3050S cryostat (Leica Biosystems, Buffalo Grove, IL). The sections 
were stored at -80°C until ready for staining, at which point they were placed at RT for 25 min before 
beginning the staining protocol. The staining solution consisted of 5 mM EDTA, 1 mM KCN, 0.2 mM 
phenazine methosulfate, 50 mM succinic acid and 1.5 mM Nitro Blue in 5 mM phosphate buffer, pH 7.6, 
filtered through Whatman paper. The stain was applied to the tissue for 10 min at 37°C in the dark, followed 
by 3 gentle and quick washes with ddH2O. The slides were coverslipped using warmed glycerin jelly as 
mounting medium. Images were collected the next day using a Nikon Eclipse 80i brightfield microscope. 
 Transmission electron microscopy: Mice were euthanized 3d after CCI injury (alongside age-
matched naïve controls) via transcardial perfusion with 40 mL 1X phosphate-buffered saline (PBS) followed 
by 80 mL 4% paraformaldehyde (PFA, Sigma) in 1X PBS at a rate of 10 mL/min. The brain was removed, 
post-fixed in 4% PFA overnight (ON) at 4°C with gentle agitation, and sectioned at a thickness of 100 μm 
using a VT1000S vibrating blade microtome (Leica Biosystems, Buffalo Grove, IL). The sections were fixed 
by gentle agitation for 1h at RT with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium 
cacodylate buffer. They were then post-fixed with 1% osmium tetroxide followed by 2% uranyl acetate, 
dehydrated through a graded series of ethanol and sandwiched between Aclar sheets for embedding in 
LX112 resin (LADD Research Industries, Burlington VT). The area of interest was cut out, glued to a blank 
resin block and ultrathin (80 nm) sections were cut on a Leica EM Ultracut UC7, stained with uranyl acetate 




Western blot for APP-C99: Protein concentration was determined using the Quick Start Bradford 
Protein Assay Kit 1 (Bio-Rad 5000201) in a Tecan Infinite F200 PRO spectrophotometer. For each fraction, 
10 μg protein was combined with 1 μL 10% Triton X-100 (Sigma) and brought to a volume of 33 μL in Vance 
buffer (225 mM D-mannitol, 25 mM HEPES-KOH, 1 mM EGTA, pH 7.4). The ratio of 10 μg Triton:1 μg 
protein was maintained. The sample was vortexed for 15 sec, incubated on ice for 1h with occasional short 
vortexes, and combined with 11 μL loading buffer (4X NuPAGE LDS sample buffer, Thermo Fisher 
Scientific, with 10% BME). The sample was heated at 95°C for 5 min and loaded into a 4-12% Criterion XT 
Bis-Tris Protein Gel, 12+2 well, midi format (Bio-Rad 3450123) using 1X XT MES Running Buffer (Bio-Rad 
1610789). Electrophoresis was conducted at 80-120V. The sample was transferred to an Immuno-Blot 
PVDF membrane (Bio-Rad 1620177) in standard tris-glycine transfer buffer with 20% methanol and 0.04% 
SDS at 150 mA for 90 min. The antibodies used are as follows: APP-C99 (Biolegend 805701, clone M3.2); 
APP C-terminus (Sigma A8717, identifies both C99 and C83); Erlin-2 (Abcam Ab129207) and TOM20 
(Santa Cruz Sc-11415). 
 Western blot for TOM20 and OxPhos complexes: Mice were euthanized 1, 3 or 7 days after CCI 
injury (alongside age-matched naïve controls) by cervical dislocation. The brain was extracted and the 
ipsilateral cortex and hippocampus (and corresponding regions in age-matched naïve animals) were 
microdissected on ice. The tissues were homogenized in a Dounce homogenizer in Vance buffer (225 mM 
D-mannitol, 25 mM HEPES-KOH, 1 mM EGTA, pH 7.4) with cOmplete Mini EDTA-free protease inhibitor 
cocktail (Sigma) added at the time of use. Protein concentration was quantified and 10 μg was combined 
with 4X Laemmli loading buffer in a final volume of 20 μL, heated at 50°C and loaded onto a Novex 
WedgeWell 4-20% tris-glycine mini SDS-PAGE gel. Electrophoresis was conducted at 80-120V using 
standard tris-glycine running buffer. The sample was transferred to an Immuno-Blot PVDF membrane (Bio-
Rad 1620177) in standard tris-glycine transfer buffer with 20% methanol and 0.04% SDS at 150 mA for 2h. 
The antibodies used are as follows: Total OxPhos Rodent WB antibody cocktail (Abcam ab110413); TOM20 
(Santa Cruz sc-11415); β-actin (Sigma A5441); and Vinculin (Sigma V4505).  
Statistical analysis: Data represent mean ± SD. All averages are the result of three or more 
separate animals, as indicated in the figure legends, processed independently. No statistical test was used 




tested. The statistical analysis was performed using Microsoft Excel and GraphPad Prism v9.0.0 (GraphPad 
Software Inc., CA, USA). Statistical significance was determined by T-test or Ordinary one-way ANOVA 
followed by Bonferroni’s multiple comparisons test, as indicated in the figure legends, at an ⍺=0.05 







The controlled cortical impact (CCI) model of TBI 
 The multiple experimental models of TBI that have been developed recapitulate human TBI 
features to varying degrees [512]. In this study, we employed the controlled cortical impact (CCI) model in 
adult male WT C57BL/6J mice. During a CCI injury, a rapidly accelerating rod penetrates the cerebral cortex 
through an opening in the skull [513]. We selected this model on the basis of its ability to recapitulate clinical 
TBI features in a reproducible manner [655,663], and the ease with which we could control injury 
parameters [513]. We performed an injury of moderate severity where the cortex is physically impacted but 
subcortical structures, including the hippocampus, are not [513].  
 We began this study by assaying known responses to brain injury in order to determine the regional 
specificity of activated molecular pathways. Our studies were conducted in the ipsilateral cortex (directly 
injured) and ipsilateral hippocampus (below the injury), and results were compared to naïve (uninjured) 
samples. We collected tissues 1, 3 and/or 7 days after injury because the APP and lipid metabolic 
phenotypes relevant to the hypothesis under study have been previously reported at these time-points 
[528,566]. Furthermore, we sought to generate insight into whether the parameters under study were 
transient or sustained during the acute phase after injury. 
A well-characterized phenotype in the CCI model is cell death, thought to be a major contributor to 
behavioral alterations after TBI [651]. Since the extent and distribution of cell death differs based on injury 
parameters, we carried out FluoroJade-C staining, which labels degenerating neurons [664], to characterize 
this response in our model. We observed widespread cell death in the cortex that was nearly absent in the 
hippocampus (Fig. 4-1A). Nonetheless, gene expression of astrocyte and microglia activation markers 
(Gfap [665] and Aif1 [666], respectively) was elevated in both regions while elevations in Cldn11 expression 
(indicative of oligodendrocyte activation [667]) was limited to the cortex (Fig. 4-1B). These results suggest 
that cell death is not a requirement for a brain region to respond to physical injury, as robust glial activation 






MAM activity is upregulated after brain injury 
 Our results in AD suggest that APP and lipid metabolic alterations lie at the heart of disease 
pathogenesis [657]. We observed that, via its capacity to bind cholesterol, C99 accumulation in the ER in 
cells from AD patients and in cellular and animal models of AD induces the formation of MAM domains by 
stimulating cholesterol trafficking to the ER and the formation of lipid rafts [105,493]. Given the role of MAM 
in cellular lipid regulation, we hypothesized that brain injury could also induce increases in MAM-localized 
C99 to stimulate lipid synthesis for membrane repair [659]. In agreement with this hypothesis, we observed 
a marked increase in C99 levels in MAM fractions from both cortical and hippocampal tissues of CCI mice 
compared to naïve mice (Fig. 4-2). This occurred in the absence of observable alterations in the expression 
of β-secretase (gene: Bace1), the enzyme that cleaves full-length APP to generate C99 (Fig. 4-8B).  
 We next sought to determine whether this result correlated with increases in MAM enzymatic 
activities. To do this, we measured phospholipid synthesis and transfer between the ER and mitochondria, 
an established proxy measure of MAM activity [483]. Briefly, phosphatidylserine (PtdSer) is synthesized by 
PtdSer synthase 1 (PSS-1) at MAM domains, after which it is transferred to mitochondria for 
decarboxylation by PtdSer decarboxylase (PISD) to form phosphatidylethanolamine (PtdEtn) [668]. Upon 
pulsing crude mitochondrial fractions with radiolabeled serine, we observed significantly increased 
production of radiolabeled PtdSer and PtdEtn in both the cortex and hippocampus of CCI mice compared 
to naïve tissues, indicating an increase in MAM activity (Fig. 4-3A).  
 As discussed above, the formation and activation of MAM domains is induced by the transport of 
cholesterol from the PM to the ER [96]. Cholesterol trafficking is facilitated by the activation of sphingo-
myelinase (SMase) enzymes [105], which hydrolyze sphingomyelin (SM), an important structural lipid that 
stabilizes cholesterol in membranes [332], to form ceramide. Therefore, cholesterol mobilization and MAM 
formation correlate with the activation of SMase [493]. To validate the increase in MAM activity after brain 
injury, we measured SMase activity in hippocampal homogenates from CCI and naïve mice and observed 
a significant increase compared to naïve tissues (Fig. 4-3B). Remarkably, among the mammalian SMases, 
only the expression of Smpd5, which encodes a putative mitochondria-associated neutral SMase (MA-




It is known that the activation of SMase activity correlates with cholesterol esterification by acyl-
coA:cholesterol acyltransferase 1 (ACAT1; gene Soat1) at MAM domains [105] to form cholesteryl esters 
(CEs) for storage in lipid droplets (LDs) [96]. In agreement with an increase in MAM activation after brain 
injury, we observed increased LDs in both the cortex and hippocampus after CCI compared to naïve 
controls (Fig. 4-3D). We confirmed these results by staining naïve and CCI tissues with Oil Red O, which 
identifies neutral lipid deposits [670], and observed increased staining in both brain regions after injury (Fig. 
4-3E). Finally, we imaged the vibrational energy of lipid-specific C-H bonds through Stimulated Raman 
Scattering (SRS) imaging one week after injury [662]. This approach revealed a clustered signal reminiscent 
of granular lipid deposition that was absent in naïve tissues (Fig. 4-9). Together, these results speak to a 
stimulation of MAM activity upon brain injury, and the activation of cholesterol esterification and cellular lipid 
trafficking.  
 
Brain lipid composition is altered after injury 
 MAM is a major hub for lipid regulation in the cell [472]. Thus, increases in MAM formation result 
in the upregulation of MAM-resident lipid metabolic enzymes that, in turn, cause progressive changes in 
lipid species constituting cellular membranes. We conducted lipidomics analysis to determine the 
progression of MAM-driven lipid changes in the ipsilateral cortex and hippocampus at 1, 3 and 7 days after 
injury (Fig. 4-4A). Moreover, to determine the contribution of different cell types to our data, we also 
determined the lipidome of isolated microglia, astrocytes, and neurons (Fig. 4-10) from both brain areas 
(Fig. 4-4B). 
 In all data sets, consistent with our observed indications of increased cholesterol trafficking and 
deposition in LDs, we observed a trend toward reductions of free cholesterol (FC), with concomitant 
increases in CE, and an increased ratio of CE:FC (Fig. 4-4A). These results are consistent with the 
activation of MAM [96]. These alterations were sustained in the cortex over the week-long period following 
injury, whereas they were nearly normalized in the hippocampus after one week. In support of this increase 
in lipid mobilization after TBI, expression of Abca1, a lipid efflux transporter [671], was increased 
significantly in both the cortex and hippocampus (Fig. 4-4C). Similarly, we observed increased expression 




acids (FAs) [672] and was robustly increased in both the cortex and hippocampus (Fig. 4-4D). Expression 
of another scavenger receptor, Scarb1 [673], was also increased in the cortex with a trend toward an 
increase in the hippocampus (Fig. 4-4D). We also assayed the expression of Ldlr and Lrp1, lipoprotein 
receptors that transport cholesterol- and triglyceride (TG)-rich lipoproteins [674]. Expression of both genes 
was increased in the cortex but not in the hippocampus (Fig. 4-4E). Finally, we also observed increased 
cortical expression of Npc2 (with a trend for an increase in the hippocampus), encoding Niemann-Pick type 
C intracellular cholesterol transporter 2, which regulates the inter-membrane transport of internalized 
cholesterol [675] (Fig. 4-4E).  
 Interestingly, among the purified cell type-specific populations, microglia showed a robust 
remodeling of their lipid composition and indications of increased MAM formation after brain injury in both 
the cortex and hippocampus. Specifically, microglia displayed the most consistent elevations in CEs and 
CE:FC ratios relative to those parameters in astrocytes and neurons (Fig. 4-4B and Fig. 4-12). In support 
of this, microglia also displayed significant reductions in SM levels with concomitant increases in ceramide, 
indicative of upregulated SMase activity (Fig. 4-3B). These results suggest that, following CCI, microglia 
undergo the greatest degree of lipid metabolic alterations that are consistent with MAM upregulation.  
In addition, microglia from CCI models showed a marked decrease in the levels of monoglycerides 
(MGs) (Fig. 4-4B), consistent with the known activation of monoglyceride lipase (gene Mgll) during 
inflammation [676]. These decreases in MGs could also be due to increased conversion to diglycerides 
(DGs) and triglycerides (TGs) as part of upregulated lipid synthesis pathways to support the assembly of 
membranes. Indeed, CCI tissues displayed significant increases in DG and TG levels, suggesting increased 
de novo DG and TG synthesis (Fig. 4-4A/B). This supports the notion that lipid synthesis and storage are 
robustly activated upon injury, presumably for membrane repair. In support of this possibility, the expression 
of Srebf1 (encoding sterol regulatory element-binding protein 1, SREBP1, a master regulator of fatty acid 
synthesis [677]), Fasn (encoding fatty acid synthase, FAS) and Acaca (encoding acetyl co-A carboxylase-
1, ACC1) [678] were significantly increased in the cortex with a trend for an increase in the hippocampus 
(Fig. 4-4F). Likewise, as discussed above, expression of FA scavenger receptor Cd36 was increased in 
both the cortex and hippocampus (Fig. 4-4D), potentially due to the known role of CD36 in microglial 




Increases in DGs and TGs were greatest in cortical microglia and hippocampal astrocytes (Fig. 4-
4B), potentially in support of the proliferation of these glial cells. Furthermore, levels of phosphatidylcholine 
(PtdCho), the most abundant phospholipid species [472], were increased significantly in astrocytes and 
neurons. More specifically, in purified cortical and hippocampal neurons, we observed increases in PtdCho 
and PtdEtn species containing long polyunsaturated fatty acyl chains at multiple time points (Fig. 4-6), 
which suggests an increase in the desaturation index of neuronal membranes after injury. 
 
Mitochondrial respiration is not significantly affected after injury 
Mitochondrial dysfunction is a widely reported phenotype in experimental TBI [575,680]. We 
therefore sought to determine the time-course and regional variation in respiratory function in our TBI model 
by Seahorse analysis. Surprisingly, we did not observe any significant alterations in oxygen consumption 
in mitochondria isolated from CCI brains at 1, 3 or 7 days after injury in either the cortex or hippocampus 
(Fig. 4-6A/B). This was observable when assaying both complex I (CI)-mediated respiration (indicative of 
pyruvate oxidation, measured in the presence of pyruvate with malate as a complex II inhibitor, Fig. 4-6A) 
and complex II (CII)-mediated respiration (indicative of fatty acid oxidation, FAO, measured in the presence 
of CII substrate, succinate, with rotenone as a CI inhibitor, Fig. 4-6B) [661]. We confirmed this through 
histological analysis of succinate dehydrogenase (SDH, full name of CII) and cytochrome c oxidase (COX, 
complex IV) activities [681], both of which showed no changes in staining intensity in either region at all 
time-points tested (Fig. 4-7C/D and Fig. 4-12A/B). We also measured the expression of the OxPhos 
respiratory complexes in both brain regions at these time-points and, as with the enzymology, similarly did 
not observe significant alterations in expression upon injury (Fig. 4-12F). 
As a control for these assays, we measured various parameters related to mitochondrial mass. We 
first assayed the expression of TOM20, a marker of the mitochondrial outer membrane, by western blot 
(Fig. 4-7E). Compared to naïve mice, we observed a slight but significant decrease in TOM20 in the cortex 
at 7d and an increase in the hippocampus at 3d. We also determined the ratio of mitochondrial DNA 
(mtDNA) to nuclear DNA (nDNA) through qPCR analysis of Cox1 (encoded by mtDNA) and Gapdh 
(encoded by nDNA). Interestingly, the ratio was unchanged in the cortex but significantly decreased in the 




lator of mitochondrial biogenesis [682], was significantly decreased in both brain regions at 3d (Fig. 4-12D). 
TBI is also reported to be associated with hypoxic stress and a consequent reduction in pyruvate 
oxidation by mitochondria [683,684]. In agreement with this, the expression of Hif1a, encoding the 
transcription factor hypoxia-inducible factor 1-⍺ (HIF1⍺) and HIF target Pdk1, which encodes pyruvate 
dehydrogenase kinase 1 (PDK1), were elevated in the cortex but not the hippocampus (Fig. 4-13). PDK1 
inhibits pyruvate dehydrogenase (PDH) activity [685] and thus reduces the use of pyruvate as a 
mitochondrial fuel, which can cause mitochondria to begin oxidizing alternative fuel sources, such as FAs. 
In support of this possibility, short-chain acylcarnitines (ACs), intermediate metabolites of mitochondrial 
FAO [686], showed significant increases in both the cortex and hippocampus at multiple time-points (Fig. 
4-7F). However, the expression of Cpt1a, which encodes carnitine palmitoyltransferase 1⍺ (CPT-1⍺), the 
enzyme that enables transport of fatty acyl-coAs into the mitochondrial matrix for oxidation [687], was 
significantly increased only in the cortex (Fig. 4-12E). When lipidomics analysis of ACs was repeated in 
purified cell type-specific populations, we observed that while microglia and astrocytes were certainly 
contributing to the bulk trends, cortical and hippocampal neurons displayed the most robust increases in 
these AC species (Fig. 4-7G). 
 
 Altogether, our results suggest that elevations in MAM-localized C99 after brain injury are 
associated with increased MAM activity. This correlates with subsequent changes in the regulation of 





The epidemiological connection between TBI and AD is well described, but the molecular mechan-
ism by which a history of TBI results in AD phenotypes has not been determined. Our group has previously 
reported that AD models display upregulated functionality of MAM domains. In this work, we present data 
that suggests that MAM functionality is similarly upregulated in a mouse model of TBI. This upregulation 
correlates with lipid metabolic alterations in multiple lipid classes, but without marked impairments in 
mitochondrial respiration. We report these phenotypes in the acute phase after a single injury, where we 
propose that MAM upregulation is a naturally activated mechanism to promote lipid synthesis for membrane 
repair [688].  
Alterations in APP metabolism, a cardinal feature of AD, have been the subject of multiple TBI 
studies. Deposition of Aβ can be observed in humans after TBI [522] but in some studies is only observable 
in a minority of patient samples [527]. This suggests that perhaps other APP processing products are 
involved in the development of AD after TBI. Indeed, we have previously shown in AD tissues and cell 
models that the Aβ precursor, C99, accumulates in the ER and induces the formation and activation of 
MAM domains [105]. This has previously been reported in TBI as well [528,529]. Here, we report that these 
elevations are most observable in MAM domains 3 days after injury. This correlates with increases in MAM 
activity, as measured by the synthesis and transfer of phospholipids between the ER and mitochondria. In 
AD, we observed that C99-mediated MAM upregulation is achieved by the induction of cholesterol transport 
from the plasma membrane (PM) to the ER, where it is esterified by ACAT1 [493]. Consistent with this, our 
lipidomics analysis of TBI tissues showed progressive reductions in free cholesterol and concomitant 
increases in cholesteryl esters, suggesting increased mobilization of cholesterol from cellular membranes. 
Thus, our data support an active role of C99 and cholesterol trafficking in triggering MAM activity after TBI, 
similar to what has been described in AD.  
These cholesterol alterations were observable throughout the week-long period after injury and in 
all cell types. Furthermore, it is known that oleoyl-CoA, or 18:1 fatty acyl CoA, is the preferred substrate for 
ACAT1 [490]. Thus, 18:1 CEs can be considered a surrogate marker of MAM activation. Indeed, robust 
increases in 18:1 CEs were readily observable after brain injury, suggesting a significant contribution of 




activity of lecithin-cholesterol acyltransferase (LCAT), the ACAT analog located at the PM. The specific 
contributions of these enzymes to the observed phenotypes requires further investigation. 
Our findings of increased MAM-mediated cholesterol trafficking after TBI are supported by previous 
publications in brain and nerve injury models. Elevated CEs have been reported previously [566,689,690], 
alongside elevations in 18:1 CE specifically [566] and the expression of ACAT1 [658]. There are also reports 
of increased expression of the lipoprotein-mediated cholesterol transporter APOE [563,567,691], the lipid 
transporter LDLR [567], and the lipid efflux pump ABCA1 [563–565]. MAM upregulation likely contributes, 
at least in part, to these phenotypes. 
Increases in the transport of cholesterol and the levels of CEs were more prominent in microglia 
than in astrocytes and neurons. Pro-inflammatory microglia have been shown to display increases in CEs 
and LDs, in part due to the phagocytosis of myelin debris [692]. The earliest reports of lipid accumulation 
in nerve injury models actually observed these LDs in brain macrophages [561,562]. Thus, perhaps 
microglia are responsible for the majority of the cholesterol trafficking alterations seen after TBI. This 
hypothesis is supported by our data on altered sphingolipid levels after injury. In particular, previous 
lipidomics studies in TBI have reported reductions in SM and increases in ceramides [566,570], speaking 
to elevated SMase activity. Indeed, multiple activators of SMase activity (such as tumor necrosis factor-⍺ 
[336], arachidonic acid [693] and glutamate [694]) are established components of TBI pathology. We 
confirmed this in our model by observing elevations in SMase enzymatic activity (Fig. 4-3B) and Smpd5 
gene expression (Fig. 4-3C). Interestingly, Smpd5 is predominantly expressed in microglia relative to 
astrocytes and neurons [695] and, in our model, only microglia displayed the SM and ceramide alterations 
that are consistent with SMase activation, that was observable throughout the week-long period after injury 
(Fig. 4-4B). Consistent with the trends we observed in cholesterol esterification, perhaps microglia are 
responsible for the elevations in SMase activity we observed. Indeed, SMase activation has been shown 
to be required for microglia to adopt pro-inflammatory phenotypes [255]. Furthermore, there is evidence 
that the SMase encoded by Smpd5 is associated with MAM domains, as in the single report characterizing 
murine Smpd5, the encoded protein co-localized with both mitochondria and ER markers [669]. Our group 
has also previously reported that SMase activity is enriched in MAM fractions [105]. Thus, SMase activity 




extent in microglia relative to astrocytes and neurons. Given the association of relevant sphingolipid 
alterations with microglial activation, perhaps chronic upregulation of SMase activity after multiple TBI 
episodes would result in sustained inflammatory phenotypes that are also characteristic of AD [696]. Of 
note, a human homolog of Smpd5 has not been characterized; thus, the relevance of these findings to 
human TBI requires further investigation. 
Glial activation is also associated with the accumulation of triglycerides (TGs) [697], which was 
observable here, especially at 1 and 3 days after injury. Interestingly, when we measured gene expression 
of lipid efflux pumps, Abca1 (enriched in astrocytes [695]) and Abcg1 (enriched in microglia [695]), only 
Abca1 was elevated after TBI (Figs. 4-4C and 4-11). This suggests that lipid efflux alterations are 
predominant in astrocytes relative to microglia. This could be representative of enhanced delivery of TGs 
from astrocytes to neurons as a natural mechanism to support neuronal functionality after injury. Metabolic 
crosstalk between astrocytes and neurons is a well-known phenomenon in neural tissues, whereby 
astrocytes provide neurons with numerous substrates for energy production [698]. This can include TGs, 
which could be harnessed for membrane repair and energy production in neurons. Further experiments are 
necessary to validate this hypothesis. 
Additional analysis of neuronal lipidomics showed marked alterations in the acyl chain composition 
of phospholipid species. Specifically, we found progressive increases in PtdCho and PtdEtn species 
containing polyunsaturated fatty acids (PUFAs), which have been shown to increase membrane fluidity 
[699]. This was observable throughout the week-long period following injury in only the hippocampus for 
PtdCho and in both the cortex and hippocampus for PtdEtn. These alterations relate to reports of membrane 
damage in AD, resulting from SAD-associated polymorphisms in genes regulating phospholipid transport 
and metabolism [700]. Increases in phospholipid desaturation are induced by the activation of specific acyl-
coA synthases (ACSLs), such as ACSL4 and ACSL6, which preferentially activate PUFAs for incorporation 
into phospholipids [701,702]. Of note, ACSLs are MAM-resident enzymes [703]. Thus, we hypothesize that 
the activities of these ACSLs will be upregulated as a result of MAM upregulation; additional studies will be 
necessary to confirm this mechanism. Nonetheless, such alterations can affect neuronal functionality, as 
the saturation index of constituent phospholipids is a major determinant of membrane permeability and 




could be compromised, impairing neurotransmission. 
Finally, despite previous reports discussing mitochondrial bioenergetic impairments after TBI [575], 
mitochondrial respiration was not significantly impaired in our model. However, our results suggest a partial 
shift in substrate preference away from pyruvate oxidation toward FA oxidation to power OxPhos activity, 
in agreement with previous reports [579,580]. Perhaps this shift in fuels is a counterbalancing mechanism 
to prevent bioenergetic failure. Indeed, reduced mitochondrial pyruvate oxidation has been demonstrated 
as a mechanism of preventing excitotoxicity [705], underlying a possible reason for this shift. This is another 
potential functional deficit that, if sustained, could become detrimental for neuronal functionality [706]. 
In summary, we propose a model in which cortical brain injury induces MAM-driven metabolic 
phenotypes in both the cortex and hippocampus during the acute, week-long phase following injury. The 
observed upregulation of cholesterol esterification and lipid trafficking correlated with elevated MAM activity 
levels and localization of APP-C99 to MAM domains, especially in microglial populations. This provides a 
potential mechanistic basis for previously observed lipid alterations after TBI. We hypothesize that, after 
multiple injuries, sustained dysregulation of these pathways would become detrimental for neuronal 
functionality, resulting in a chronic phenotype that resembles AD. Our data lay the groundwork for 
indications of an important role for MAM functionality in mediating metabolic homeostasis in the acute phase 





Limitations of Study 
While this work suggests the activation of a novel cellular pathway that combines APP metabolism, 
ER-mitochondria connectivity and lipid trafficking in a manner that resembles AD pathogenesis, there are 
several questions that could not be answered.  
First, we used uninjured (“naïve”) mice as controls rather than sham-injured animals, the 
convention in experimental TBI. The sham model for CCI consists of anesthesia, skin incision and craniec-
tomy but lacks tissue punch. Preliminary experiments comparing naïve and CCI samples to sham animals 
showed that the extent of pathology in the sham group was nearly matched to that in CCI animals. This is 
in agreement with a published report also observing marked pathology after sham surgery [707]. This 
means that the sham surgery almost constitutes a full TBI in and of itself. Indeed, the craniectomy is highly 
disruptive to brain homeostasis and is considered “clinically irrelevant,” as skull fracture is absent in the 
majority of human TBI cases [513]. Craniectomy can induce loss of blood brain barrier integrity, alterations 
in intracranial pressure and brain edema, speaking to the severe damage this procedure causes to the 
brain [513]. We thus deemed naïve tissues to be a more appropriate control group for assaying the 
molecular effects of brain injury as a whole, as both sham and CCI surgeries severely damage the brain. 
We also do not include analyses of the contralateral hemisphere. This is of special interest to the 
TBI field given the description of “coup-contrecoup” effects during concussion, where an impact on one side 
of the head can cause damage to the brain on the opposite side as the shaking motion causes the brain to 
bump into the skull [708]. While we did collect preliminary data from these regions, we found that the 
relationship between the contralateral and ipsilateral regions was not consistent among the different assays 
conducted and would be best examined as the subject of a separate study. 
 The temporality of the reported results is a compelling aspect of this study. The lipidomics and 
histological results display a strong dependence on time-point, whereas the mitochondrial data fails to show 
a robust response throughout the time-course. This indicates that lipid metabolic alterations predominate 
relative to other assayed parameters during the study timeline. Most other assays, including the trans-
criptional studies, were conducted only at 3d after injury. While this could be considered a limitation of the 
study, our data indicate that many of the assayed pathologies peak at this time-point. Thus, at this stage of 




The qPCR data is normalized by Gapdh, the selected reference gene for these studies. Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) activity constitutes one step in the glycolysis pathway, a 
process that is directly assayed in this work. Thus, the use of Gapdh as a reference gene may appear 
questionable. However, in control experiments (data not shown), we measured the expression of Gapdh 
and Rn18s/Rn45s (encoding the 18S and 45S subunits of ribosomal RNA) in the same well, as the latter 
displays invariant expression across cell and tissue types as well as biological conditions, and is expressed 
at a considerably higher level [709]. Gapdh expression did not change between experimental groups when 
normalized to Rn18s/Rn45s (data not shown), validating its reliability as a reference gene in these studies. 
Given the finding of C99 elevations in this model, and our work in AD showing that increased 
localization of C99 to MAM domains is responsible for MAM upregulation [105], a logical set of experiments 
would be to confirm that MAM-C99 is responsible for MAM elevations in this model as well. This could be 
achieved by a C99-overexpressing mouse model [198], treatment of mice with inhibitors of BACE1 (the 
enzyme responsible for C99 production) [201], or a BACE1-KO mouse model [710]. Each of these models 
has been demonstrated to be viable without overt phenotypic alterations or deficits. The repetition of the 
MAM assays in these models represents an important future direction for this work. 
Finally, a set of experiments that is especially crucial for the mechanistic implications of this work 
is the cell type-specific studies. Here, we present only lipidomics analysis in collected microglial, astrocytic 
and neuronal populations from the ipsilateral cortex and hippocampus after injury. We acknowledge that 
additional assays in these populations would generate invaluable information. However, lipidomics analysis 
provides a substantially comprehensive picture (from the lipid-oriented perspective undertaken in this study) 
into cell type-specific responses to brain injury. Additionally, the Jia Qian Wu and Ben A. Barres groups 
published cell type-specific RNA sequencing results from the mouse cortex [695] (also accessible at 
www.brainrnaseq.org). Through this database, it can be learned which cell type(s) a given gene is enriched 
in, allowing for the determination of whether the reported transcriptional changes arise from certain cell 
types over others. This can supplement our conclusions about cell type-specific responses to brain injury. 
Altogether, we acknowledge that there remain multiple unanswered questions within this work. Our 
goal was to generate a new framework for understanding TBI pathogenesis and the molecular basis for the 
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Figure 4-1: Regional specificity of glial proliferation and cell death. 
(A) Fluoro-Jade C staining (FJC, representative of 3 independent replicates) of ipsilateral cortex and 
hippocampus at indicated time-points after CCI injury shows that neuronal degeneration occurs to a 
substantially greater degree in the cortex vs. the hippocampus during the post-injury period. (B-D) 
Increased proliferation of astrocytes and microglia in both the ipsilateral cortex and ipsilateral hippocampus 
3 days after injury, normalized to Gapdh. (B) Measurement of Gfap gene expression via qPCR as an 
indicator of astrocytic proliferation. (C) Measurement of Aif1 gene expression (protein: IBA1) via qPCR as 
an indicator of microglial proliferation. (D) Measurement of Cldn11 gene expression (protein: 
oligodendrocyte-specific protein, OSP) via qPCR as an indicator of oligodendrocyte proliferation. Each data 
point represents a separate mouse (biological replicate) and is representative of 3 technical replicates 
(qPCR wells). Error bars represent standard deviation among biological replicates. For all assays, 
comparisons are made to naïve (uninjured) tissues harvested and assayed alongside CCI tissues. **, 






Figure 4-2: Localization of APP-C99 to MAM domains is increased after CCI. 
Subcellular fractionation of ipsilateral cortical and hippocampal homogenates 3 days after injury shows that 
APP-C99 (14 kDa) levels are elevated upon injury in the MAM fraction. This is consistent with enhanced 
signal using an antibody for the C-terminus for APP, which would include APP-C83 (13 kDa). Erlin-2 and 
TOM20 serve as MAM and mitochondrial markers, respectively. This western blot is representative of 3 
independent replicates. Naïve (uninjured) tissues were harvested and assayed alongside CCI tissues. CM, 








Figure 4-3: MAM functionality is upregulated after CCI in both the cortex and hippocampus. 
All CCI samples shown in this sample are from the ipsilateral hemisphere. Naïve samples were processed 
alongside the CCI samples. (A) Analysis of phospholipid synthesis 3 days after injury shows increased 
synthesis of both phosphatidylserine (PtdSer) and phosphatidylethanolamine (PtdEtn), indicating increased 
communication between the ER and mitochondria. (B) Sphingomyelinase (SMase) activity assay showing 
increased SMase activity in the hippocampus 3 days after injury. (C) Gene expression analysis via qPCR 
of the Smpd genes, which encode the five mammalian SMase isoforms, 3 days after injury, normalized to 
Gapdh. Expression of Smpd5, but not the other genes, is significantly increased. Each data point represents 
a separate mouse (biological replicate) and the average of 3 technical replicates (qPCR wells). Error bars 
represent standard deviation among biological replicates. *, p<0.05; **, p<0.01; T-test. (D) Representative 
electron microscopy image 3 days after injury with visible lipid droplets. (E) Representative Oil Red O 
staining of the ipsilateral cortex and hippocampus 3 days after injury shows lipid deposition in both brain 





Figure 4-4: Elevations in cellular lipid trafficking and synthesis are observable in both bulk 
homogenates and purified cell type-specific populations after CCI. 
(A, B) Heatmap of fold changes of indicated lipid species at 1, 3 and 7 days after CCI over naïve, in (A) 
bulk cortical and hippocampal homogenates and (B) sorted populations of microglia, astrocytes and 
neurons. (C-F) Expression of genes important in cellular lipid metabolism 3 days after injury, normalized to 
Gapdh. Each data point represents a separate mouse (biological replicate) and the average of 3 technical 
replicates (qPCR wells). Error bars represent standard deviation among biological replicates. *, p<0.05; **, 
p<0.01; T-test. (C) Increased gene expression of lipid efflux pump, Abca1, is observable in both the cortex 
and hippocampus. (D) Gene expression of scavenger lipid receptors, Cd36 and Scarb1. Cd36 is increased 
in both the cortex and hippocampus, while Scarb1 is increased in the cortex and displays a trend for an 
increase in the hippocampus. (E) Gene expression of mediators of lipoprotein uptake (Ldlr and Lrp1) and 
hydrolysis (Npc2) mediators. Increases are observable in the cortex but not the hippocampus. (F) Gene 
expression of Srebf1, Acaca and Fasn, regulators of de novo lipogenesis, is significantly increased in the 






Figure 4-5: Lipidomics analysis indicates increased cholesteryl ester (CE) concentrations 
throughout the post-injury time course, especially in microglia. 
(A) Lipidomics levels of individual CE species in bulk ipsilateral cortical and hippocampal homogenates at 
the indicated time-points after injury. (B) Lipidomics levels of individual CE species in sorted populations of 





Figure 4-6: Increased levels of polyunsaturated PtdCho and PtdEtn species in cortical and 
hippocampal neurons. 
Lipidomics analysis in neurons purified at indicated time points after CCI from the ipsilateral cortex and 










Figure 4-7: Cortical and hippocampal mitochondria display a moderate switch in substrate 
preference without impairments in bioenergetics. 
(A,B) Mitochondrial oxygen consumption rate (OCR) measured in the Seahorse XF Analyzer in crude 
mitochondrial fractions collected at the indicated time-points from the indicated ipsilateral brain regions. 
OCR values are shown by respiratory state: State 2, baseline; State 3, after ADP addition to stimulate 
electron flow; State 4, after oligomycin (ATP synthase inhibitor) addition to determine the portion of oxygen 
consumption occurring for the purpose of ATP production; State 3-uncoupled (3U), after trifluoromethoxy 
carbonylcyanide phenylhydrazone (FCCP) addition in order to uncouple electron flow and oxygen 
consumption from ATP production. (A) Respiration in the presence of pyruvate and malate (complex-II 
inhibitor) in order to assay the contribution of complex-I (i.e., glucose oxidation) to cellular respiration. (B) 
Respiration in the presence of succinate (complex-II substrate) and rotenone (complex-I inhibitor) in order 
to assay the contribution of complex-II (i.e., fatty acid oxidation) to cellular respiration). Overall, 
mitochondrial respiration levels were not strongly affected by CCI injury. (C) Representative succinate 
dehydrogenase (SDH, complex-II) activity staining images in the ipsilateral cortex (outlined in blue) and 
ipsilateral hippocampus (outlined in yellow) 3 days after CCI. (D) Representative cytochrome C oxidase 
(COX) activity staining images in the ipsilateral cortex (outlined in blue) and ipsilateral hippocampus 
(outlined in yellow) 3 days after CCI. (E) Expression of TOM20 (a marker for mitochondrial mass) in cortical 
and hippocampal homogenates at the indicated time-points after injury. Each lane is a separate mouse 
(biological replicate). β-actin is the loading control for the cortex and vinculin is the loading control for the 
hippocampus. Densitometry is shown as well. (F) Bulk lipidomics analysis of total acylcarnitines (ACs), 
which become elevated with increased fatty acid β-oxidation, shows increases in the both the ipsilateral 
cortex and hippocampus at multiple time points after injury. (G) Lipidomics analysis of total ACs in 
astrocytes and microglia from both the cortex and hippocampus. ACs are highest in both cell types at the 






Figure 4-8 (Supplemental Figure 1): APP processing after CCI.  
(A) Subcellular fractionation of ipsilateral cortical and hippocampal homogenates 3 days after injury shows 
enhanced signal using an antibody for the C-terminus for APP, which includes both APP-C99 (14 kDa) and 
APP-C83 (13 kDa) upon injury in the MAM fraction. Erlin-2 and TOM20 serve as MAM and mitochondrial 
markers, respectively. This western blot is representative of 3 independent replicates. TH, total 
homogenate. CM, crude membranes fraction. (B) Gene expression analysis via qPCR of Bace1, which 
encodes β-secretase (the enzyme responsible for C99 production from full-length APP), 3 days after injury, 
normalized to Gapdh. Bace1 expression is not significantly changed in either brain region (T-test, ⍺=0.05). 
Each data point represents a separate mouse (biological replicate) and the average of 3 technical replicates 
(qPCR wells). Error bars represent standard deviation among biological replicates. Naïve (uninjured) 






Figure 4-9 (Supplemental Figure 2): Stimulated Raman Scattering (SRS) imaging of lipid-specific 
C-H bonds 7 days after CCI. 
Stimulated Raman scattering (SRS) microscopy image of C-H bonds in lipid channel showing increased 














Figure 4-10 (Supplemental Figure 3): Expression levels of cell type-specific mRNA markers in 
sorted cell populations from whole adult mouse brain. 
(A, B) Gene expression analysis of indicated genes in sorted ACSA-2+ (astrocytes) and CD11b+ (microglia) 
populations (collected after removal of myelin via magnetic beads) as well as remaining cells, considered 
to be enriched for neurons. The threshold-crossing cycle (Ct) value for each gene was normalized by the 
Ct value of Rn18s/Rn45s. The cell populations were each collected from 4 separate mice, with each data 
point representing the average of 3 technical replicates (qPCR wells) from each mouse. Error bars 
represent standard deviation among biological replicates. Statistical analysis by conducted by Ordinary 
one-way ANOVA followed by Bonferroni’s multiple comparisons test at an ⍺=0.05 significance level; *, 
p<0.5; **, p<0.01; ***, p<0.001; ****, p<0.0001. (A) Organized by population. (B) Organized by marker. (C, 
D) Cldn11 (protein: claudin-11, oligodendrocyte-specific protein, OSP) is used as an oligodendrocyte 
marker. (C) Gene expression analysis of Cldn11 in Cd11b+ (microglia), Cd11b-/ACSA-2+ (astrocyte) and 
Cd11b-/ACSA-2- (neuron) populations shows that final flow-through retains substantial Cldn11 expression 
compared to other populations. (D) Gene expression analysis of indicated cell type markers in eluted myelin 
shows that, while Cldn11 expression is higher than Itgam and Dcx, the myelin retains substantial expression 






Figure 4-11 (Supplemental Figure 4): Expression of additional lipid metabolic genes in the cortex 
and hippocampus after CCI. 
Expression of genes important in cellular lipid metabolism 3 days after injury, normalized to Gapdh. Gene 
expression of Npc1, Abcg1 and Abcg4 are unchanged following CCI. Each data point represents a separate 
mouse (biological replicate) and the average of 3 technical replicates (qPCR wells). Error bars represent 










Figure 4-12 (Supplemental Figure 5): Mitochondrial regulation after CCI.  
(A) Representative succinate dehydrogenase (SDH, complex-II) activity staining images in the ipsilateral 
cortex (outlined in blue) and ipsilateral hippocampus (outlined in yellow) at multiple time points after CCI 
injury. (B) Representative cytochrome C oxidase (COX) activity staining images in the ipsilateral cortex 
(outlined in blue) and ipsilateral hippocampus (outlined in yellow) at multiple time points after CCI injury. 
(C) Ratio of mitochondrial DNA (determined by Cox1 DNA quantity) to nuclear DNA (determined by Gapdh 
DNA quantity) in the ipsilateral cortex and hippocampus at indicated time-points after CCI injury. By 3 days 
and lasting through 7 days, the ratio was decreased in the hippocampus. Each data point represents a 
separate mouse (biological replicates) and the average of 3 technical replicates (qPCR wells). Error bars 
represent standard deviation among biological replicates. *, p<0.05; **, p<0.01; T-test. (D) Gene expression 
analysis via qPCR of Ppargc1a, encoding PGC1⍺, a regulator of mitochondrial biogenesis, 3 days after 
injury. Expression was significantly reduced in both assayed brain regions. (E) Gene expression of Cpt1a, 
which regulates mitochondrial fatty acid β-oxidation, is increased in the cortex but not in the hippocampus. 
(F) Western blot of OxPhos complexes in both the cortex and hippocampus in naïve and CCI tissues (1, 3 






Figure 4-13 (Supplemental Figure 6): Expression of genes involved in hypoxic signaling and 
pyruvate regulation in the cortex and hippocampus after CCI. 
These analyses were done in ipsilateral cortical and hippocampal homogenates collected 3 days after CCI. 
(A) Gene expression of Hif1a, a chief mediator of the hypoxic signaling pathway, is increased in cortex with 
a trend for an increase in the hippocampus. (B) Gene expression of Pdk1, which encodes pyruvate 
dehydrogenase kinase 1, is increased in the cortex but not in the hippocampus, suggesting that conversion 
of pyruvate to acetyl co-A is reduced in the cortex after CCI. Each data point represents a separate mouse 
(biological replicate) and the average of 3 technical replicates (qPCR wells). Error bars represent standard 






Table 4-1: Composition of mtDNA/nDNA ratio qPCR reaction 
Component Volume Sequence 
TaqMan Fast Advanced Master Mix 10 μL  
Gapdh TaqMan probe  
(nuclear gene) 1 μL 
See TaqMan assay ID Mm99999915_g1, 
VIC-MGB_PL 
Cox1 TaqMan probe  
(mitochondrial gene) 




Cox1 forward primer 0.18 μL (900 nM final concentration) 5’-TGCTAGCCGCAGGCATTACT-3’ 
Cox1 reverse primer 0.18 μL (900 nM final concentration) 5’-CGGGATCAAAGAAAGTTGTGTTT-3’ 
DNA 2 μL (50 ng)  
Water 6.6 μL  
Table 4-2: TaqMan probes used for bulk qPCR experiments 






























Table 4-3: TaqMan probes used for qPCR experiments in MACS-sorted populations 


















Chapter 5: AKT functionality at MAM domains: localization and 
binding partners 
 
 The data presented in this chapter has been collected as part of an additional project that is still in 
progress. This project was developed as part of my off-topic Qualifying Examination proposal, and we were 
fortunate to receive funding from the Naomi Berrie Diabetes Center as part of the Pilot and Feasibility Grant 
program to begin these studies. These experiments demonstrate that metabolic master regulator, RAC-
beta serine/threonine-protein kinase (AKT), localizes to MAM domains. At MAM, AKT interacts with 
hexokinase-II (HK-II), an important enzyme in cellular glucose metabolism. These results suggest that MAM 
regulation contributes to the control of glucose metabolism, and could help explain the well-known 
association between Alzheimer’s Disease (AD), characterized by sustained MAM upregulation, and the 
defects in insulin signaling that appear in the course of the disease. This work has relevance for 
epidemiological correlations between cognitive impairment and insulin resistance, and regulation of brain 





Disruptions in glucose metabolism are an established phenotype of AD, with reduced brain glucose 
uptake (as determined by PET analysis) being an important test in the diagnosis of AD. Because of this, 
AD is sometimes described as “Type-3 Diabetes” [304]. Indeed, studies in AD patients have shown 
improvements in cognitive outcomes with intranasal insulin treatment [317,318] as well as treatment with 
insulin sensitizer, rosiglitazone [321]. Additionally, a large proportion of dementia patients present with 
systemic insulin resistance [315,316], and type-2 diabetes mellitus and obesity are known risk factors for 
AD, with many diabetic patients displaying cognitive symptoms [309–314]. Since AD can be characterized 
by the upregulation of MAM functionality at early disease stages [96], perhaps MAM is acting upstream in 
promoting these disruptions in insulin signaling and consequent glucose metabolism. Indeed, it has been 
shown that genetic or pharmacological inhibition of MAM functionality inhibits the insulin signaling pathway 
[711,712]. Specifically, these MAM loss-of-function models displayed a failure to activate AKT, an intra-
cellular effector of insulin signaling known for its role as a master regulator of cellular glucose uptake and 
metabolism. Thus, examination of the relationship between MAM domains and AKT activity can generate 
insight into the etiology of insulin signaling alterations in diseases such as AD, and roles of MAM therein. 
4.  
AKT: a regulator of cellular metabolism 
AKT is a serine/threonine kinase that regulates many processes involved in cellular growth, 
metabolism and survival [713]. AKT is expressed in three isoforms, AKT1/AKT2/AKT3, that share ~80% 
nucleotide and amino acid identity [714]. As a result, these isoforms have a highly homologous structure 
that contains a pleckstrin homology (PH) domain at the N-terminus, a helical linker domain, a catalytic 





Figure 5-1: AKT isoforms and sequence homology. Adapted from [716] and [717]. 
 
Under basal conditions, AKT is localized to the cytoplasm [718]. Upon binding of insulin or other 
extracellular growth factors to their respective receptors on the outer surface of the plasma membrane 
(PM), intracellular phosphoinositide 3-kinase (PI3K) becomes activated to phosphorylate phosphatidyl-
inositol 4,5-bisphosphate (PIP2) to PIP3 at the PM [713]. AKT’s PH domain has a high affinity for PIP3, 
causing AKT to accumulates at the PM with increased PIP3 levels. Binding to PIP3, allows AKT to undergo 
a conformational change that exposes two regulatory residues: Thr308 in the activation loop of its kinase 
domain and Ser473 in its C-terminal regulatory domain (these residue positions are for AKT1)  [719]. 
Phosphorylation by 3-phosphoinositide-dependent kinase 1 (PDK1) [720] and mammalian target of 
rapamycin complex 2 (mTORC2) [721] at these residues, respectively, activates AKT [713]. Activated AKT 
can then translocate to other regions of the cell, such as the nucleus, cytosol or mitochondria, to 
phosphorylate its substrates [722]. 
 The different AKT isoforms differ in their tissue distribution and functions. Expression of AKT1 and 
AKT2 is ubiquitous while that of AKT3 is limited to the central nervous system and testes [714]. Additionally, 
AKT2 is most highly expressed in insulin-responsive tissues such as skeletal muscle, adipose tissue and 
the liver [714]. It has been demonstrated that AKT1 is important in organismal growth and cellular survival, 





Figure 5-2: Differential functions of AKT isoforms (from [714]). 
 
Hexokinase is an important metabolic substrate of AKT 
Because glucose is able to diffuse across the PM in both directions (albeit through transporter 
proteins), the cell needs to sequester internalized glucose for utilization. This is achieved by the activation 
of hexokinase (HK) activity, which is promoted upon phosphorylation by AKT [723]. HK phosphorylates 
intracellular glucose at C6 to render it negatively charged, preventing its diffusion out of the cell [724]. This 
is the first step of glycolysis. Of the four mammalian HK isoforms (I-IV), HK-II is the most highly expressed 
isoform in insulin-sensitive tissues such as skeletal muscle, adipose tissue and cardiac muscle [725,726]. 
 HK-II associates with voltage-dependent anion channel-1 (VDAC1) in the outer mitochondrial 
membrane (OMM) [724,727,728]. Since VDAC1 regulates the exchange of Ca2+, ATP and ADP across 
mitochondrial membranes [729], binding of HK-II to VDAC1 gives HK-II preferential access to newly synth-
esized ATP [725]. This can power the phosphorylation of glucose and promote the initiation of glycolysis.  
 
AKT promotes HK-II-VDAC1 interaction by localizing to mitochondria 
Growth factors such as insulin promote HK-II activity and translocation to mitochondria [730–732]. 
This is largely mediated by AKT, which has been shown to translocate to the OMM to carry out this role 
[723,733] (Fig. 5-3). It was also reported that AKT loss-of-function reduces translocation of HK-II to 
mitochondria, and promotion of cell survival conferred by constitutively active AKT is lost when the HK-II-
mitochondria interaction is prevented [734]. However, in spite of these reports of AKT-mitochondria 
interactions being beneficial for cell survival during stress, our understanding of how translocation of AKT 





Figure 5-3: Regulation of mitochondrial HK-II activity by activated AKT and relation to cellular 
stress responses. Adapted from [731]. 
 
A possible pool of mitochondrial AKT at MAM domains 
Of the many contacts mitochondria make with other organelles, the most understood is that with 
the endoplasmic reticulum (ER) [735]. These are known as mitochondria-associated ER membranes, or 
“MAM” domains. Current literature suggests that a pool of mitochondrial AKT may be MAM-localized. In 
addition to reports detecting AKT in MAM fractions [712,736,737], HK-II and VDAC1 have also been 
detected at MAM [738–741]. VDAC1 directly participates in ER-mitochondria communication by forming a 
complex with inositol-1,4,5-triphosphosphate receptor-3 (IP3R3), an ER Ca2+ release channel also enriched 
at MAM, to physically tether the two organelles [740]. Of note, IP3R is another AKT substrate [742,743]. 
AKT has also been shown to interact with and phosphorylate phosphofurin acidic cluster protein 2 (PACS2) 
[736,744], another MAM tether [745]. 
An AKT-MAM relationship is also suggested from the perspective of AKT regulation. Upon insulin 
stimulation, mTORC2 has been shown to localize to MAM and physically interact with AKT, VDAC1 and 
IP3R3 [736]. In fact, the mTORC2-AKT interaction was markedly reduced in MAM-deficient cells, and MAM 
has even been suggested to be the predominant locus of mTORC2-mediated AKT phosphorylation 




cholesterol content [747]. MAM domains are enriched in cholesterol owing to their lipid raft nature; thus, 
perhaps mitochondrial pools of HK-II are enriched in mitochondria-ER contact sites.  
Through the experiments presented in this chapter, we tested the hypothesis that the AKT-HK-II-
VDAC1 complex localizes to MAM domains. We observed that insulin stimulation in cultured hepatocyte 
and myoblast cell lines promotes the translocation of AKT to mitochondria and MAM domains. Studies with 
BioID proximity labeling technology to identify AKT binding partners provided support for our hypothesis, 
revealing that labeled HK-II and VDAC1 are present in MAM fractions. Finally, proteomics analysis of the 
AKT interactome at MAM domains revealed many glycolytic and lipid metabolic enzymes are AKT binding 
partners and localize to MAM. These results provide preliminary support for a mechanistic relationship 
between the AKT-HK-II-VDAC1 complex and MAM domains. Further validation of this hypothesis would 
spatially and mechanistically link cellular lipid and glucose metabolism [95,472], and help us understand at 
the molecular level why neurodegenerative disorders like AD often present with both glucose and lipid 





Materials and Methods 
 
Materials 
 C2C12 cells were a gift from Dr. Stavroula Kousteni. Lyophilized insulin from bovine pancreas was 
purchased from Millipore Sigma (C979A09). Mitotracker Green was purchased from ThermoFisher 
(M7514). The pEGFP-AKT2 plasmid was a gift from Thomas Leonard and Ivan Yudushkin (Addgene 
plasmid 86593). The myc-BioID2-MCS plasmid was a gift from Kyle Roux (Addgene plasmid 74223). Biotin 
was purchased from Millipore Sigma (C988J88). Streptavidin-conjugated Sepharose beads were pur-
chased from Cell Signaling Technologies (CST, 3419S). The antibodies used for immunocytochemistry and 
western blots are as follows: Akt, total (CST 9272S); Akt2, phospho-S474 (CST 8599S); β-actin (Abcam 
ab8227); Erlin-2 (Abcam ab129207); ERp72 (CST 5033S); HK-II (Abcam ab209847); Rab5 (CST 3547S); 
Rab7 (CST 9367S); TOM20 (Santa Cruz SC11415); VDAC1 (Abcam ab34726). Fluoromount-GTM mounting 
medium was purchased from ThermoFisher (00-4958-02). 
 
Cloning of plasmid encoding myc-BioID2-hAKT2 
Plasmid cloning and preparation was done using standard procedures. Human AKT2 (hAKT2) was 
cloned into the multiple cloning site (MCS) of the myc-BioID2-MCS plasmid using the EcoRI (5’ end of 
hAKT2) and HindIII (3’ end of hAKT2) restriction sites. To clone hAKT2 with flanked by these restriction 
sites, a PCR was performed using the pEGFP-hAKT2 plasmid as a template, with the forward primer (5’-
AAAGAATTCGGTGGCGGAATGAATGAGGTGTCTGTCATC-3’) and the reverse primer (5’-AAAAAGCTT-
TCACTCGCGGATGCTGGCCGAG-3’). The PCR product was digested with EcoRI and HindIII and ligated 
into the myc-BioID2-MCS plasmid, which had also been digested with the same enzymes. 
 
Immunocytochemistry and quantification 
Undifferentiated C2C12 cells were grown in DMEM on coverslips, treated with or without 100 nM 
insulin for 30 min in the presence of 10% FBS, and stained with Mitotracker Red for 10 min to label 
mitochondria. The cells were fixed with 4% PFA for 30 min at room temperature (RT), permeabilized with 




overnight (ON) at 4°C and secondary antibody (anti-rabbit conjugated to AlexaFluor594), with extensive 
washing in between each step. The coverslips were mounted with Fluoromount-G and visualized by 
confocal microscopy using a Leica SP8 confocal microscope at 60x magnification at the focal plane where 
the most mitochondria were visible.  
 
Subcellular fractionation 
HepG2 or C2C12 cells were cultured in DMEM and treated with or without 100 nM insulin for 30 
min in the presence of 10% FBS. For BioID experiments, 1 day before insulin treatment, the cells were 
transfected with pEGFP-Akt2 using Lipofectamine 2000 for 6h in serum-free DMEM following manufacturer 
instructions. The cells were then collected, lysed on ice in the presence of protease and phosphatase 
inhibitors, and subjected to subcellular fractionation as previously described [660]. 20 μg total protein was 
loaded for each fraction in a 4-20% Tris-Glycine SDS-PAGE mini gel. Following transfer to a PVDF 
membrane, the TH (total homogenate, crude lysate), MAM, ER and mitochondrial fractions were probed 
with antibodies for the indicated proteins as markers.  
 
Sucrose density gradient ultracentrifugation 
 Undifferentiated C2C12 cells were grown in DMEM and transfected with treated with or without 100 
nM insulin for 30 min in the presence of 10% FBS. The cells were then collected, lysed on ice in the 
presence of protease and phosphatase inhibitors, and crude membrane fractions were collected as 
previous described [660]. These fractions were treated with 0.2% Triton X-100 for 1h at 4°C under rotation, 
then loaded onto a continuous 10-40% sucrose density gradient. Upon 16h centrifugation at 100,000g at 
4°C, 24 fractions (200 μL each) were sequentially collected from the top without disturbing the gradient. 
Equal volumes (30μL) were used for western blot.  
 
BioID proximity labeling of binding partners 
Undifferentiated C2C12 cells were transfected with a plasmid encoding myc-BioID2-hAkt2 using 
Lipofectamine 2000 for 6h in serum-free DMEM following manufacturer instructions. The next day, the cells 




treated with biotin for 4h. The cells were collected and lysed on ice in the presence of protease and 
phosphatase inhibitors and subjected to subcellular fractionation. Total homogenate and MAM fractions 
were incubated with streptavidin beads to immunoprecipitate (IP) biotinylated proteins. All samples, 
including inputs (samples before IP), were run on a western blot and probed for the indicated proteins.  
 
Proteomics analysis 
In-gel digestion of immunoprecipitated proteins for mass spectrometry 
Immunoprecipitated samples were separated on 4-12% gradient SDS-PAGE and stained with 
SimplyBlue (Thermo Fisher Scientific). Protein gel slices were excised and in-gel digestion performed as 
previously described [748], with minor modifications. Gel slices were washed with 1:1 Acetonitrile and 
100mM ammonium bicarbonate for 30 min then dehydrated with 100% acetonitrile for 10 min until shrunk. 
The excess acetonitrile was then removed and the slices dried in speed-vacuum at room temperature for 
10 minutes. Gel slices were reduced with 5 mM DTT for 30 min at 56°C in an air thermostat, cooled down 
to room temperature, and alkylated with 11 mM IAA for 30 min with no light. Gel slices were then washed 
with 100 mM of ammonium bicarbonate and 100% acetonitrile for 10 min each. Excess acetonitrile was 
removed and dried in a speed-vacuum for 10 min at room temperature and the gel slices were re-hydrated 
in a solution of 25 ng/μl trypsin in 50 mM ammonium bicarbonate for 30 min on ice and digested overnight 
at 37°C in an air thermostat. Digested peptides were collected and further extracted from gel slices in 
extraction buffer (1:2 ratio by volume of 5% formic acid: acetonitrile) at high speed, shaking in an air 
thermostat. The supernatants from both extractions were combined and dried in a speed-vacuum. Peptides 
were dissolved in 3% acetonitrile/0.1% formic acid. 
 
Liquid chromatography with tandem mass spectrometry (LC-MS/MS) 
 Desalted peptides were injected in an EASY-SprayTM PepMapTM RSLC C18 50cm X 75cm ID 
column (Thermo Scientific) connected to an Orbitrap FusionTM TribridTM (Thermo Scientific). Peptides 
elution and separation were achieved at a non-linear flow rate of 250 nL/min using a gradient of 5%-30% 
of buffer B (0.1% (v/v) formic acid, 100% acetonitrile) for 110 minutes with a temperature of the column 




spectrometer was used for peptide tandem mass spectroscopy (MS/MS). Survey scans of peptide 
precursors are performed from 400 to 1500 m/z at 120K full width at half maximum (FWHM) resolution (at 
200 m/z) with a 2 x 105 ion count target and a maximum injection time of 50 ms. The instrument was set to 
run in top speed mode with 3-second cycles for the survey and the MS/MS scans. After a survey scan, 
MS/MS was performed on the most abundant precursors, i.e., those exhibiting a charge state from 2 to 6 
of greater than 5 x 103 intensity, by isolating them in the quadrupole at 1.6 Th. We used collision-induced 
dissociation (CID) with 35% collision energy and detected the resulting fragments with the rapid scan rate 
in the ion trap. The automatic gain control (AGC) target for MS/MS was set to 1 x 104 and the maximum 
injection time was limited to 35ms. The dynamic exclusion was set to 45s with a 10 ppm mass tolerance 
around the precursor and its isotopes. Monoisotopic precursor selection was enabled. 
 
LC-MS/MS data analysis 
 Raw mass spectrometric data were analyzed using the MaxQuant environment v.1.6.1.0 [749] and 
Andromeda for database searches [750] at default settings with a few modifications. The default is used for 
first search tolerance and main search tolerance (20 ppm and 6 ppm, respectively). MaxQuant was set up 
to search with the reference mouse proteome database downloaded from UniProt. MaxQuant performed 
the search trypsin digestion with up to 2 missed cleavages. Peptide, site and protein false discovery rates 
(FDR) were all set to 1%. The following modifications were used for protein identification and quantification: 
oxidation of methionine (M), acetylation of the protein N-terminus, and deamination for asparagine or 







AKT localizes to mitochondria upon insulin stimulation 
 The localization of AKT to mitochondria upon insulin stimulation has been described previously in 
numerous reports [723,751–754]. We sought to validate our cell culture system by replicating this result 
through confocal microscopy. We utilized C2C12 mouse myoblast cells, as AKT-mediated glucose 
metabolism in skeletal muscle is known to be regulated by insulin, and skeletal muscle develops insulin 
resistance during metabolic disorders. Through preliminary immunocytochemistry experiments in 
undifferentiated C2C12 mouse myoblast cells, we observed that insulin stimulation shifted the localization 
of AKT from the nucleus to mitochondria (Fig. 5-4). While this preliminary data suggests that this model is 
appropriate for studying the subcellular localization of activated AKT, further studies are necessary to 
confirm this result in a quantitative manner with a greater sample size.   
 
AKT localizes to MAM domains 
Previous literature suggests an important role for MAM domains in cellular insulin signaling and 
AKT activation [711,712]. Since AKT is a master regulator of cellular glucose metabolism, perhaps AKT 
signaling represents a mechanism by which MAM contributes to glucose regulation. To answer this 
question, we sought to determine whether AKT localizes to MAM domains in an insulin-responsive manner. 
We selected a cell line derived from another insulin-responsive tissue, the liver. We treated HepG2 hepato-
cellular carcinoma cells with or without insulin and collected subcellular fractions in order to generate insight 
into how the subcellular localization of AKT changes upon insulin treatment in our model. We performed a 
western blot on the subcellular fractions for both total AKT (all isoforms) and AKT2 that is phosphorylated 
at Ser474, thought to be necessary for AKT activation (Fig. 5-5A). Phosphorylated AKT2 was enriched in 
MAM and mitochondrial fractions relative to the total homogenate (TH, or crude lysate before fractionation) 
and ER, whereas the total AKT signal was considerably enriched in the TH. Since the TH includes the 
cytosol, this is consistent with AKT’s known cytosolic localization prior to activation upon insulin treatment. 
To address the possibility that MAM fractions were cross-contaminated with other low-density 




membrane (CM) fractions (the intermediate fraction between TH and MAM) by density gradient ultra-
centrifugation. Specifically, we treated CM from insulin-treated C2C12 cells with the detergent, triton X-100, 
to enrich for lipid rafts (LRs), which we then separated through a continuous sucrose gradient. In support 
of the subcellular fractionation result, we observed that both total AKT (all isoforms) and phospho-AKT2 co-
migrated most closely with MAM marker, Erlin-2 [467], relative to endosome and mitochondrial LR markers 
(Fig. 5-5B). Through these results, we were able to confirm that a pool of both total and phosphorylated 
AKT localizes to MAM, and is perhaps the predominant intracellular membrane-associated pool. Of note, 
HK-II was also observed to co-migrate with MAM markers, providing support for our hypothesis that the 
HK-II-VDAC1 interaction occurs at MAM domains. 
 
AKT2 interacts with HK-II at MAM 
As discussed above, HK-II is an important AKT substrate in regards to glucose metabolism as HK-
II phosphorylates glucose upon its entry into the cell, preventing glucose from diffusing out of the cell. In 
order to learn whether MAM is a locus of HK-II phosphorylation (and thus stimulation) by AKT, as suggested 
by previously published data [736], we utilized BioID technology [566,755,756] to determine whether AKT 
and HK-II interact at MAM domains. Human AKT2 was tagged with BioID2, a derivative of the BirA biotin 
protein ligase that biotinylates primary amines (lysine, asparagine, glutamine and sometimes arginine 
residues) on proteins within a ~10 nm radius. These proteins are considered binding partners and can be 
immunoprecipitated using streptavidin beads, followed by analysis via proteomics or western blot. 
 We first validated that the AKT2-BioID2 fusion protein is a reliable model to study AKT biology by 
confirming its responsiveness to varying durations of insulin treatment. Indeed, we observed the expected 
relationship between insulin treatment time and AKT phosphorylation levels (Fig. 5-7A). We also found that 
the subcellular localization of the fusion protein mirrored that of endogenous AKT (Fig. 5-7B). These results 
validated the use of this fusion protein to determine AKT binding partners. Furthermore, it was decided that 
30 min of insulin treatment time would be maintained (as in Figs. 5-4 and 5-5) as the fusion protein 
displayed maximal phosphorylation at this time point (Fig. 5-7A).  
  HK-II was also markedly detectable in MAM fractions (Fig. 5-7B), consistent with the sucrose 




the subcellular fractionation experiment but with the addition of a 4h biotinylation period after insulin 
treatment. After collection and lysis, both the TH (crude lysate) and MAM fractions were incubated with 
streptavidin beads to pull down any biotinylated proteins. Upon western blot for the proteins indicated in 
Fig. 5-8, it was observed that HK-II was biotinylated by AKT2-BioID2, confirming the known interaction of 
the two proteins. Interestingly, similar to the previous subcellular fractionation, biotinylated HK-II was 
present in both the TH and MAM fractions, and this localization was increased upon insulin treatment. It is 
possible that this is a result of AKT2 interacting with HK-II at MAM domains. Interestingly, biotinylated 
VDAC1 – a known binding partner of HK-II – was also present in MAM fractions. This could be due to AKT2 
interacting with VDAC1 at MAM domains as well, and indeed VDAC1 biotinylation was higher in insulin-
stimulated conditions. When we further analyzed proteins biotinylated by AKT2-BioID2 by proteomics in 
both the TH and MAM fractions, HK-II and VDAC1 were detectable, with greater abundance in the MAM 
upon insulin stimulation (Fig. 5-9). These results offer preliminary support for our hypothesis that the 
interaction of AKT with the HK-II-VDAC1 complex occurs at MAM domains, indicating that MAM is a 
potential locus of AKT activity. Further experiments are necessary to confirm this possibility.  
 
Proteomics analysis of the AKT interactome 
 We continued our proteomics-based analysis of the AKT interactome to identify additional binding 
partners, in order to generate insight into additional pathways regulated by AKT at MAM domains. The 
identified proteins were ranked on the basis of overall abundance in both the TH and MAM fractions and 
grouped by pathway (Table 5-1). In addition to HK-II, VDAC1 and Erlin-2, the biotinylome also consisted of 
multiple enzymes that constitute the glycolysis pathway, including the two other rate-limiting steps of 
glycolysis (in addition to HK): phosphofructokinase and pyruvate kinase. Enzymes that regulate the 
metabolism of glycolysis product, pyruvate, were also detected, including lactate dehydrogenase, which 
catalyzes the interconversion between pyruvate and lactate. Of note, glycogen-synthase kinase-3 beta 
(GSK3b), a master regulator of glycogen synthesis and other metabolic processes, was also detected and 
is a known substrate of AKT. Next, in addition to these glucose metabolic enzymes, proteomics analysis 
revealed the biotinylation of multiple enzymes that regulate cellular lipid metabolism. Specifically, enzymes 




acylation, and cholesterol biosynthesis pathways. The final pathway to be identified was the metabolism of 
phosphatidylinositols, the membrane phospholipid species that AKT’s PH domain associates with for 
activating phosphorylation. This suggests that AKT interacts with factors that regulate its own activation. Of 
note, the interaction of AKT with many of these proteins was increased upon insulin treatment, indicating 
that these interactions are a property of activated AKT. Altogether, the proteins identified through this 
proteomics analysis of the AKT interactome suggest that AKT participates in multiple signaling pathways 
that pertain to glucose and lipid metabolism at MAM domains. Furthermore, many of these interactions 
were  experiments are necessary to determine whether these are direct or indirect interactions and/or their 





In this chapter, we study the relationship between cellular metabolic master regulator, AKT, and 
MAM domains. Using insulin-responsive C2C12 mouse myoblast and HepG2 human hepatocellular 
carcinoma cell lines, we observe that activated (Ser473-phosphorylated) AKT localizes to MAM domains. 
Localization to MAM relative to other fractions was enriched for Ser473-phosphorylated AKT but not for 
total AKT, suggesting that MAM localization is a property of activated AKT. This was accompanied by HK-
II, the enzyme that catalyzes the first step of glycolysis. Through BioID2 technology, we confirmed that 
AKT2 interacts with both HK-II and VDAC1, confirming previous reports of these three proteins existing in 
a complex. Observation of biotinylated HK-II and VDAC1 in MAM fractions raises the possibility that AKT2 
interacts with these proteins at MAM. Many other biotinylated glycolytic enzymes were detectable in MAM 
fractions as well, suggesting that MAM is a locus of AKT’s regulatory roles in glucose metabolism.   
Specifically, seven of the 10 glycolytic enzymes were detected, many at relatively high rankings 
compared to other proteins included. Of these, only HK and glyceraldehyde-3-phosphate dehydrogenase 
GAPDH are known substrates; however, given previous reports of glycolytic enzymes existing in a series 
of complexes [757] alongside unpublished data from our group, this could contribute to the observed results. 
Interestingly, pyruvate carboxylase (at the highest ranking among the proteins listed), phosphoenolpyruvate 
carboxykinase and lactate dehydrogenase were also biotinylated. These enzymes dictate the fate of 
pyruvate produced through glycolysis. Glucose-6-phosphate 1-dehydrogenase X was also biotinylated and 
is also the first step of the pentose phosphate pathway. Based on this data, AKT might regulate multiple 
steps of glucose metabolism through functionality at MAM domains.  
It was especially interesting to observe that multiple proteins involved in lipid synthesis were 
biotinylated by AKT and present in MAM fractions. These include enzymes important in de novo lipogenesis 
(acetyl CoA carboxylase 1, ACC1; fatty acid synthase, FAS; and glycerol-3-phosphate dehydrogenase), 
three acyl coA synthases that enable fatty acid incorporation into di- and tri-glycerides, as well as an enzyme 
involved in cholesterol biosynthesis (lanosterol 14 alpha-demethylase). ACC1 and FAS were detectable in 
considerably higher abundance compared to other listed proteins. MAM’s role in cellular lipid synthesis is 
well known, and the experiments presented in this chapter suggest a role of MAM in glucose metabolism 




lipogenesis upon insulin stimulation, and perhaps MAM is a common locus for these activities [713]. In 
agreement, previously published data indicate that MAM contributes to the hepatic glucose-sensing system, 
allowing regulation of mitochondrial dynamics and function during the fed-to-fasting transition [758]. 
Moreover, these data also suggest that chronic disruption of MAM may participate in hepatic mitochondrial 
dysfunction associated with insulin resistance [759]. 
Finally, enzymes responsible for phosphatidylinositol (PI) phosphorylation to form PI-4,5-bisphos-
phate (PI-4,5-P2) were also biotinylated, alongside enzymes responsible for PI-4,5-P2 dephosphorylation to 
regenerate PI. This is significant for AKT regulation because the additional phosphorylation of PI-4,5-P2 to 
generate PI-3,4,5-P3 is a necessary step in AKT activation, as AKT’s PH domain associates with PI-3,4,5-
P3 on the inner leaflet of the plasma membrane in order to undergo a conformational change that exposes 
its regulatory resides (Thr308 and Ser473) for activating phosphorylation [719]. The interaction of AKT with 
these enzymes suggests the existence of feedback loops whereby AKT promotes or attenuates the 
activation of its own signaling cascade. Further experiments are necessary to ascertain this. Of note, intra-
cellular pools of PI-3,4,5-P3 have also been identified that have the capability of activating the AKT signaling 
pathway [760]. This could explain why these proteins were detectable in intracellular, MAM fractions.  
An important future direction of this work is replicating the localization studies in neural models, as 
a major motivation of this project is the link between neurodegenerative disorders and insulin resistance. 
While AKT is ubiquitously expressed and MAM activity has been observed in numerous cell types and 
tissues, the regulation of these functionalities differs considerably by cell type. There are multiple isoforms 
of AKT and HK, differential dependence on MAM functionality of basic metabolic functions, and differential 
reliance on insulin signaling for glucose uptake. Thus, neuronal, astrocytic or microglia cell lines, and mouse 
brain tissue, would be appropriate model systems for these studies. Another important future direction is 
elucidation of the relationship between AKT phosphorylation and localization to MAM. While S473 
phosphorylation by mTORC2 has been thought to occur at the plasma membrane due to the known 
anchorage of AKT to membrane-embedded phosphatidylinositol triphosphate (PIP3) [719,760,761], 
intracellular loci of AKT phosphorylation have been described [762–764], such as MAM [736]. A separate 
report confirmed that PIP3-mediated AKT activation occurs at lipid raft microdomains [765], and MAM is a 




phosphorylatable AKT2 mutants (T309A and S474A) localize to MAM to the same degree. If they do, that 
would suggest that phosphorylation is not necessary for translocation to MAM, and perhaps occurs at MAM 
itself. The studies outlined here would generate insight into the regulation of AKT translocation to MAM.   
 Altogether, we hypothesize that MAM domains are a regulatory locus for both lipid and glucose 
metabolism. Chapters 2, 3 and 4 examine MAM’s roles in lipid metabolism, and the data presented in this 
chapter offer preliminary indications for potential roles of MAM in regulating AKT activity as it pertains to 
HK-II-mediated glucose metabolism. While further experiments are necessary to confirm this hypothesis 
(including those assaying AKT and HK-II activity upon artificial modulation of MAM activity levels), these 






Figure 5-4: Insulin stimulates the localization of AKT to mitochondria. 
Undifferentiated C2C12 cells treated with or without 100 nM insulin for 30 min in the presence of 10% FBS. 
The cells were stained with Mitotracker Green to label mitochondria and were subjected to 
immunocytochemistry using an antibody for total AKT (all isoforms, red). Confocal images were collected 
at 60x magnification at the focal plane where the most mitochondria were visible. Increased co-localization 
between AKT and Mitotracker is observable upon insulin treatment, represented by increased yellow signal. 






Figure 5-5: AKT localizes to MAM domains.  
(A) HepG2 cells were treated with or without 100 nM insulin for 30 min in the presence of 10% FBS. 
Subcellular fractions were collected and analyzed via western blot. Total AKT (all isoforms) shows 
enrichment in the TH fraction, whereas phospho-AKT2 is enriched in MAM and mitochondrial fractions. (B) 
Undifferentiated C2C12 cells were treated with 100 nM insulin for 30 min in the presence of 10% FBS. 
Crude membrane were collected and treated with 0.2% Triton X-100 for 1h at 4°C under rotation, then 
loaded onto a continuous 10-40% sucrose density gradient. Fractions 2-12 (out of 24 total) were analyzed 
by western blot. Total AKT and phospho-AKT2 co-migrate most closely with MAM marker, Erlin-2, relative 











Figure 5-7: AKT2-BioID2 fusion protein is phosphorylated upon insulin treatment and undergoes 
similar subcellular localization as endogenous AKT. 
(A) Undifferentiated C2C12 cells were transfected with Myc-BioID2-hAKT2 and treated with 100 nM insulin 
for the indicated times in the presence of 10% FBS. Lysates (collected in the presence of protease and 
phosphatase inhibitors) were analyzed by western blot. AKT phosphorylation displays a time-dependent 
trend, with maximal phosphorylation upon 30 min and 1h insulin treatment. (B) Undifferentiated C2C12 
cells were transfected with Myc-BioID2-hAKT2 and treated with or without 100 nM insulin for 30 min. 
Subcellular fractions (collected in the presence of protease and phosphatase inhibitors) were analyzed by 






Figure 5-8: AKT2 interacts with HK-II and VDAC1 at MAM. 
Undifferentiated C2C12 cells were treated with or without 100 nM insulin for 30 min in the presence of 10% 
FBS, and then all cells were treated with biotin for 4h. Total homogenate and MAM fractions (collected in 
the presence of protease and phosphatase inhibitors) were incubated with streptavidin beads, and the 
inputs and pull-downs were analyzed by western blot. Biotinylated HK-II and VDAC1 were observed in the 
MAM fractions. Erlin-2 was assayed as a MAM marker to confirm the localization of AKT2 to MAM domains 







Table 5-1: Selected proteins biotinylated by AKT2-BioID2 fusion protein, with abundance rankings 
in three independent experiments.  
Undifferentiated C2C12 cells were treated with or without 100 nM insulin for 30 min in the presence of 10% 
FBS, and then all cells were treated with biotin for 4h. Total homogenate and MAM fractions (collected in 
the presence of protease and phosphatase inhibitors) were incubated with streptavidin beads, and the pull-
downs were analyzed by proteomics. Of the identified proteins, those that participate in cellular pathways 
of interest are listed. Abundance rankings, based on total spectrum count values across untreated TH, 
untreated MAM, insulin-treated TH and insulin-treated MAM, are shown for each independent experiment 
performed. A lower number indicates higher abundance, and vice-versa. Gene names are indicated in 




Chapter 6: Discussion and Future Directions 
 
Introduction 
Alzheimer’s Disease (AD) is a complex neurological disorder that has been the subject of over a 
century of research. Multiple molecular triggers have been proposed, including pathways centering around  
amyloid-β (Aβ), tau, inflammation, calcium, glucose, lipids and mitochondria. Epidemiological studies have 
been similarly diverse, examining genetic risk loci, age of onset, sex differences, ethnicity differences, 
biomarkers, use of common medications (e.g., statins), lifestyle factors (e.g., traumatic brain injury, TBI), 
and more. Through this research, we have generated considerable knowledge about different processes 
that ensue in the AD brain as well as different lifestyle and genetic risk factors for the disease. In spite of 
this, the field has failed to reach a consensus as to which molecular pathway is responsible for a shared 
set of symptoms across a variety of potential causes.  
In this thesis, I focus on the regulation of lipid metabolic alterations in AD, owing to the consistency 
and early presentation of these phenotypes (discussed in Chapter 1). Previous research from our group 
revealed that upregulated functionality of mitochondria-associated ER membranes, or MAM domains, is 
responsible for these metabolic alterations [96], and also relates to the production of AD hallmark, Aβ [89]. 
In Chapter 2, it is demonstrated that AD-associated elevations of Aβ precursor, C99, are most significant 
in MAM domains and are responsible for upregulated MAM functionality [105]. As shown in both FAD and 
SAD samples, this contributes to mitochondrial dysfunction through alteration of sphingolipid metabolism 
[105]. In Chapter 3, the mechanism by which C99 upregulates MAM functionality is determined: through its 
cholesterol-binding domain, C99 promotes cellular cholesterol uptake and trafficking to the ER to promote 
the formation of lipid rafts such as MAM [493]. In Chapter 4, an environmental cause of AD – TBI – is 
studied from the perspective of MAM regulation, resulting in the observation that MAM functionality is 
upregulated in the acute phase after brain injury. Consistent with MAM’s role as a locus where many lipid 
classes under-go turnover, this correlates with widespread lipidomic alterations that include changes in the 
composition of phospholipids, sphingolipids and acylcarnitines. Cell type-specific lipidomics revealed that 
microglia displayed lipidomic alterations consistent with MAM upregulation to the greatest extent, while 




of MAM to glucose metabolism are explored, leading to the observation that AKT, HK-II and VDAC1 localize 
to MAM domains, where they also potentially interact. A BioID-based proteomics screen of AKT’s 
interactome revealed potential interactions between AKT and glycolytic and lipid synthetic enzymes at 
MAM, suggesting that AKT may regulate MAM-mediated glucose and lipid metabolism. Altogether, this 
thesis argues that MAM functionality is a driver of metabolic alterations in familial, sporadic and 
environmental forms of AD. 
In the following sections, I will discuss the relationship between amyloid precursor protein (APP), 
MAM regulation and cholesterol homeostasis. I will also discuss how this axis relates to pathogenic 
mechanisms of familial AD (FAD), sporadic AD (SAD) and TBI, and how MAM dysfunction contributes to 
other well-known phenotypes of the disease (Fig. 6-1).  
 
 
Figure 6-1: Convergence of familial, sporadic and environmental AD triggers on MAM upregulation, 
with cellular consequences. 
 
APP metabolism and cholesterol regulation: a potential mechanism in FAD 
It has been almost two decades since >250 mutations in APP, PSEN1 and PSEN2 were found to 
cause dominant forms of early-onset AD, but the mechanism by which these mutations cause the disease 
is still not clear. Given that presenilins are members of the ɣ-secretase complex, which cleaves APP to 




that FAD mutations result in a gain of ɣ-secretase function (due to mechanisms that were unknown). As a 
result, there have been many therapeutic efforts directed toward the inhibition of ɣ-secretase and the 
reduction/elimination of Aβ. However, trials for ɣ-secretase inhibitors failed to ameliorate cognitive 
symptoms, indicating that increased Aβ production is insufficient to explain AD etiology (discussed in 
Chapter 1). This necessitates an alternative explanation for how APP/PSEN1/PSEN2 mutations cause AD.  
A major limitation in the AD field is the lack of consensus regarding the physiological function of 
APP. Interestingly, it has previously been shown that APP metabolism is closely associated with cellular 
cholesterol homeostasis [767]. For example, increases in cellular cholesterol are known to induce APP 
internalization and processing, promoting Aβ production [76,79], while cholesterol-lowering drugs and 
inhibitors of cholesterol esterification attenuate these processes [768,769]. This compelling connection 
between cholesterol and AD is further supported by multiple reports showing that APP processing occurs 
preferentially in cholesterol-rich lipid raft (LR) domains [90,588]. Thus, understanding cellular cholesterol 
metabolism can provide valuable insight into the regulation of APP processing. 
The concentration of cholesterol in cellular membranes is tightly regulated by cross-talk between 
the plasma membrane (PM), where most cellular cholesterol resides, and the ER, where the protein 
machinery that regulates cellular cholesterol levels resides. The de novo synthesis of cholesterol is 
regulated at the transcriptional level by the sterol regulatory element-binding proteins (SREBPs), the master 
regulators of lipid synthesis and uptake [627]. Under conditions of sufficient cholesterol supply, SREBPs 
are retained in ER membranes. Upon lipid depletion, SREBP translocates to the Golgi apparatus and is 
cleaved into a transcriptionally active form that, upon entry into the nucleus, regulates the expression of 
several genes including those encoding hydroxymethyl glutaryl-CoA reductase (HMGCR), low density 
lipoprotein receptor (LDLR) and SREBP1/SREBP2 themselves [627]. 
Although all cells have the capacity to synthesize cholesterol, most of this lipid is imported through 
the uptake of lipoproteins mediated by PM receptors like LDLR. Once internalized, cholesteryl esters (CEs) 
are hydrolyzed and resultant free cholesterol (FC) is transported to the PM [770]. As PM function is highly 
sensitive to cholesterol concentrations, once PM cholesterol levels surpass a cell type-specific threshold, 
the excess cholesterol is transported to the ER for detoxification; specifically, in the ER cholesterol is 




(cytosolic lipid droplets) [486] (Fig. 6-2). This cycle is controlled by a sensor protein in the ER that has yet 
to be identified and is capable of triggering communication between the PM and ER cholesterol pools [486]. 
Based on previous studies [646] and the results presented in Chapter 3 [493], we propose that C99 is a 
major sensor protein, and that MAM is the specific LR domain that acts as signaling platform in the 
regulation of cholesterol homeostasis. 
 
 
Figure 6-2: Cholesterol trafficking from the plasma membrane to MAM domains of the ER. 
 
Specifically, previously published reports and our own data have led us to propose the following 
mechanism (Fig. 6-3). Internalized cholesterol from extracellular lipoproteins increases the concentration 
of cholesterol in the PM, which causes the PM to undergo reorganization and phase separation into LRs (a 
liquid-ordered domain) and neighboring liquid-disordered domains [473]. LRs will be enriched in cholesterol 
and cholesterol-binding proteins such as APP. The liquid-disordered domains generated by this phase 
separation would facilitate inward curvature of the membrane, leading to the formation of endocytic vesicles 
that would include PM LR domains [79], and therefore APP as well. This newly formed endosome would 
fuse with lysosomes as part of the endocytic pathway, resulting in the formation of endolysosomes with 
acidic luminal environments. This will render BACE1, a membrane-associated aspartyl protease that also 
clusters into LRs, active as BACE1 activity is restricted to acidic environments [79]. As a result, APP would 
undergo cleavage by BACE1 to generate C99 [79]. Through unknown mechanisms, C99- and cholesterol-
rich endosomes would traffic to the ER and cluster into MAM domains, likely in a pathway that resembles 




recruited to MAM regions upon MAM formation [105], such as ACAT1 and lipid droplet formation. The C99-
mediated formation of MAM domains would also promote interaction between C99 and ɣ-secretase [75] to 
induce the cleavage of C99 [89]. This is in agreement with previous reports showing that this cleavage 
occurs in intracellular rafts such as MAM [89,470]. Clearance of MAM-localized C99 by ɣ-secretase activity 
inactivates the cholesterol-scaffolding properties of C99’s cholesterol-binding domain (CBD), preventing 
further recruitment of cholesterol to MAM domains and thereby attenuating MAM formation. In agreement 
with this data, our laboratory observed that CBD-mutant C99 is incapable of promoting cholesterol 
internalization and MAM formation [493]. Based on these results, we propose a scenario where APP is a 
mediator of cross-talk between the PM and the ER in order to regulate cellular cholesterol levels and 
respond to environmental triggers that modulate cellular cholesterol homeostasis (Fig. 6-3). 
 
 
Figure 6-3: Schematic representation of the potential role of C99 in the regulation of cholesterol 




To place this pathway into the context of AD pathogenesis, failure to cleave C99 (due to ɣ-secretase 
loss-of-function) results in a futile cycle of cholesterol turnover, where the sustained formation of MAM 
domains is enabled by the upregulated internalization of extracellular cholesterol and its trafficking to the 
ER. Consequent elevations in MAM-localized C99 promote MAM formation and push MAM-specific 
enzymatic activities to pathogenic levels. C99 elevations have also been shown to result in other 
impairments to cellular homeostasis, such as endocytic and autophagic dysfunction, mitochondrial 
alterations, hippocampal degeneration and cognitive impairment, determined through studies of artificial 
C99 elevation in cell and animal models [192,201,203,534]. Mechanisms by which elevations in C99 and 
MAM activity can explain other AD phenotypes are described below. 
 
A shared phenotype with distinct triggers: familial AD and sporadic AD 
Our proposed mechanism of disease describes increased levels of uncleaved C99 at the ER as a 
primary trigger of pathogenesis. In FAD, these elevations in C99 could be explained by mutations in PSEN1/ 
PSEN2/APP. These mutations can alter the conformation, interaction and processivity of these proteins to 
result in modulated ɣ-cleavage of C99, which in turn could explain increased cholesterol trafficking to the 
ER and the subsequent formation of MAM domains [771]. However, how does this proposed mechanism 
relate to sporadic forms of AD that lack mutations in the proteins responsible for C99 production?  
Interestingly, C99 elevations are also characteristic of SAD models [192], but the mechanism by 
which this fragment is increased in SAD is unknown. It has been shown that simply treating cells with 
cholesterol can promote APP internalization, induce increases in C99, and replicate known AD phenotypes 
such as increased ratio of Aβ42:40 [76,77,79,640]. Moreover, data from our laboratory has also shown that 
primary AD patient fibroblasts and neurons from AD mouse models show increases in MAM activity when 
incubated with conditioned media from astrocytes expressing human ApoE4 [772]. ApoE is the principal 
cholesterol carrier in the brain, and the most common mutation in SAD (and in AD in general) encodes the 
ε4 allele (vs. wildtype ε3) of this gene. It is hypothesized that impairments in the recycling of internalized 
ApoE-containing lipoproteins associated with ε4 (vs. wildtype ε3) result in increased endosomal and 
lysosomal cholesterol content, increasing cholesterol delivery to the ER and eventually MAM [772,773]. 




levels (hypercholesterolemia) and AD risk [355,356], with increased circulating lipoproteins and total 
cholesterol being associated with cerebral Aβ deposition in humans [361]. Furthermore, the use of statins 
(inhibitors of de novo cholesterol synthesis) is associated with reduced incidence of AD [364–366] and 
midlife statin use has been suggested to prevent AD [355,367,368].  
Altogether, we propose that FAD and SAD converge on an increase in cellular cholesterol [329,566] 
and C99 levels [192,529], which are internalized and trafficked to MAM in concert [76,493,640], but differ 
in terms of which phenotype initiates the pathogenic cascade (Fig. 6-1). From this perspective, any genetic 
variant associated with SAD results in increased cholesterol internalization, C99 levels and MAM activation. 
Consequences of AD-associated mutations in APOE were discussed above, but other genes containing 
SAD-associated polymorphisms, including SORL1, CLU and ABCA7, are also implicated in cholesterol 
trafficking and likely contribute to cholesterol alterations in AD [649]. Thus, in forms of AD that lack 
mutations in the genes responsible for C99 production (APP/PSEN1/PSEN2), elevated cellular cholesterol 
is likely responsible for the hyperactivation of MAM functionality. Thus, AD can be considered a disorder of 
cellular cholesterol metabolism.  
 
Linking MAM alterations to other AD phenotypes: Aβ and tau 
Amyloid-β deposition 
As mentioned above, increases in Aβ production or increased production of longer forms of Aβ are 
often blamed for AD pathogenesis. While AD tissues indeed display increases in the ratio of Aβ42-43:40, 
AD tissues and animal models also show an increase in C99 (as discussed above); specifically, increases 
in C99 are greater than increases in Aβ, translating to an increased ratio of C99:Aβ [105,135,187,190]. 
From the lens of familial AD specifically, this suggests that PSEN mutations cause a reduction in the 
enzymatic activity of this complex, a topic that has been the subject of intense debate in the AD field [104]. 
Nonetheless, existing literature supports the notion that PSEN mutations cause a reduction in ɣ-secretase 
activity [195,201] and, in some models, recapitulate impairments in hippocampal memory without causing 
Aβ deposition [199]. It has thus been proposed that AD cells should not only be defined by an elevated ratio 
of longer versus shorted species of Aβ [115], but also by an elevated ratio of C99:Aβtotal [116]. Furthermore, 




thus considered “neurotoxic” [774], the aforementioned γ-secretase alterations are thought to reduce not 
only the quantity of Aβ produced (relative to the amount of available substrate, C99), but also the “quality” 
of this Aβ. Thus, pathogenicity of AD-associated PSEN mutations is due to both of these outcomes [104]. 
Relating this to the MAM hypothesis, our laboratory and others have published that Aβ production 
occurs in MAM domains [89,470,471], in line with the known localization of C99 to MAM discussed 
extensively above. It may thus be intuitive to hypothesize that increased MAM formation would lead to 
increases in Aβ production, and indeed the activity of MAM-resident enzyme ACAT1 positively correlates 
with Aβ pathology [642,775,776]. However, previously published data makes it difficult to conclude that that 
such a direct cause-and-effect relationship exists. First, as described in the previous paragraph, AD is 
associated with greater increases in C99 than in Aβ [105,135,187,190]; it thus appears that increased C99 
localization to MAM does not result in its increased cleavage. Second, it has been shown that ɣ-secretase 
activity is highly sensitive to alterations in the surrounding lipid milieu [129–131]. Previous reports have 
demonstrated that ɣ-secretase cleavage is slow [777] and unspecific [778], and the length of the produced 
Aβ peptides is modulated by membrane lipid composition and thickness [129]. Thus, upregulated MAM 
functionality and consequent alterations in the cellular lipidome will also alter the membrane microdomains 
containing ɣ-secretase, affecting enzymatic activity. Finally, it has been shown that increased density of 
C99 can promote C99 dimerization through its cholesterol binding domain, and protect it from cleavage by 
ɣ-secretase [779]. This underlies another mechanism by which increased MAM formation might not 
necessarily lead to increased Aβ production. Altogether, increased levels of C99 at the MAM will not only 
reduce amyloid production in this domain, but will also affect membrane lipid composition and Aβ length.  
 
Cytoskeletal dysregulation and tau hyperphosphorylation 
Another commonly studied protein in AD and TBI, and in other neurodegenerative diseases, is tau. 
Hyperphosphorylated tau, a common but inconsistent AD feature (similar to Aβ), can aggregate into tangles 
and disrupt cytoskeletal stability and axonal trafficking. Interestingly, it was recently reported that CE 
production in an AD patient fibroblast-derived neuronal model is an upstream driver of tau pathology at 
early disease stages [642]. Promotion of cholesterol efflux by non-esterification-based mechanisms (e.g., 




pathology was dependent on cholesterol esterification [642]. These results speak to an important role of 
cholesterol esterification, a MAM-regulated function, in promoting tau pathology. Furthermore, inhibition of 
β-secretase but not ɣ-secretase has been shown to reduce phosphorylated tau levels in FAD neurons 
[609,780], indicating that C99 is at the heart of this effect. Thus, published data indicates that MAM function-
ality potentiates tau pathology characteristic of neurodegenerative disorders such as AD. 
 
MAM upregulation as a driver of neurodegenerative disease 
The importance of lipids in the maintenance of brain homeostasis 
 How does upregulation of MAM functionality lead to neurological disorders? In other words, how 
does MAM upregulation impair neuronal functionality to the point where cognitive functions are 
compromised? The answer to these questions lies in MAM’s role as a center of cellular lipid metabolic 
regulation, where multiple lipid classes are simultaneously metabolized by MAM-localized enzymes. Lipids 
regulate multiple basic brain functions [698,704], including action potentials, synaptic vesicle release, 
endocytic transport, cellular signaling and pathogen recognition [704,781]. Many of these roles arise by 
virtue of the fact that lipids are the principal constituent of cellular membranes, where their differential 
charges and shapes modulate membrane properties. As such, lipids can control the recruitment, 
conformation, and interaction of membrane-associated proteins like receptors, channels and enzymes 
[782]. Lipids also regulate membrane curvature, important for the budding and fusion of vesicles containing 
neurotransmitters and other cargo. Lipids additionally regulate membrane permeability and fluidity, which 
is largely dependent on the fatty acid composition and saturation of constituent phospholipids. Furthermore, 
lipids are the primary constituent of myelin, which ensheathes axons and enables efficient conductance of 
action potentials. Finally, lipids represent a natural mechanism of energy storage and transport, and can 
serve as reservoirs of bioactive signaling molecules. The brain is actually one of the most lipid-rich tissues 
of the body (second only to adipose tissue), as lipids comprise 50% of brain dry weight (mostly in myelin) 
[704]. It is thus not surprising that lipid alterations can be drivers of neurodegenerative diseases [783,784], 






MAM dysregulation is an early phenotype of AD 
 An important aspect of the MAM hypothesis is the fact that associated metabolic signatures are 
detectable at early disease stages. In our own research, we have observed elevations in C99 and lipid 
droplets in cortical neurons isolated from AD mouse models at young ages (postnatal day 0) [105]. This 
was consistent with reports from other groups showing similar elevations in C99 at early stages of AD 
mouse models [187,192], as well as increased CEs in peripheral blood mononuclear cells from 
asymptomatic AD patients [323]. Increases in ceramide, the product of MAM-enriched SMase activity, have 
also been reported in brain tissue [337] and blood [785,786] of mild dementia patients. Finally, deficits in 
mitochondrial respiration and brain glucose usage have been reported during asymptomatic stages 
[303,403]. Thus, this evidence of metabolic alterations occurring at pre-symptomatic disease stages, even 
before the appearance of histopathological hallmarks [374], speaks to a relatively upstream role of MAM 
functions in AD pathogenesis. 
 
Modulation of membrane saturation and function 
Phospholipids are the most abundant lipid class in biological membranes and undergo synthesis 
and turnover at MAM regions [345]. MAM alterations can modulate cellular phospholipid profiles, with 
implications for membrane function. First, MAM regulates the relative ratios of different phospholipid 
classes, which are known to have different shapes (cylindrical or conical) [787]. This can alter the curvature 
of membranes, an essential process for the formation and fusion of vesicles carrying nutrients and 
neurotransmitters [788]. These endo-/exo-cytic pathways are essential for synaptic communication and 
neurotransmission, meaning that phospholipid alterations can disrupt the balance of these processes. 
Furthermore, MAM alterations can modulate the fatty acid composition of phospholipids – specifically, the 
saturation index of constituent fatty acids. This is due to the MAM-localized acyl coA synthase enzymes 
(ACSLs), which convert long-chain and very long-chain fatty acids into fatty acyl coA esters [703,789]. This 
enables their incorporation into phospholipids. Different ACSL isoforms display differential specificities for 
varying fatty acid chain lengths and saturation indices; thus, alterations in their activities due to MAM 
alterations will affect the saturation of cellular phospholipids. This can affect membrane fluidity and 




and action potentials [790]. The TBI results presented in Chapter 4 show increases in neuronal phospholipid 
species containing polyunsaturated fatty acyl chains at the same time-point that we found MAM activity to 
be upregulated. It is thus possible that, in this model, MAM upregulation promotes increased phospholipid 
unsaturation, perhaps through selective upregulation of ACSL4 and ACSL6 activities, which are known to 
preferentially acylate polyunsaturated fatty acids [701,702]. Altogether, this information describes how MAM 
upregulation, as in AD and TBI, can modulate phospholipid homeostasis and functionality of membranes. 
 
MAM upregulation in different cell types: promotion of sphingomyelinase activity and inflammation 
Inflammatory signaling is a major area of study in the AD and TBI fields [696,791]. Microglial 
activation is a characteristic feature of both conditions. In AD, this can be induced by SAD-associated 
genetic polymorphisms, Aβ deposits or myelin debris. In TBI, microglial activation can be induced by cellular 
or myelin debris that results from physical tissue damage. It has been shown that cellular lipid metabolic 
networks intimately modulate innate immune responses [255]. Specifically, sphingolipid alterations are 
associated with microglial activation, and activation of sphingomyelinase (SMase) activity is associated for 
this process [255]. Indeed, the results in TBI presented in Chapter 4 suggest that injury-induced SMase 
activity is enriched in microglia relative to other cell types. But how can this be promoted by upregulation of 
MAM functions? First, microglial activation is known to be associated with increases in CEs and 
accumulation of lipid droplets [692]; thus, MAM upregulation correlates with pro-inflammatory states. 
Second, a mechanism of clearing Aβ deposits is phagocytosis by microglia, the brain’s resident 
macrophages. A major microglial cell-surface mediator of this is the Toll-like receptor (TLR) family of 
proteins [792,793], which are known to be enriched in LRs [794]. Thus, early-stage upregulation of MAM 
activity could promote TLR function and hyperactivation of inflammatory signaling. Finally, TLR priming has 
been shown to result in the assembly and activation of the NLRP3 inflammasome, a multi-protein complex 
that triggers the release of pro-inflammatory cytokines, thereby being essential for a complete cellular 
immune response [248]. MAM domains are a locus of NLRP3 inflammasome assembly [795]. Thus, MAM 
upregulation could promote inflammatory phenotypes mediated by NLRP3, activation of which has been 
reported in both AD and TBI [796–798]. Altogether, upregulation of MAM functionality is associated with, 




Ceramide elevations and mitochondrial dysfunction 
Another outcome of activated SMase activity is the increased production of ceramide, with 
ceramide increases emerging as an early AD signature [322,340]. Our lab observed that SMase activity is 
enriched in MAM fractions under both baseline and disease conditions, confirming that upregulated SMase 
activity goes hand-in-hand with upregulated MAM functions. As a result, there are marked elevations in 
ceramide levels in MAM regions and mitochondrial membranes, which can impair mitochondrial 
functionality [604,799]. Specifically, ceramide has been shown to potentiate pore formation in the 
mitochondrial outer membrane and trigger apoptosis [799], while also inhibiting mitochondrial respiratory 
complex activity and potentiating ROS formation [604]. This is significant in the context of AD because of 
the wealth of literature regarding mitochondrial dysfunction in AD. Putting this data into the context of 
ceramide data in AD, correlated with cholesterol trafficking and SMase activity, allows for the conclusion 
that MAM dysfunction could impart toxicity in AD through ceramide-mediated mitochondrial dysfunction. 
 
Calcium elevations and bioenergetics 
Both AD and TBI are characterized by neuronal overactivation, mediated by elevated intracellular 
Ca2+ levels due to a variety of reasons that converge on mitochondrial dysfunction [268,800]. In AD, reasons 
for these aberrations include reduced production of sAPP⍺	 [276], membrane pore formation by Aβ 
[277,278], PSEN mutations [285,286] and increased expression of ryanodine receptors [275]. In TBI, this 
is thought to be due to increased release of excitatory neurotransmitters like glutamate and aspartate due 
to cellular shearing [537,538]. Given the important role of Ca2+ in neuronal action potentials and as a 
cofactor for many enzymes (including mitochondrial metabolic enzymes), sustained Ca2+ alterations will 
inevitably be detrimental for cognitive functioning. One of the primary cellular mechanisms of buffering 
elevated cytosolic Ca2+ levels is uptake by mitochondria [288], a buffering capacity that can eventually break 
down when exceeded. ER-mitochondria connections are a major source of mitochondrial Ca2+ uptake, as 
Ca2+ transfer through IP3R3-GRP75-VDAC1 channels is one of the main functions of these contact sites 
[287]. Thus, increased MAM functionality in AD and TBI will lead to increased mitochondrial Ca2+ levels. 
While this may initially boost TCA cycle activity and respiration, excessive intra-mitochondrial Ca2+ can 




apoptotic factors [288,540]. Thus, increased MAM functionality is likely a potent contributor to reported 
excitotoxic phenotypes in both AD and TBI. 
 
Glucose metabolic alterations 
Chapter 5 of this thesis examines a possible relationship between MAM domains and cellular 
insulin signaling as it relates to glucose metabolism. This is studied specifically from the perspective of 
AKT, a serine/threonine kinase that is a master regulator of cellular metabolism. AKT is activated upon 
insulin stimulation and associates with hexokinase-II (HK-II), which catalyzes the first step of glycolysis. 
HK-II is known to bind VDAC1 at the mitochondrial outer membrane, and previous reports in the literature 
as well as our own results suggest that AKT, HK-II and VDAC1 exist in a complex together. Our data, 
presented in Chapter 5, provides support for the possibility that this complex is localized to MAM domains, 
potentially as a mechanism of carrying out glycolytic regulation at MAM regions. Indeed, unpublished data 
from our group demonstrates that other enzymes in the glycolytic pathway localize to MAM, and our BioID-
proteomics analysis of the AKT interactome at MAM indeed identified many of the same proteins. 
Interestingly, proteins in involved in cellular lipid metabolism were also identified, underlying the primary 
goal of this project: to learn whether MAM, a hub of cellular lipid metabolism may also be a locus of glucose 
metabolic regulation. These results on the subcellular localization and binding partners of AKT suggest that 
this may indeed be the case, with AKT as a potential effector of this co-regulation. This is relevant in the 
context of AD because, not only are MAM functions and lipid metabolism altered in this disorder, but so are 
glucose metabolic pathways. Glucose hypometabolism is a diagnostic indicator of AD development, many 
AD patients present with systemic insulin resistance, and brain cells themselves can develop impairments 
in insulin signaling to the point where AD is sometimes called “type-3 diabetes” [304,307]. The data 
presented in this chapter suggests that MAM upregulation could affect early steps of cellular glucose 
metabolism, and perhaps contribute to insulin signaling defects observable in AD cells.  
 
 Through these cellular processes, MAM upregulation has the ability to disrupt cellular homeostasis 
and induce pathology. When the cause is genetic, MAM functions will likely be upregulated in every cell of 




their functionality. But the story is different for the brain, as neurons are highly dependent on lipids for their 
primary function: carrying out cognition. Unlike glia, neurons proliferate minimally after development; thus, 
the neuronal lipidome undergoes minimal turnover outside of homeostatic membrane-mediated processes 
like endo-/exo-cytosis. This makes neurons especially sensitive to systemic lipid alterations as would be 
caused by dysregulation of the cell’s lipid factory, MAM. This explains why MAM alterations, when chronic, 
are detrimental for the nervous system and have been reported in multiple neurodegenerative disorders 
such as PD [801], ALS [802] and Charcot-Marie-Tooth disease [803].  
 
The role of MAM functionality in the injured brain 
Promotion of cellular recovery in the acute phase 
 The studies presented in Chapter 4 describe assays of MAM functionality in a mouse model of TBI, 
specifically in the acute phase (week-long period) after a single injury. We find evidence that MAM functions 
are indeed upregulated, but why would the brain upregulate these activities after injury? We hypothesize 
that these functions represent natural cell survival, and repair, mechanisms after physical injury. The first 
insult experienced by cells directly impacted by injury is shearing of the plasma membrane (PM), which can 
abrogate cellular permeability, communication with the extracellular environment and synaptic 
communication. The major structural unit of membranes is lipids, so the cell would activate lipid synthesis, 
uptake and trafficking pathways to support membrane repair. Indeed, lipoprotein and cholesterol trafficking 
to axons after injury has been shown to support regeneration and remyelination [561,567,688]. We 
hypothesize that the upregulated internalization and trafficking of these lipids (specifically cholesterol) 
would upregulate MAM functionality. 
Additional reports speak to a beneficial role of MAM activity after TBI, in line with our reasoning that 
MAM activation promotes membrane repair. A recent study describes astrocytic ER-mitochondria tethering 
and Ca2+ transfer as being critical in promoting vascular remodeling and angiogenesis after injury [804], 
while another paper describes local upregulation of the same functions in injured axons as a mechanism 
of promoting axon regeneration [805]. Indeed, cellular Ca2+ signaling is thought to be a determinant of 





Pathogenicity of potentially chronic MAM upregulation after multiple TBIs 
Our data in AD suggest a significantly pathogenic role for MAM upregulation, in contrast to the 
protective roles after TBI suggested above. We explain this difference by noting that AD is a chronic 
disorder, meaning that MAM upregulation is a sustained phenotype over years and potentially decades. 
Once cellular mechanisms of counterbalancing resultant metabolic alterations are exhausted, cellular 
homeostasis becomes permanently altered, resulting in the other discussed AD phenotypes. Ultimately, 
neuronal functionality would break down, impairing neurotransmission.  
How could such a phenotype be induced after TBI? We hypothesize that this might be observable 
after multiple injuries where activated pathways would not have the opportunity to normalize. In other words, 
for populations such as athletes in high-contact sports or active-combat military populations exposed to 
multiple blasts, activated pathways are unable to return to baseline before another triggering episode. This 
could create a state of chronic MAM upregulation where MAM functions become maladaptive (Fig. 6-4). 
This has actually been discussed in a recent review article, which suggests that regulation of inflammatory 
and autophagic pathways by MAM may be problematic following TBI [807]. Indeed, we see early signatures 
of potential pathogenic consequences of MAM upregulation in neurons purified after injury. Specifically, we 
observed increases specifically in PtdCho and PtdEtn species containing polyunsaturated fatty acyl chains. 
If sustained and exacerbated by multiple injuries, this can increase the permeability and fluidity of neuronal 
membranes, which could prevent efficient neurotransmission [699]. Altogether, we hypothesize that the 
molecular link between TBI and AD lies in this phase of chronic MAM upregulation after multiple injuries. 
 
Figure 6-4: Schematic representation of hypothesized MAM response after single vs. multiple TBI 




Divergent mitochondrial alterations in AD and TBI despite a shared upregulation of MAM functions 
In AD samples, we observed that increased localization of C99 to MAM domains upregulates 
SMase activity and therefore ceramide production at MAM regions. This results in increased mitochondrial 
ceramide content and marked reductions in mitochondrial respiration through both complex I (C-I, 
responsive to pyruvate oxidation) and complex II (C-II, responsive to fatty acid oxidation) [105]. Given that 
we observe MAM upregulation in TBI samples as well, we hypothesized that mitochondrial respiration would 
be reduced in our model as well. Indeed, this has been reported previously in TBI [575,680] similar to AD 
and has been attributed to excitotoxic cascades and loss of mitochondrial Ca2+ homeostasis. However, we 
failed to observe significant impairments in respiratory at any of the time-points tested and in either brain 
region in this model. We attribute this to two possible reasons: methodological differences between other 
experimental TBI reports and our assays, as well as differences in the chronicity of MAM upregulation 
between our TBI model and AD samples. 
There are multiple methodological differences between other TBI reports and our experiments. 
First, regarding mitochondrial isolation, many papers subject crude mitochondrial preparations to high 
concentrations of nitrogen gas in order to release synaptosomal mitochondria [808–810]. This would create 
a hypoxic environment (albeit briefly), affecting respiratory activity and arguably introducing artifacts. The 
detergent, digitonin, is also sometimes used for this purpose and can also alter mitochondrial function 
[811,812]. Furthermore, many papers isolate mitochondria through ficoll or Percoll density gradients to 
enrich for “still-functional” mitochondria [813–815]; however, this approach is counterproductive as the less 
“functional” mitochondria likely better represent the impact of TBI on mitochondrial functionality. Next, in 
terms of experimental protocol, assaying the function of respiratory C-II requires the addition of succinate, 
the C-II substrate. In many papers, succinate is added to the reaction mixture after FCCP, a protonophore 
that abolishes mitochondrial membrane potential and uncouples respiration from ATP production [814–
816]. Assessment of C-II activity in the presence of FCCP would produce an artifactually high reading. 
Finally, regarding experimental design, many papers look at timepoints earlier than those examined in this 
thesis (<24h after injury) and, while certainly crucial, the results are inconsistent. In addition, control groups 
vary across studies (with some comparing TBI to sham [569,579,817,818] and others to the contralateral 




making comparison of studies difficult. Nonetheless, when the papers with similar experimental approaches 
as our studies are analyzed, it can be concluded that respiration through C-I can be depressed for up to 
24h after TBI, and sometimes longer [576–579]. There are also indications that respiration through C-II is 
slightly elevated [579,580], perhaps as a compensatory mechanism. In our model, the earliest time-point 
we examine is 24h after injury, which might be after mitochondrial functionality has been restored. Further, 
we do observe indications of elevated C-II-mediated respiration, consistent with previous reports. Thus, the 
difference between our results and other studies in the TBI field can be explained. 
The divergence between our mitochondrial data in TBI and AD now merits explanation. As 
discussed above, AD is a chronic disease that is often associated with genetic polymorphisms that are 
present since birth. Thus, effects of these mutations on cellular homeostasis would be lifelong and 
sustained compared to the week-long period following a single injury. Indeed, we did not observe reductions 
in respiration in AD mouse models (PSEN1-M146V knock-in) until 3-5 months of age, yet C99 elevations 
and increased lipid droplets are observable in cortical neurons isolated from 14-day-old embryos from the 
same mice. Thus, any effects of MAM upregulation on mitochondria likely arise from chronic upregulation 
of MAM functionality for a sustained period of time.  
 
Regional specificity of MAM-related metabolic alterations 
 In this model, the cortex is physically injured during impact but the underlying hippocampus is not. 
This is reflected in the Fluorojade-C staining, where cell death is observable to a much lesser degree in the 
hippocampus than in the cortex. Yet, the activation of a number of molecular pathways is observable in the 
hippocampus, including glial activation, C99 elevations at MAM, MAM-mediated lipid trafficking (PL transfer 
and SMase activities, elevated Smpd5 gene expression, lipid deposition) and lipidomic alterations). 
Mitochondrial respiratory deficits are not observable in either brain region, but a considerable reduction in 
the ratio of mitochondrial DNA to nuclear DNA is observable at days 3 and 7 in the hippocampus. Viewed 
altogether, it can be concluded that, for the most part, the assayed parameters are comparably affected in 
both brain regions. This result can serve as confirmation of the possibility that secondary metabolic 
pathologies predominate over the post-injury time-course. Indeed, many of the clinical symptoms of TBI 




[652,653]. The relative absence of cell death in the hippocampus in spite of this evidence for an important 
role of this region in post-injury neurological sequelae suggests that cell death is not responsible 
hippocampal phenotypes after injury, but rather metabolic alterations are key. 
 
Clinical applications of the MAM hypothesis: a potential early-stage diagnostic tool 
The purpose of disease research is to better understand pathogenic mechanisms with the goal of 
ameliorating, and potentially preventing, adverse outcomes in affected patients. As discussed in Chapter 
1, the premier challenge in the AD field is that by the time patients start displaying neurological symptoms, 
the disease has likely reached an irreversible stage [27]. Therefore, early diagnosis is a critical capability 
for successful attenuation of disease processes. We propose that the utility of the MAM hypothesis lies 
here. MAM alterations are present at early disease stages and can also help explain other disease 
phenotypes that are often blamed. Thus, detection of MAM alterations in neural tissues at early, 
asymptomatic disease stages is the key. Patients at risk include those with family histories, carriers of 
common SAD polymorphisms, and those with a history of exposure to environmental and lifestyle risk 
factors for AD. Ongoing studies in our group are conducting MAM assays and lipidomics analysis in fibro-
blasts and peripheral blood mononuclear cells from patients at risk for AD alongside age-matched controls 
in order to determine whether this is a reliable early-stage diagnostic tool (i.e., a biomarker). The ultimate 
goal is to develop a high-throughput lipidomics-based system to detect AD at asymptomatic stages. If this 
early diagnostic test is successfully validated, methods to prevent MAM-mediated disturbances in cellular 
metabolism from progressing could be developed. Further research is needed to determine how the 
methods we have developed in the laboratory to downregulate MAM functionality can be applied clinically.  
 
Future directions 
There are multiple future directions that emerge from the TBI studies presented here. To our 
knowledge, this work is the first interrogation of MAM activity in TBI, and as such offers many routes for 
follow-up studies. To begin with, given our hypothesis that MAM relates to the development of AD pheno-
types after multiple injuries, many of these studies would need to be repeated in a multiple injury model and 




indeed result in sustained MAM upregulation. Conducting the mitochondrial experiments at these later time-
points after multiple injuries would be especially informative as that would confirmation of whether sustained 
MAM upregulation is indeed necessary to observe a mitochondrial phenotype, in line with our hypothesis.  
Our overall hypothesis is that MAM functionality is responsible for the development of AD pheno-
types after TBI. Specifically, chronic elevation of MAM functionality (potentially an outcome of multiple 
injuries) could dysregulate neuronal functionality. This would manifest as behavioral deficits that have 
indeed been observed in TBI models, especially in CCI [513]. While these experiments were outside of the 
scope of the present study, it would be important to confirm whether MAM functionality contributes to 
behavioral alterations. This would be achieved by conducting such behavioral assays after single or 
repeated TBIs in MAM loss-of-function mice. Such models have not been directly described, but conditional 
knock-outs of known MAM tethers, such as Mitofusin-2 (MFN2) [600],  are likely to be appropriate. Complete 
MFN2 knock-out mice are not viable due to impaired developmental pathways [825]; however, fibroblasts 
from this mouse line are reliable cell models of downregulated MAM functionality [96], and brain-specific 
constitutive and conditional Mfn2 knock-out mouse lines are viable [826]. Thus, TBI studies in these models 
would allow us to learn the extent to which MAM contributes to TBI-induced behavioral alterations. 
It further merits determining the molecular mechanism(s) by which MAM functionality becomes 
upregulated. We hypothesize that upon physical injury to brain cells, lipid mobilization (synthesis, turnover 
and trafficking) will be stimulated in response to a cellular need to rebuild broken membranes and 
remyelinate axons. But how does this “need” manifest at the molecular level, and how is it communicated 
throughout the cell in a manner that the necessary pathways become activated and coordinated? We 
hypothesize that this is a relatively passive process, triggered by elevations of APP-C99 at MAM domains. 
In AD models, we have confirmed that APP-C99 is a primary cause of MAM upregulation, and MAM is a 
primary driver of cellular lipid metabolic alterations. In TBI, these connections are still correlational and merit 
confirmation. Repetition of the MAM assays after CCI in Bace1 knock-out mice, which are fertile, viable, 
and do not produce C99, would help answer this question. Of course, it is possible that reduced β-cleavage 
of full-length APP and other BACE1 substrates will result in confounding phenotypes; however, experiments 
from our group have demonstrated that BACE1 loss-of-function systems are appropriate for addressing the 




previously [532,533,827], indicating that this is a relevant model in the TBI field. As a converse approach, 
subjecting conditional ɣ-secretase loss-of-function models [199,828] to TBI could provide further 
confirmation of the role of C99 in TBI-induced MAM upregulation. 
These studies notwithstanding, it would remain to be determined how the cell increases steady-
state levels of C99 at MAM. Interrogation of the activity and expression of APP processing enzymes would 
provide key insight into this question, as would analysis of levels of full-length APP and Aβ fragments. Even 
with this information, it would not be elucidated how membrane rupture results in accumulation of C99 at 
MAM, and consequent MAM upregulation. One possible pathway is through activation of SMase activity by 
inflammatory cytokine, TNF-⍺ [336,693,829], and excitatory neurotransmitters like glutamate [694], both of 
which are released during TBI [800,830]. It has also been reported that the promoter region for the Bace1 
gene has an NFkB response element [831], and inflammation-related NFkB elevations are a known 
consequence of TBI [832], underlying another possible molecular mechanism of MAM-C99 elevations. 
Finally, published work suggests that SMase activity is indeed induced upon membrane lesioning, 
supporting the idea that SMase activation could lie at the heart of MAM upregulation [833]. These pathways 
are important starting points for follow-up studies on the mechanisms of MAM and C99 elevation in TBI. 
 As discussed above, the ideal outcome of disease-oriented research is to improve patient 
outcomes. Given our hypothesis that TBI is a MAM disorder similar to FAD and SAD, the idea of exploiting 
MAM functionality as an “early diagnostic” tool holds here as well. In particular, it is known that not all cases 
of TBI result in AD later in life. Parameters such as recurrence, severity, sex, genotype, diet, medications, 
and other factors all play into downstream sequelae. In other words, TBI is a highly heterogeneous type of 
injury, and so is the population of people at greatest risk for TBI. Furthermore, AD is not the only neuro-
degenerative disease that is observed in patients with a history of TBI; PD, ALS and FTD are also reported. 
Thus, perhaps assays of MAM functionality can help define a subset of TBI cases that are at higher risk of 
resulting in AD, creating an opportunity for therapeutic interventions aimed at reducing MAM functionality 
in the brain. Of course, further validation of this hypothesis through a plethora of studies is necessary to 
begin testing this idea clinically; however, this is a potential therapeutic application of this work. A high-
throughput method of assaying this clinically would be especially key here, such as a lipidomics-based 




 Altogether, this thesis discusses published and unpublished findings describing the multiple 
molecular factors driving metabolic alterations in neurodegenerative disease. These are presented in the 
context of existing hypotheses for AD and TBI pathogenesis. Far more mechanistic research has been 
conducted into AD pathogenesis compared to TBI pathogenesis; however, given the fact that TBI cases 
can result in AD, existing AD research provides a valuable framework for TBI studies. This is the approach 
undertaken in the experiments and discussions included in this thesis. The MAM hypothesis is a new idea 
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